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ABSTRACT 
The DNA damage response (DDR) forms a signaling cascade rapidly activated upon 
exposure to genotoxic stress. The DDR safeguards genomic integrity by halting cell 
cycle progression to allow repair of damaged DNA or by inducing cell death. Myc 
proteins are key regulators of cell proliferation that transcriptionally control the cell 
cycle machinery. Amplification of N-myc in neuroblastomas (MNA-NB) is associated 
with abrogation of the regulatory mechanisms that normally prevent aberrant cell 
proliferation and the interplay between N-myc and the DDR was here analysed. 
Initially, an association between N-myc and the cdk inhibitor p21 was investigated in 
MNA-NB as a possible mechanism by which p21 is functionally suppressed in these 
cells. Although an N-myc/p21 interaction was not observed, MNA-NB cells appear to 
express short N-myc isoforms with the potential to associate with p21. Expression of N-
myc rendered Rat-1 cells resistant to the cell cycle block imposed by serum starvation 
but these cells were not able to bypass a G1 arrest imposed by ectopic p21 suggesting N-
myc does not abolish p21 activity through regulation at the protein level. Analysis of the 
N-myc response to DNA damage in MNA-NB cells revealed that N-myc is 
downregulated in a proteasome-dependent manner in response to UVC or a UV-
mimetic carcinogen, 4NQO. This effect was not reproduced with other agents such as 
IR which like UVC were found to repress cyclin D1 expression likely indicating that 
alternative DDR signaling pathways differently regulate N-myc. N-myc was found to 
interact with the DDB2 subunit of the damaged-DNA binding (DDB) complex, a 
substrate receptor for the DDB1-Cul4A
DDB2
 E3 ligase. The DDB complex has been 
implicated in UV-induced protein ubiquitylation suggesting it may play a role in the N-
myc response to UVC radiation. These findings highlight the complexities of the DDR 
and uncover potentially important mechanisms of cell cycle control through regulation 
of N-myc. 
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CHAPTER 1 - INTRODUCTION 
 
1.1 Eukaryotic cell cycle  
The eukaryotic cell cycle is a highly regulated process that leads to the duplication of 
the genetic information and concomitant cell division. The mammalian cell cycle can be 
divided into four phases; gap1 (G1), synthesis (S), G2 and mitosis (M) (Figure 1.1). In S 
phase DNA is replicated producing an exact copy of the genome and in M phase 
distribution of the replicated chromosomes between daughter cells and cell division 
(cytokinesis) occurs. During early/mid G1, in response to exogenous mitogenic 
stimulation, cells irrevocably commit to completion of the cell cycle even in the absence 
of further exposure to mitogens; this decision point is termed the ―restriction point‖ (R 
point) and is the central event in normal cellular proliferation control (Pardee, 1974, 
Pardee, 1989). Alternatively, if the signals received during this period are not 
favourable for cell division, the cell may revert to a quiescent stage and enter the G0 
phase, or may commit itself to enter a postmitotic, differentiated state. 
 
Key transitions in the cell cycle are mediated predominantly by phosphorylation of 
specific targets by protein serine/threonine kinases named cyclin-dependent kinases 
(cdks) (Figure 1.1). Monomeric cdks have very low kinase activity and require binding 
of cyclin subunits as an initial step in their activation process. Association with cyclins 
provides a regulatory mechanism since the oscillatory levels of cyclins allow phase-
specific activation of cdks whose levels remain relatively stable throughout the cell 
cycle (Ekholm and Reed, 2000). To date, 11 genes encoding cdks and 29 encoding 
cyclins have been identified, although only some are actively implicated in the 
regulation of the cell cycle (Malumbres and Barbacid, 2005). Cdk4 and cdk6 are 
activated by D-type cyclins (D1, D2 and D3) whose expression, unlike the remaining 
cyclins, is not oscillatory but is instead activated in response to growth factors (Pardee, 
1989, Sherr, 1995). Active cdk4/6-cyclin D complexes phosphorylate the 
retinoblastoma family of proteins (pRb, p107, p130), which are negative regulators of 
cell-cycle progression (Figure 1.1) (Ewen et al., 1993, Kato et al., 1993, Connell-
Crowley et al., 1997). In their hypophosphorylated form, pRb-family members associate 
with different subsets of the E2F family of transcription factors (E2F1-5) and prevent 
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expression of proteins required for G1/S transition and DNA synthesis such as E- and A-
type cyclins and proliferating cell nuclear antigen (PCNA), the processivity factor for 
DNA polymerases  and  (Chellappan et al., 1991, Hiebert et al., 1992, Dyson, 1998, 
Black and Azizkhan-Clifford, 1999). pRb phosphorylation by cdk4/6-cyclin D 
complexes in early G1 results in partial inactivation and allows transcription of E2F-
regulated genes (Flemington et al., 1993). In mid- to late G1, pRb proteins are further 
phosphorylated by cdk2-cyclin E complexes, fully disrupting their association with 
E2Fs (Lundberg and Weinberg, 1998, Harbour et al., 1999). Cdk2 interacts with E- and 
A-type cyclins during late G1 and S phase, respectively, to activate DNA synthesis 
(Girard et al., 1991, Koff et al., 1992, Pagano et al., 1992, Zindy et al., 1992). Cdk1 
(also known as cdc2) in association with A- and B-type cyclins drives cells into and 
through mitosis (Draetta et al., 1989, Riabowol et al., 1989, Malumbres and Barbacid, 
2009). 
 
1.1.1 Cyclins regulatory mechanisms 
The oscillations in cyclin concentrations observed during the cell cycle result from 
orchestrated gene transcription and protein degradation. The E2F family of transcription 
factors is especially important in cyclin expression since it activates transcription of 
cyclins E and A (Black and Azizkhan-Clifford, 1999). Cyclin degradation occurs 
through ubiquitin-dependent proteolysis (Glotzer et al., 1991). G1 cyclins have small 
motifs designated PEST sequences that are thought to confer instability and lead to a 
very short half-life and mitotic cyclins have a sequence near the amino (N) terminus 
known as the ―destruction box‖ which mediates their degradation (Rechsteiner and 
Rogers, 1996). Proteolysis of mitotic cyclins requires a ubiquitin-activating enzyme (E1) 
and a ubiquitin-conjugating enzyme (E2) in addition to the Anaphase-Promoting 
Complex (APC), or cyclosome, which acts as an E3 enzyme to catalyze the transfer of 
ubiquitin to various mitotic substrates allowing transition from metaphase to anaphase 
(King et al., 1995, Sudakin et al., 1995). The ubiquitin-mediated degradation of G1 
cyclins requires moreover phosphorylation (Clurman et al., 1996, Diehl et al., 1997). 
Some cyclins are also subject of an additional form of regulation at the level of their 
subcellular localization (Yang and Kornbluth, 1999). 
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1.1.1.1 Cyclin D1 
Expression and accumulation of D-type cyclins is dependent on mitogenic stimulation 
and they therefore act as transducers that relay extracellular signals to the cell cycle 
machinery (Matsushime et al., 1991, Sherr, 1995, Musgrove, 2006). Cyclin D1 is the 
best characterised member of this family given its nearly ubiquitous expression and the 
high frequency at which it is deregulated in human cancers (Lukas et al., 1994, Hall and 
Peters, 1996, De Falco et al., 2004). Expression of cyclin D1 is regulated at different 
levels by Ras signaling pathways. Transcription of the cyclin D1 gene is upregulated by 
a cascade involving Ras-Raf-mitogen-activated protein kinase (MAPK) kinase (MEK)-
extracellular signal-regulated kinase (ERK) in response to growth factors (Aktas et al., 
1997, Weber et al., 1997, Cheng et al., 1998). Ras additionally activates the 
phosphatidylinositol-3 kinase (PI3K)-Akt-mTOR pathway that promotes cyclin D1 
translation through activation of ribosomal protein S6 kinase 1 (Muise-Helmericks et 
al., 1998, Koziczak and Hynes, 2004). Cyclin D1 proteolysis is also attenuated by the 
PI3K-Akt pathway through phosphorylation and consequent inhibition of glycogen 
synthase kinase-3 (GSK3 (van Weeren et al., 1998). Phosphorylation of cyclin D1 at 
Thr286 by GSK3 promotes its nuclear export where it associates with the SCFFbx4-
αBcrystallin
 E3 ligase complex being subsequently degraded by the proteasome (Diehl et 
al., 1997, Diehl et al., 1998, Lin et al., 2006). Phosphorylation at Thr288 by the 
Mirk/dyrk1B kinase is also reported to destabilize cyclin D1, and degradation of free 
cyclin by the ubiquitin-proteasome pathway was shown to be independent of 
phosphorylation at both Thr286 and Thr288 (Germain et al., 2000, Zou et al., 2004). 
 
1.1.2 Cdks regulatory mechanisms 
Complete activation of cdks requires phosphorylation at a conserved threonine residue 
(Thr160 and Thr161 in human cdk2 and cdk1, respectively) located in a region 
designated the T-loop; this phosphorylation is catalyzed by the cdk-activating kinase 
(CAK) complex formed by cdk7 and cyclin H (Solomon et al., 1992, Fesquet et al., 
1993, Poon et al., 1993, Fisher and Morgan, 1994). The conformational changes 
resulting from phosphorylation are particularly important in the activation of certain 
complexes such as cdk1-cyclin B where cyclin binding alone has little effect on cdk 
activity, or cdk1-cyclin A where high-affinity binding to the cyclin cannot occur 
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without cdk phosphorylation (Desai et al., 1995, Larochelle et al., 1998). Cdks are 
additionally controlled by inhibitory phosphorylation of residues close to the catalytic 
site (Tyr15 and/or Thr14) catalyzed by the Wee1 and Myt1 kinases (Lundgren et al., 
1991, Gu et al., 1992, Parker and Piwnica-Worms, 1992, Mueller et al., 1995). 
Dephosphorylation at these sites by phosphatases of the cdc25 family is necessary for 
cdk activation and progression through the cell cycle (Gautier et al., 1991). Three 
isoforms have been identified in mammalian cells (A, B and C) (Nilsson and Hoffmann, 
2000, Boutros et al., 2006). Cdc25A is thought to regulate both G1/S and G2/M 
transitions through activation of cdk2-cyclin E/A and cdk1-cyclin B complexes, 
respectively (Jinno et al., 1994, Blomberg and Hoffmann, 1999, Mailand et al., 2002). 
Cdc25B and C appear to have a more specific role regulating cdk1-cyclin B during 
G2/M transition although knockdown experiments of cdc25B or cdc25C showed that 
these two phosphatases are also involved in the control of S-phase entry (Peng et al., 
1997, Lammer et al., 1998, Takizawa and Morgan, 2000, Turowski et al., 2003, 
Lindqvist et al., 2005). 
 
The activity of many cdk-cyclin complexes is also regulated by cdk inhibitory proteins. 
In mammalian cells CKIs have been divided into two classes. Members of the INK4 
family (p16
INK4A
, p15
INK4B
, p18
INK4C
, p19
INK4D/ARF
) bind cdk4 and cdk6 and inhibit their 
activity by interfering with their association with D-type cyclins (Hannon and Beach, 
1994, Hirai et al., 1995, McConnell et al., 1999). Members of the Cip/Kip family 
(p21
Cip1
, p27
Kip1
, p57
Kip2
) have a homologous N-terminal region that enables them to 
bind both cyclin and cdk subunits and can effectively inhibit cdk1, cdk2, cdk3, cdk4 and 
cdk6 (Harper et al., 1993, Toyoshima and Hunter, 1994, Harper et al., 1995, Lee et al., 
1995, Sherr and Roberts, 1999).  
 
1.1.2.1 p21
WAF1/CIP 
Cdk inhibition by p21 results from the direct association with cdk-cyclin complexes; 
two cyclin-binding sites (Cy1 and Cy2) and an independent cdk-binding site (K) 
mediate interaction with these complexes (Adams et al., 1996, Chen et al., 1996b). 
Inhibition of cdk2 requires interaction with both the cyclin and cdk binding motifs, as 
complexes in which p21 binds uniquely through one of the motifs were found to retain 
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kinase activity (Fotedar et al., 1996). p21 is additionally responsible for blocking DNA 
replication required for S phase progression by binding and inhibiting PCNA through 
the carboxyl (C) terminal region (Bravo et al., 1987, Prelich et al., 1987, Flores-Rozas 
et al., 1994, Waga et al., 1994). More recently, a role for p21 as a positive regulator of 
the cell cycle has arisen. Phosphorylation of nuclear p21 at the NLS (T145) by the 
serine/threonine kinase Akt leads to its relocalization to the cytoplasm (Zhou et al., 
2001). Cytoplasmic p21 promotes the stabilization and consequent activation of the 
cdk4/6-cyclin D complexes, their subsequent translocation to the nucleus and 
prevention of their nuclear export (LaBaer et al., 1997, Cheng et al., 1999, Alt et al., 
2002). This property is shared with another member of the Cip/Kip family, p27, and 
results in an increase in active cdk-cyclin D complexes that leads to pRb 
phosphorylation and consequent progression through the G1 phase of the cell cycle. The 
mechanism behind the contrasting effect of p21 and p27 on cdk-cyclin D is not 
understood; some studies have proposed that p21 and p27 act as inhibitors at higher 
cellular concentrations whereas others have demonstrated cdk/cyclin inhibition by a 
single CKI molecule (Zhang et al., 1994, Harper et al., 1995, Russo et al., 1996, Hengst 
et al., 1998). More recently, the phosphorylation status of p27 was observed to 
determine its ability to inhibit or activate cdk-cyclin complexes (James et al., 2008). In 
agreement with this hypothesis, differential phosphorylation of p21 has also been shown 
to regulate its distinct functions (Järviluoma et al., 2006). An additional role for p21 in 
progression into mitosis has been reported through association and activation of cdk1-
cyclin B complexes following phosphorylation of residue T57 by cdk2 at the S/G2-
phase transition (Dash and El-Deiry, 2005).  
 
p21 is a transcriptional target of the tumour suppressor p53 and plays a crucial role in 
mediating growth arrest when cells are exposed to DNA damaging agents (El-Deiry et 
al., 1993, El-Deiry et al., 1994). Other factors apart from p53 are known to activate p21 
transcription in response to anti-proliferative or differentiation signals including Sp1 
and the BRHLH transcription factor MyoDamong others (Halevy et al., 1995, Biggs et 
al., 1996, Gartel and Tyner, 1999). Expression of p21 is also implicated in protection 
from p53-dependent and independent apoptosis (Gartel and Tyner, 2002). The pro-
survival activity of p21 relies in part on localization in the cytoplasm where it interacts 
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with the pro-apoptotic proteins stress-activated protein kinase (SAPK) and the apoptosis 
signal regulating kinase 1 (ASK1) inhibiting their activity and preventing apoptosis 
(Shim et al., 1996, Asada et al., 1999). Furthermore, interaction of p21 with procaspase-
3 on the mitochondria inhibits its activation and blocks Fas-mediated cell death (Suzuki 
et al., 1998). Several studies have suggested an additional role for p21 as transcriptional 
cofactor. Expression of p21 was shown to inhibit several genes involved in cell cycle 
progression such as DNA polymerase , cyclin B and cdk1, and it can regulate the 
activity of NF-B, STAT3, c-Myc and E2F transcription factors, as well as the histone 
acetyltransferase CBP/p300 (Delavaine and La Thangue, 1999, Chang et al., 2000, 
Coqueret and Gascan, 2000, Kitaura et al., 2000, Snowden et al., 2000). 
 
1.2 The DNA damage response 
The accurate transmission of genetic information during cellular proliferation is 
essential for the survival of organisms and requires the faithful replication of DNA and 
correct chromosome segregation during the cell cycle and the ability to respond to 
spontaneous and induced DNA lesions. The integrity of the genome is under constant 
challenge by both external and internal sources of damage including ultraviolet (UV) 
light, ionizing radiation (IR) or products of normal cellular metabolism such as reactive 
oxygen species (ROS). To protect the genome, cells have developed a signalling 
network - collectively termed the DNA damage response (DDR) – that detects 
replication stress and DNA lesions, signals their presence and coordinates the repair 
process, progression through the cell cycle and apoptosis; the nature and extent of the 
lesions is believed to determine the type of response induced (Hoeijmakers, 2001, 
Sancar et al., 2004). 
 
1.2.1 DNA damage signaling 
The regulatory pathways that control cell-cycle progression in response to DNA lesions 
are termed DNA damage checkpoints and are defined as G1/S, intra-S and G2/M 
checkpoints depending on the transition that is inhibited following damage (Figure 1.3). 
Recent evidence suggests the checkpoint machinery is largely comprised of proteins 
that determine normal progression through the cell cycle and is therefore operational in 
unperturbed cells. Despite the existence of distinct checkpoints, the proteins responsible 
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for sensing the presence of damaged DNA as well as their downstream targets that 
transduce and amplify the DDR signaling are thought to be common to all three 
pathways. The phase-specific nature of the checkpoint is provided by the effector 
proteins which directly enforce the cell cycle arrest (Zhou and Elledge, 2000, McGowan 
and Russell, 2004, Sancar et al., 2004). 
 
The signaling cascade that forms the DNA damage response is mainly mediated by two 
members of the family of PI3K related kinases (PIKK), the ataxia-telangiectasia 
mutated (ATM) and the ATM/Rad3-related (ATR) kinases which target an overlapping 
set of substrates to promote cell-cycle arrest and DNA repair (Abraham, 2001). ATM is 
primarily activated in response to genotoxic stresses that generate double-strand breaks 
(DSBs) such as IR and is recruited to DNA lesions by the Mre11-Rad50-NBS1 complex 
(Andegeko et al., 2001, Lee and Paull, 2005). ATR is thought to respond to a variety of 
lesions that generate single-stranded DNA (ssDNA) such as stalled replication forks, 
base adducts, crosslinks and DSBs and is recruited by ATR-interacting protein (ATRIP) 
to ssDNA, formed both during DNA replication and repair, that has been coated by 
replication protein A (RPA) (Costanzo et al., 2003, Zou and Elledge, 2003, Shechter et 
al., 2004b, Cimprich and Cortez, 2008). Unlike ATM, ATR is essential for the viability 
of proliferating cells as it also regulates the firing of replication origins in S phase and 
prevents the premature onset of mitosis (Brown and Baltimore, 2000, de Klein et al., 
2000, Cortez et al., 2001, Shechter et al., 2004b). 
 
One of the early events initiated by DSBs is the phosphorylation of the histone H2A 
variant, H2AX, on serine 139 (γH2AX) by ATM and the subsequent formation of 
γH2AX foci at DSBs chromosomal sites (Rogakou et al., 1998, Rogakou et al., 1999, 
Burma et al., 2001). Although H2AX accumulation does not seem to be essential for 
the initial recognition of DSBs it aids the recruitment and retention of repair factors on 
damaged DNA as well as the activation of checkpoints regulators (Paull et al., 2000, 
Celeste et al., 2002, Fernandez-Capetillo et al., 2002, Celeste et al., 2003). Subsequent 
dephosphorylation of H2AX is required for efficient repair of DNA lesions and 
recovery from the DNA damage checkpoint (Nazarov et al., 2003, Chowdhury et al., 
2005, Keogh et al., 2006, Macurek et al., 2010). The ATR kinase similarly mediates 
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H2AX accumulation in response to replicational stress and DNA intermediates 
generated during repair of UV lesions and elimination of H2AX is also required for 
repair execution (Ward and Chen, 2001, Hanasoge and Ljungman, 2007).  
 
Activated ATM and ATR phosphorylate and activate checkpoint kinase 1 and 2 
(Chk1/2), two key downstream signal transducers with overlapping substrate 
specificities (Bartek and Lukas, 2003, Reinhardt and Yaffe, 2009). In mammalian cells, 
Chk2 is primarily activated by ATM whereas ATR is responsible for activation of Chk1 
(Matsuoka et al., 1998, Ahn et al., 2000, Guo et al., 2000b, Liu et al., 2000, Zhao and 
Piwnica-Worms, 2001). However, ATR is also phosphorylated by ATM in response to 
DSBs resulting in indirect Chk1 activation (Jazayeri et al., 2006, Myers and Cortez, 
2006). Reciprocally, ATM acts downstream of ATR in response to UV irradiation or 
replication fork stalling leading consequently to activation of Chk2 (Stiff et al., 2006). 
 
The phosphorylation of H2AX in response to IR is primarily mediated by ATM kinase 
and occurs at chromosomal sites of DSBs (Rogakou et al., 1998, Rogakou et al., 1999, 
Burma et al., 2001). Although H2AX accumulation does not seem to be essential for 
the initial recognition of DSBs it aids the recruitment and retention of repair factors and 
checkpoint regulators to these sites (Paull et al., 2000, Celeste et al., 2002, Fernandez-
Capetillo et al., 2002, Celeste et al., 2003). Subsequent dephosphorylation of H2AX is 
required for efficient repair of DNA lesions and recovery from the DNA damage 
checkpoint (Nazarov et al., 2003, Chowdhury et al., 2005, Keogh et al., 2006, Macurek 
et al., 2010). Activation of ATR by replicational stress similarly results in H2AX 
phosphorylation and elimination of H2AX is also required for repair execution (Ward 
and Chen, 2001, Hanasoge and Ljungman, 2007, Chowdhury et al., 2008). 
 
1.2.2 DNA damage checkpoints 
Activation of the G1/S checkpoint prevents replication of damaged DNA in S phase. 
Following genotoxic stress, either the ATM/Chk2 or the ATR/Chk1 pathway is 
primarily activated depending on the type of lesion induced. Phosphorylation of cdc25A 
phosphatase by active Chk1 or Chk2 accelerates cdc25A proteolysis thereby preventing 
activation of cdk2 and progression into S phase (Mailand et al., 2000, Xiao et al., 2003). 
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The ATM/ATR-dependent cyclin D1 proteolysis following genotoxic stress also 
contributes to a rapid G1 arrest by maintaining pRb in a hypophosphorylated and 
subsequently active form thus preventing transcription of E2F target genes required for 
S-phase entry (Hitomi et al., 2008, Pontano et al., 2008, Santra et al., 2009). The two 
pathways also converge on p53; ATM/ATR and Chk2/Chk1 phosphorylate p53 on 
Ser15 and Ser20, respectively (Banin et al., 1998, Canman et al., 1998, Lakin et al., 
1999, Tibbetts et al., 1999, Shieh et al., 2000). Phosphorylation of p53 inhibits its 
nuclear export and blocks the association with the MDM2 E3 ligase, a negative 
regulator of p53 stability, thus promoting p53 accumulation and activity (Shieh et al., 
1997, Zhang and Xiong, 2001). Furthermore, MDM2 is also phosphorylated by ATM 
which largely impairs its ability to promote p53 degradation (Khosravi et al., 1999, 
Maya et al., 2001). Activation of p21 gene expression by p53 results in the inhibition of 
cdk4/6- and cdk2-associated kinase activity further contributing to pRb-mediated 
inactivation of E2F and a sustained G1 arrest (El-Deiry et al., 1994, Jabbur et al., 2000). 
 
ATR can alternatively induce suppression of p21 expression following UV exposure 
(Bendjennat et al., 2003, Zhong et al., 2005, Lee et al., 2007). Lee and colleagues 
demonstrated the GSK3 kinase acted downstream of ATR to phosphorylate p21 after 
UV irradiation and trigger its proteasomal degradation (Lee et al., 2007). Activation of 
p53 following UV exposure can promote cell cycle arrest and apoptosis through 
upregulation of target genes such as p21 and Bax, respectively (Oren, 2003, Latonen 
and Laiho, 2005).The cellular outcome appears to be dependent, among other factors, 
on the extent of the inflicted damage since lower doses of UV predominantly induce cell 
cycle arrest whereas higher doses trigger apoptosis (Cotton and Spandau, 1997, Reinke 
and Lozano, 1997, Allan and Fried, 1999). 
 
The intra-S phase checkpoint also activates the rapid degradation of cdc25A mediated 
by the ATM/Chk2 or ATR/Chk1 pathways leading to inhibition of cdk2-cyclin E/A 
complexes which are required for replication of DNA and progression through S phase 
(Mailand et al., 2000, Falck et al., 2001, Costanzo et al., 2003, Sørensen et al., 2003). 
Entry into mitosis is blocked by the G2/M checkpoint mainly through inhibition of 
cdk1-cyclin B complexes. This is achieved by activation of the cdk2 negative regulator, 
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Wee1 kinase and inactivation of the positive regulators, cdc25B and C phosphatases 
(Peng et al., 1997, Sanchez et al., 1997, Yarden et al., 2002). The p53-dependent 
expression of p21 has also been shown to prevent cdk1-cyclin B activity by blocking 
nuclear export and consequent activation of these complexes (Bunz et al., 1998, Smits 
et al., 2000, Charrier-Savournin et al., 2004). 
 
1.2.3 Nucleotide excision repair (NER) 
NER deals with a broad range of single-strand lesions that destabilize the double helix 
such as DNA adducts generated by agents like UV, cisplatin and 4-nitroquinoline-1-
oxide (4NQO) (Yang et al., 1991, Zamble et al., 1996, Thoma, 1999). Two different 
subtypes of NER have been described; transcription-coupled repair (TCR) which occurs 
relatively rapidly and preferentially repairs the template strand of transcriptionally 
active DNA, and global genomic repair (GGR) which occurs slower and operates 
throughout the genome (Hanawalt, 2002, Shuck et al., 2008). The two predominant UV-
induced lesions, cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-
4PPs), exhibit different repair patterns; CPDs are removed faster in actively transcribed 
genes whereas 6-4PPs are rapidly removed from the overall genome without any 
obvious bias towards transcriptionally active genes (Bohr et al., 1985, Mellon et al., 
1986, Mellon et al., 1987, May et al., 1993). The repair of CPDs is nevertheless much 
slower than 6-4PPs due to imposition of a relatively mild DNA distortion that makes 
them a weaker NER substrate (Franklin and Haseltine, 1984, Mitchell et al., 1985, Kim 
et al., 1995, van Hoffen et al., 1995, Chandrasekhar and Van Houten, 2000). 
Preferential repair of active genes has been demonstrated to other agents that produce 
bulky adducts such as cisplatin (Jones et al., 1991, Larminat et al., 1993, May et al., 
1993). A notable exception is the case of 4NQO adducts which appear to be mainly 
repaired via GGR (Snyderwine and Bohr, 1992). 
 
The DNA damage-binding (DDB) and the xeroderma pigmentosum group C (XPC) 
protein complexes are exclusively involved in GG-NER and can recognize a broad 
spectrum of lesions (Payne and Chu, 1994, Sugasawa et al., 1998, Tang et al., 2000, 
Wittschieben et al., 2005). DDB exhibits a much higher binding affinity and specificity 
for damaged DNA than XPC, particularly with regard to 6-4PPs (Treiber et al., 1992, 
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Reardon et al., 1993, Fujiwara et al., 1999, Batty et al., 2000, Sugasawa et al., 2005). 
Despite this, cells lacking DDB activity exhibit a marked reduction in the removal of 
CPDs from the global genome, while GGR of 6-4PPs is only moderately impaired (Chu 
and Chang, 1988, Reardon et al., 1993, Hwang et al., 1999). Moreover, ectopic 
expression of human DDB2 in human and rodent cells enhances GGR of CPDs (Tang et 
al., 2000, Fitch et al., 2003a). Moser and colleagues demonstrated however that DDB 
can accelerate 6-4PPs repair by recruiting XPC to the lesion sites shortly after 
irradiation (Moser et al., 2005). 
 
DDB consists of two subunits, DDB1 (p127) and DDB2 (p48), that associate with the 
E3 ligase formed by cullin4A, Roc1 and COP9 signalosome (Chu and Chang, 1988, 
Takao et al., 1993, Hwang et al., 1998, Shiyanov et al., 1999b, Groisman et al., 2003). 
Following UV exposure, DDB2, as the substrate receptor for the DDB1-Cul4A
DDB2 
complex, recruits XPC to these sites and mediates ubiquitylation of XPC and DDB2 
itself (Nag et al., 2001, Fitch et al., 2003b, Moser et al., 2005, Sugasawa et al., 2005, El-
Mahdy et al., 2006). The subsequent proteolysis of DDB2 but not XPC appears to 
facilitate handover of the lesion to XPC to promote efficient damage repair. Stoyanova 
and colleagues demonstrated that DDB1-Cul4A
DDB2
 ligase can additionally target p53 
and p21 for degradation following UV irradiation thus preventing p21 accumulation 
(Stoyanova et al., 2008, Stoyanova et al., 2009). In addition to being a component of the 
DNA replication machinery, PCNA is also required for NER and conflicting results 
exist in regard to the role of p21 in DNA repair (Bravo et al., 1987, Prelich et al., 1987, 
Nichols and Sancar, 1992, Shivji et al., 1992). Some groups have reported that binding 
to PCNA by p21 inhibits DNA synthesis but does not block DNA repair (Li et al., 1994, 
Shivji et al., 1994). Others have shown that p21 depletion following UV is required for 
NER activity (Pan et al., 1995, Cooper et al., 1999, Stoyanova et al., 2008).  
 
1.3 NF-B family of transcription factors 
The NF-B family of transcription factors are key coordinators of innate immune 
responses and inflammation that promote expression of a wide range of target genes, 
including cytokines, growth factors and immunoreceptors (Blackwell and Christman, 
1997). Several recent studies have also uncovered a role for NF-B in cancer 
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development through transactivation of genes that drive tumour cell proliferation, 
survival, migration, inflammation and angiogenesis (Aggarwal, 2004, Karin, 2006). 
Activation of NF-B proteins in G1 phase leads to upregulation of molecules involved 
in the cell cycle machinery such as D-type cyclins and c-Myc (Baldwin et al., 1991, 
Duyao et al., 1992, Hinz et al., 1999). Cyclin D1 is a direct target of NF-B activation 
by virtue of an NF-B binding sequence in the cyclin D1 promoter (Guttridge et al., 
1999, Hinz et al., 1999, Joyce et al., 1999, Ouyang et al., 2005). The positive effect of 
NF-B on cell cycle progression appears however, to be cell-specific since its activation 
has also been shown to induce growth inhibition (Bash et al., 1997, Hinata et al., 2003). 
Similarly, NF-B activation in response to stimuli such as the cytokine tumour necrosis 
factor- (TNFα), IR or chemotherapy can protect cells against apoptosis but its activity 
can be modulated by other transcriptional regulators to yield different cellular outcomes 
(Beg and Baltimore, 1996, Wang et al., 1996a). p53 appears to have a particularly 
relevant role in regulating NF-B transcriptional targets, including cyclin D1, to block 
NF-B-mediated survival and induce cell cycle arrest (Ravi et al., 1998, Webster and 
Perkins, 1999, Culmsee et al., 2003, Rocha et al., 2003). 
 
NF-B consists of homo- or heterodimers of Rel domain-containing proteins: Rel-A 
(also called p65), Rel-B, c-Rel, p50 (also called NF-B1) and p52 (also called NF-B2) 
(Hayden and Ghosh, 2004, Perkins, 2007). Phosphorylation-dependent cleavage of p100 
produces p52, whereas p105 is cleaved to form p50. In unstimulated cells, NF-B 
complexes, predominantly Rel-A/p50 heterodimers, are held inactive in the cytoplasm 
through association with a family of inhibitory proteins (IB) of which IB is the 
primary member (Figure 1.3) (Baeuerle and Baltimore, 1988a, Baeuerle and Baltimore, 
1988b). The IKK complex formed by two catalytic subunits, IKKα and IKKβ, and a 
regulatory subunit, IKK (also known as NF-κB essential modifier, NEMO), is 
activated by pro-inflammatory stimuli such as TNF and phosphorylates IB at 
serines 32 and 36 (DiDonato et al., 1997, Mercurio et al., 1997, Zandi et al., 1997, 
Rothwarf et al., 1998). IB phosphorylation leads to its degradation by the ubiquitin-
proteasome pathway and consequent release and nuclear translocation of NF-B (Beg et 
al., 1993, Henkel et al., 1993, Naumann and Scheidereit, 1994, Palombella et al., 1994, 
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Traenckner et al., 1994, Brown et al., 1995, Chen et al., 1995b). Multiple 
phosphorylation events on NF-B subunits, some of which are mediated by IKK, 
further regulate their transcriptional activity (Wang and Baldwin, 1998, Zhong et al., 
1998, Sakurai et al., 1999, Salmerón et al., 2001, Vermeulen et al., 2003). 
 
1.3.1 NF-B and DNA damage signaling 
Genotoxic stress as a result of UV or IR exposure can lead to NF-B activation through 
partly distinct mechanisms (Brach et al., 1991, Li and Karin, 1998). Activation of NF-
B by agents that directly or indirectly generate DSBs such as IR or topoisomerase 
inhibitors proceeds through the canonical IKK-mediated pathway of IB 
phosphorylation and degradation (Huang et al., 2000, Bottero et al., 2001). However, 
unlike other cellular stimuli that similarly activate this pathway, the NF-B response to 
these agents is dependent on ATM (Lee et al., 1998, Piret et al., 1999, Li et al., 2001b). 
DNA damage induces sumoylation of IKK which results in its nuclear accumulation 
and subsequent phosphorylation by ATM; following ubiquitylation, IKK translocates 
to the cytoplasm where it activates the IKK complex (Huang et al., 2003, Wu et al., 
2006).  
 
In contrast, the early NF-B activation following UVC irradiation (<24h) is 
independent of a nuclear signal generated by UV-induced DNA damage and is instead 
triggered by a membrane-initiated signaling cascade (Devary et al., 1993, Simon et al., 
1994, Bender et al., 1998). Although proteasomal degradation of IB was found to be 
essential in this response, the initial studies on the mechanism involved in UV-induced 
activation of NF-B yielded apparently conflicting results. Some reports failed to 
observe activation of the IKK complex in response to UV irradiation and excluded a 
role for IB phosphorylation at Ser32 and 36; instead, the C-terminal region of IB 
appeared to be required for IB degradation (Bender et al., 1998, Li and Karin, 1998). 
Casein kinase 2 (CK2) had been previously implicated in the constitutive 
phosphorylation and basal turnover of free and NF-B-bound IB through 
phosphorylation of a cluster of residues in the C-terminal PEST domain of IB 
(Barroga et al., 1995, Krappmann et al., 1996, Lin et al., 1996, McElhinny et al., 1996, 
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Schwarz et al., 1996). Kato and colleagues demonstrated that the ability of CK2 to 
phosphorylate IB was strongly enhanced by UV exposure resulting in accelerated 
degradation of IB and NF-B activation (Kato et al., 2003). Another study however, 
detected no activation of NF-B in IKK/ double KO cells exposed to UV and further 
demonstrated that replacing the IKK phospho-acceptor sites of IB with 
nonphosphorylatable residues abolished UV-induced NF-B activation (Huang et al., 
2002). Recent work by O’Dea and colleagues may have clarified this issue by 
demonstrating a requirement for the constitutive activity of both IB degradation 
pathways described above resulting in the depletion of free and NF-B-bound IB 
(O'Dea et al., 2008). Oxidative stress resulting from IR or hydrogen peroxide exposure 
for instance, activates NF-B independently of the DNA damage inflicted but this effect 
appears to be highly cell-specific and may involve different mechanisms (Schreck et al., 
1991, Meyer et al., 1993, Anderson et al., 1994, Brennan and O'Neill, 1995). 
Inactivation of IB by oxidative stress can proceed through IKK-mediated 
phosphorylation at Ser32 and 36 and lead to its proteasomal degradation (Storz and 
Toker, 2003, Gloire et al., 2006). An alternative pathway involves phosphorylation of 
IB at Tyr42 by various putative tyrosine kinases including Syk and c-Src and results 
in either its degradation or dissociation from NF-κB (Imbert et al., 1996, Schoonbroodt 
et al., 2000, Livolsi et al., 2001, Fan et al., 2003, Takada et al., 2003) 
 
Recently, a role for the IKK/NF-B pathway in regulating the DNA damage response 
has also arisen.  NF-kB can modulate the ATR-mediated cell cycle checkpoint through 
transcriptional control of claspin (Kenneth et al., 2010). Claspin is an adaptor protein 
that mediates phosphorylation and consequent activation of Chk1 by ATR in response 
to replication stress (Kumagai and Dunphy, 2000, Chini and Chen, 2003, Kumagai et 
al., 2004). Claspin can also interact in a specific manner with chromatin at both 
unperturbed and disrupted replication forks which suggests an additional role in 
monitoring DNA synthesis (Lee et al., 2003, Lee et al., 2005, Petermann et al., 2008, 
Scorah and McGowan, 2009). Consistent with this, cellular depletion of claspin is 
associated with a delayed progression rate of replication forks during S phase as well as 
a failure to block DNA synthesis and cell cycle progression in response to replication 
blocks (Kumagai and Dunphy, 2000, Chini and Chen, 2003, Petermann et al., 2008). 
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Kenneth and colleagues demonstrated that in response to UV and hydroxyurea IKK 
phosphorylates the NF-B subunit, c-Rel, promoting its binding to the claspin promoter 
and consequent activation of gene expression (Kenneth et al., 2010). Disruption of c-Rel 
and IKK or the regulatory subunit IKK, but not IKK, impaired the DNA damage-
induced checkpoint by indirectly affecting activation of Chk1. More recently, IKK was 
shown to promote the repair of IR-induced DSBs in MCF-7 breast cancer cells (Wu et 
al., 2011). IKK was found not to be required for this function but the requirement for 
NF-B transcriptional activity was not fully explored and it has yet to be elucidated if 
IKK acts through a NF-B independent mechanism. 
 
1.4 Neuroblastoma 
Neuroblastoma is the most common extracranial solid tumour in infancy; it accounts for 
8-10% of reported cancer cases in children and is responsible for approximately 15% of 
all childhood cancer deaths. The tumour develops from precursor cells of the 
sympathetic nervous system, a branch of the autonomous nervous system which is 
responsible for mobilizing and preparing the body for situations of stress or danger. 
Neuroblastomas arise in the adrenal glands or the sympathetic chain during fetal or 
early
 
childhood development (Shimada et al., 1999a). 
 
Neuroblastomas can exhibit distinct patterns of clinical behaviour: spontaneous 
regression, maturation to benign ganglioneuroma, or aggressive progression despite 
intensive therapy. The mechanisms leading to this biological heterogeneity are largely 
unclear (Shimada et al., 1999a). Analyses of tumours has allowed the identification of 
several structural genomic aberrations including ploidy changes, amplification of the 
proto-oncogene MYCN, gains of chromosome arm 17q, and deletions of different 
genomic regions including chromosome bands 1p36 (30-35% of primary tumours), 
11q23 (44%) and 14q23-qter (22%) (Maris and Matthay, 1999, Borriello et al., 2002). 
These deletions suggest the existence of neuroblastoma suppressor genes at these 
locations. Based on genetic and biological markers, neuroblastomas can be arranged in 
subsets with distinct clinical and biological behaviours. The International 
Neuroblastoma Staging System (INSS) classifies neuroblastomas in five stages, 1-4 and 
4S. Low risk patients (stages 1, 2 and 4S) have a survival rate greater than 85% with 
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little or no chemotherapy, whereas the survival probability for high risk cases, which 
comprise approximately 50% of diagnosed cases, is lower than 50% (Shimada et al., 
1999b, Maris, 2010).  
 
1.4.1 MYCN-Amplified (MNA) Neuroblastoma (NB) 
Human primary neuroblastoma tumours and established cell lines often carry karyotypic 
abnormalities that signal gene amplification, such as double minute (DM) chromatin 
bodies and homogeneously staining regions (HSRs), respectively (Brodeur et al., 1981, 
Yoshimoto et al., 1999). In 1984, partial homology to the MYC proto-oncogene allowed 
identification of the amplified sequence at the core of these chromosomal structures as 
the MYCN gene (Schwab et al., 1984b). MYCN amplification occurs in about 25% of all 
neuroblastoma cases and is strongly associated with advanced disease stages, rapid 
tumour progression, and treatment failure (Table 1) (Seeger et al., 1985). Targeted 
expression of MYCN has been reported to cause neuroblastoma in transgenic mice 
further suggesting a crucial role for deregulated
 
MYCN in tumour development (Weiss 
et al., 1997). Aside from MYCN, no other oncogene has been shown to be consistently 
mutated or overexpressed in neuroblastoma, including Ras family genes, commonly 
activated in other human cancers (Moley et al., 1991, Dam et al., 2006). 
 
The MYCN gene maps to the chromosomal region 2p23-24 whereas the genomic region 
amplified in neuroblastomas (MYCN amplicon) is generally situated in different 
chromosomes. The amplicon can extend from 100 kilobases (kb) to more than 1 
Megabase (Mb) in length; a core domain of 100-200kb encompassing the MYCN locus 
is found consistently amplified without rearrangements. Amplification values may 
range between 3 to over 300-fold, but values of 50-100-fold are typically seen in 
tumours (Schwab et al., 1984b, Brodeur and Seeger, 1986). The mechanism of 
amplification is unknown, but cytogenetic studies suggest a model whereby the MYCN 
locus might undergo unrestrained replication and recombination to produce circular 
extrachromosomal elements visualized as DMs, while maintaining the single gene copy 
at the original locus. These structures could then become integrated into any 
chromosomal site to form an HSR and undergo further in situ amplification (Brodeur 
and Seeger, 1986).  
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The complexity of the MYCN amplicon suggests that additional genes could be co-
amplified with MYCN and contribute to tumour phenotype providing a molecular basis 
for the clinical heterogeneity observed in patients with MYCN amplification. The DDX1 
(DEAD/H-BOX 1) gene is amplified in about 40-50% of MNA neuroblastomas and 
encodes an RNA helicase involved in the 3’ end processing of pre-mRNA (George et 
al., 1997, Bléoo et al., 2001, Chen et al., 2002). Preliminary studies have demonstrated 
relative transforming activity with the NIH3T3 cell line as well as tumorigenic potential 
in immunodeficient mice (Godbout et al., 2007). The neuroblastoma amplified gene 
(NAG) is amplified alongside MYCN in a significant proportion (60-70%) of MNA 
neuroblastomas (Wimmer et al., 1999). The NAG protein has been recently implicated 
in vesicular trafficking between the Golgi apparatus and the endoplasmic reticulum 
(Aoki et al., 2009). To date, however, MYCN remains the only consistently amplified 
target in neuroblastomas and in fact no amplification of the described genes without 
concomitant amplification of MYCN has been observed suggesting that it is functionally 
responsible for the maintenance of the amplified genomic region. It is possible 
nonetheless that these adjacent genes contribute to the malignant nature of some subsets 
of MNA neuroblastomas.  
 
All copies of MYCN are transcriptionally active in MNA neuroblastoma cells and a 
strong correlation therefore exists between gene amplification and overexpression at 
both the mRNA and protein levels (Nisen et al., 1988, Slavc et al., 1990, Chan et al., 
1997, Lutz and Schwab, 1997). MYCN overexpression in neuroblastomas confers an 
aggressive tumour growth potential (Schwab et al., 1984a, Seeger et al., 1985). Potential 
mediators of MYCN-dependent malignant tumour progression have been identified 
among genes activated by N-myc: MRP (Multidrug Resistance-associated Protein) 
which confers wide drug resistance by acting as an efflux pump, CDC25A required for 
the G1 to S phase transition, and MDM2, a major negative regulator of p53 (Norris et 
al., 1997, Freedman et al., 1999, Slack et al., 2005, Murphy et al., 2011). 
Transcriptional repression of target genes also contributes to the malignant phenotype of 
MNA tumours as observed with NCAM (neural cell adhesion molecule) which functions 
in cell-cell adhesion, the angiogenesis inhibitor inhibitin  A, and HLA-B (MHC class I 
antigen) required for immune surveillance of target cells (Bernards et al., 1986, Akeson 
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and Bernards, 1990, Breit et al., 2000). Additionally, MYCN is also controlled by N-
myc protein with both negative and positive effects on gene expression having been 
observed in neuroblastomas (Sivak et al., 1997, Kim and Carroll, 2004, Suenaga et al., 
2009). 
 
Single-copy tumours can also display enhanced levels of MYCN expression but the 
relationship between N-myc overexpression and clinical prognosis in neuroblastoma 
lacking amplification is controversial, suggesting that a threshold level of N-myc 
expression has to be exceeded for an unfavourable outcome to occur (Grady-Leopardi et 
al., 1986, Nisen et al., 1988, Chan et al., 1997, Cohn et al., 2000, Tang et al., 2006). 
Enhanced expression or activation of N-myc as a result of amplification is also seen at 
much lower frequencies in several additional pediatric tumours, usually of 
neuroectodermal origin, including rhabdomyosarcoma, medulloblastoma and primitive 
neuroectodermal tumours, retinoblastoma, astrocytoma, glioblastoma, small cell lung 
carcinoma, and Wilms’ tumours (Schwab, 2004). High expression of MYCN, equivalent 
to neuroblastomas carrying 150-fold amplification, is a normal feature of various tissues 
of the mammalian embryo (Grady et al., 1987). This suggests that enhanced expression 
in some tumours which do not carry amplification simply reflects the tissue and the 
state of differentiation from which they arise. 
 
1.5 Myc family of transcription factors 
The Myc proteins are important regulators of eukaryotic cells that belong to the basic 
region/helix-loop-helix/leucine zipper (BRHLHZip) family of transcription factors 
(Kaddurah-Daouk et al., 1987, Murre et al., 1989b, Luscher and Larsson, 1999). The 
ongoing identification of target genes reveals a role in the regulation of diverse aspects 
of cellular physiology including protein biosynthesis, ribosome biogenesis, cell cycle 
control, DNA metabolism and other metabolic pathways but it is not yet clear which 
targets are essential for Myc-induced cell growth, apoptosis or transformation (Dang, 
1999, Li et al., 2003, Adhikary and Eilers, 2005, Hoffman and Liebermann, 2008). 
Enhanced expression can additionally, increase genomic instability and angiogenesis as 
well as block differentiation and reduce cell adhesion (Cole, 1986). This class of 
transcription factors also includes the Myc heterodimerization partner Max (Myc 
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associated protein X) and the Mad/Mnt proteins which are alternative partners for Max 
and antagonizers of Myc; with Max in the center, these three types of proteins define the 
so called Myc/Max/Mad network (Figure 1.4B) (Grandori et al., 2000, Massari and 
Murre, 2000).  
 
In mammals, the Myc family consists of five proteins: c-Myc, N-myc, L-myc and s-
Myc, which are functionally and structurally related, and B-Myc which despite showing 
significant homology to the N-terminal region of the other Myc proteins, lacks essential 
domains in the C-terminus (Vennstrom et al., 1982, Nau et al., 1985, Kohl et al., 1986, 
Ingvarsson et al., 1988, Sugiyama et al., 1989). N-myc and c-Myc are the most closely 
related members differing by 68% in their amino acid-coding sequences (Stanton et al., 
1986). The members of this family are involved in the initiation and progression of 
several human cancers such as Burkitt lymphoma (c-Myc) (Dalla-Favera et al., 1982), 
neuroblastoma (N-myc) and ovarian cancer (L-myc) (Wu et al., 2003a). Early studies 
claimed N-myc and c-Myc to be equally potent in transforming primary embryonic rat 
fibroblasts in vitro in collaboration with an activated ras oncogene (Schwab et al., 1985, 
Yancopoulos et al., 1985), but Mukherjee and colleagues (1992) reported a stronger 
oncogenic potential by c-Myc (Mukherjee et al., 1992). In contrast, L-myc is more than 
ten times less effective (Birrer et al., 1988). Although the majority of functional studies 
have been focused on c-Myc, the N-myc protein appears to operate in a similar manner 
in respect to most cellular pathways. In fact, replacing the mouse Myc gene with Mycn 
by homologous recombination resulted in viable mice in which N-myc was similarly 
regulated and functionally complementary to c-Myc (Malynn et al., 2000). 
 
In addition to their role in cell proliferation, Myc proteins can also promote or sensitize 
cells to apoptosis in conditions of limited availability of growth factors or in the 
presence of DNA damage (Hoffman and Liebermann, 2008). The coupling of 
proliferation and apoptosis prevents cells from growing under inappropriate conditions 
and blockage of the apoptotic response is therefore an essential step in the development 
of many tumours. In neuroblastomas cells, the role of MYCN in apoptosis remains 
unclear. Studies by Lutz and colleagues showed that enhanced N-myc expression leads 
to an increase in apoptotic susceptibility following exposure to chemotherapeutic agents 
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or in combination with the proliferation inhibitor -interferon (Lutz et al., 1998, Fulda et 
al., 1999). Other studies, however, observed increased drug sensitivity and induction of 
apoptosis in addition to decreased proliferation and/or differentiation following 
downregulation of N-myc protein expression in neuroblastoma cells by gene silencing 
or inhibition of protein translation (Negroni et al., 1991, Haber et al., 1999, Tonelli et 
al., 2005, Kang et al., 2006, Nara et al., 2007). In fact, neuroblastoma tumours are often 
resistant to therapy in spite of high N-myc protein expression, indicating that 
neuroblastomas with amplified MYCN may have acquired defects in molecular 
pathways governing apoptosis sensing or execution (Maris et al., 2007). The low 
frequency of mutations in the p53 pathway in primary tumours is noteworthy since 
inactivation of this tumour suppressor gene is one of the most common genetic changes 
in human malignancies (Vogan et al., 1993, Hosoi et al., 1994). However, expression of 
the p53 negative regulator, MDM2, is directly activated by N-myc in neuroblastoma 
cells and functional impairment by cytoplasmatic sequestration has been reported and 
shown to correlate with attenuated cell cycle arrest and apoptosis (Moll et al., 1995, 
Moll et al., 1996). Additionally, the transcription factor H-Twist, a negative regulator of 
the p53 pathway, is frequently overexpressed in MYCN-amplified neuroblastomas 
(Maestro et al., 1999, Valsesia-Wittmann et al., 2004). These observations suggest the 
existence of alternative mechanisms for functional inactivation of p53 in neuroblastoma 
cells. 
 
1.5.1 Regulation of Myc proteins 
The MYC gene was first identified as the cellular homologue of the avian retrovirus 
transforming gene, v-myc (Cole, 1986). Identification of the MYCN gene was made 
possible on the basis of its homology to c-Myc in amplified sequences of neuroblastoma 
cells (Kohl et al., 1983, Schwab et al., 1983). The expression patterns of MYC and 
MYCN genes are distinct, albeit overlapping, during early embryogenesis. However, 
MYC remains widely expressed in adult tissues and organs in proliferation, whereas 
MYCN expression is mainly observed in the developing embryo and restricted to a 
limited number of organs, namely gut, lung and heart and at highest levels in the central 
nervous system  (Zimmerman et al., 1986, Stanton et al., 1992). After birth, protein 
levels rapidly decrease and in adults N-myc expression can only be detected at early 
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stages of B-cell development (Morrow et al., 1992, Li et al., 2001a). Unlike c-Myc 
which is associated with rapidly dividing cells, N-myc expression is not necessarily 
associated with cells in mitosis and persists through cellular differentiation suggesting 
that these proteins play distinct roles (Zimmerman et al., 1986, Mugrauer et al., 1988). 
 
Despite the differences in their expression patterns which reflect distinct regulatory 
regions, the promoters of c-Myc and N-myc retain nonetheless some common domains. 
A short region exhibiting high homology between the two promoters harbours a binding 
site for the growth-promoting E2F family of transcription factors shown to both activate 
and repress MYCN expression in neuroblastomas and a GC-rich element termed ME1a1 
in the c-Myc promoter and a CT-box in the N-myc which are targeted by members of 
the Sp family of transcription factors (Asselin et al., 1989, Thalmeier et al., 1989, 
Mudryj et al., 1990, Majello et al., 1995, Tuthill et al., 2003). The transforming growth 
factor- (TGF-), a negative regulator of cell growth, also regulates expression of c- 
and N-myc through a TGF- inhibitory element (TIE) present in both promoters (Serra 
et al., 1994, Chen et al., 2001, Satterwhite et al., 2001). 
 
Like MYC, MYCN is positively or negatively regulated by various signalling cascades 
directing cell proliferation or arrest, respectively. Mitogen stimulation induces 
transcription of Myc proteins as an immediate-early response gene whose expression is 
essential and sufficient for G1/S progression (Kelly et al., 1983, Dean et al., 1986, Lutz 
et al., 1996). Sonic hedgehog (Shh) signaling, a regulator of embryonic development, 
directly activates MYCN expression to promote proliferation of neuronal progenitor 
cells (Kenney et al., 2003, Oliver et al., 2003, Hatton et al., 2006). Ras signaling has an 
essential role in cell cycle progression and exerts differential effects over N-myc 
expression (Peeper et al., 1997). Induction of the MAPK pathway by the Ras-related 
Rap1 has been shown to lead to decreased N-myc expression (Woo et al., 2003). 
Activation of MAPK by the Ras protein following stimulation by growth factors such as 
the insulin-like growth factor (IGF) however, results in upregulation of MYCN (Misawa 
et al., 2000, Wittrock et al., 2002, Ren et al., 2004). Transcriptional activation of several 
components of the IGF system by N-myc has been demonstrated in neuroblastomas and 
could contribute to the proliferative potential of these tumours through continuous high 
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expression of MYCN (Chambéry et al., 1999, Brown et al., 2007). Despite amplification, 
MYCN appears, nevertheless, to be normally regulated in MNA neuroblastoma cells, as 
demonstrated by the ability of different agents such as retinoic acid, -interferon or 
nerve growth factor to induce NB cell differentiation through transcriptional repression 
of N-myc expression (Amatruda et al., 1985, Thiele et al., 1985, Wada et al., 1997, Woo 
et al., 2003). 
 
Expression of N-myc is also regulated post-transcriptionally through different 
mechanisms. Increased MYCN translation as a result of mRNA stabilization has been 
observed following association of neuronal-specific factors and the MDM2 protein to 
the 3’-untranslated region (UTR) (Lazarova et al., 1999, Gu et al., 2012). Binding of 
this region by miR-34a, a microRNA molecule, leads instead to translational 
suppression and mRNA degradation (Wei et al., 2008). The N-myc mRNA may be 
further regulated by an antisense N-myc RNA (N-cym) which is transcribed from the 
opposite DNA strand and overlaps the 5’ end of N-myc (Armstrong and Krystal, 1992). 
The two transcripts are co-expressed during normal foetal development as well as 
oncogenesis and form duplexes within the cell possibly affecting RNA processing 
(Krystal et al., 1990). Additionally, the 5’-UTR region of N-myc mRNA was found to 
carry an internal ribosome entry segment which enhances translation initiation in 
neuronal cells (Jopling and Willis, 2001). 
 
1.5.2 Structure of the Myc proteins 
Human MYCN encodes two polypeptides, 464 and 456 amino acids long, carrying 
distinct N-terminal regions as a result of two in-frame translation start sites (Stanton et 
al., 1986, Mäkelä et al., 1989). N-myc, like c- and L-myc, is a nuclear phosphoprotein 
with a short half-life of 20-30 minutes (Ikegaki et al., 1986, Ramsay et al., 1986). The 
structure can be divided into an N-terminal domain (NTD) involved in transactivation 
and repression and a C-terminal domain (CTD) that contains a nuclear localization 
signal, a basic region (BR) essential for DNA binding and a helix-loop-helix/leucine 
zipper domain (HLHZip) (Figure 1.4A). The NTD of Myc proteins holds highly 
conserved elements designated Myc Homology Boxes (MB) with the best characterized 
of these regions being MBI and MBII (Kohl et al., 1986, Cowling and Cole, 2006).  
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MBI harbours closely located serine and threonine residues that regulate protein 
stability. Phosphorylation of N-myc at Ser62 during mitosis by the cyclin B/cdk1 
complex is mediated by Shh signaling and primes N-myc for phosphorylation by 
GSK3 at Thr58 which promotes protein turnover allowing cells to exit cell cycle 
(Figure 1.4A) (Kenney et al., 2004, Sjostrom et al., 2005). Activation of PI3K by Ras 
signaling indirectly stabilizes N-myc by antagonizing the activity of GSK3 (Yaari et 
al., 2005, Chesler et al., 2006). Manabe and colleagues (1996) also reported a role for 
MAPK activity in Ser62 phosphorylation but did not established whether N-myc, like c-
Myc, was a direct target for MAPK (Manabe et al., 1996). Three additional residues in 
the N-myc protein are targets for phosphorylation by CK2; Ser261 and Ser263 in the 
acidic region and Ser375 proximal to the C-terminus (Hamann et al., 1991, Hagiwara et 
al., 1992). Although the role of these phosphorylation events is not clear, Channavajhala 
and Seldin reported a correlation between CK2 activity and c-Myc protein levels 
suggesting that phosphorylation might result in protein stabilization (Channavajhala and 
Seldin, 2002). Phosphorylation at Thr58 by GSK3 promotes association of N-myc 
with the F-box protein Fbxw7, a component of the SCF (Skp-Cullin-F-box protein) E3 
ubiquitin ligase complex resulting in ubiquitylation and consequent degradation of N-
myc by the proteasome (Ciechanover et al., 1991, Bonvini et al., 1998, Welcker et al., 
2004, Otto et al., 2009). The E3 ligases Huwe1 and TRPC4AP/TRUSS have also been 
shown to ubiquitylate N-myc but appear to function independently of GSK3 activity 
(Zhao et al., 2008, Choi et al., 2010). 
 
The MBII is essential for most Myc functions as it mediates the association with 
cofactors necessary for transcriptional regulation and transformation and it is required 
for Myc proteins to induce apoptosis and block differentiation (Figure 1.4B) (Freytag et 
al., 1990, Evan et al., 1992, Sakamuro and Prendergast, 1999). Activation of target 
genes can result from direct association with regulatory DNA sequences and 
recruitment of histone acetyl-transferase (HAT) and ATP-dependent chromatin 
remodeling complexes that cooperate in promoter clearance and facilitate gene 
expression (Amati et al., 2001). The importance of chromatin modification in Myc 
function was demonstrated with the identification of TRRAP (transformation/ 
transcription domain-associated protein), a component of various HAT complexes that 
  A. Duarte 
38 
 
interacts with c- and N-myc, as an essential cofactor for Myc-induced transformation 
(McMahon et al., 1998, Park et al., 2001, Nikiforov et al., 2002). Knoepfler and 
colleagues have further demonstrated a crucial role for N-myc in promoting wide 
cellular chromatin activation in both neuronal progenitors and neuroblastoma cells 
(Knoepfler et al., 2006, Cotterman et al., 2008). The TIP48 and TIP49 ATPase/helicase 
proteins, found in several chromatin remodeling complexes, can interact with the MBII 
domain independently of TRRAP and act as transcriptional co-activators or co-
repressors of Myc (Wood et al., 2000, Frank et al., 2003, Etard et al., 2005). The CREB-
binding protein (CBP) and p300 HATs also interact with Myc although the protein 
region mediating the association remains unclear with conflicting reports implicating 
the N- or C-terminal regions of Myc in CBP/p300 recruitment to target genes 
(Vervoorts et al., 2003, Faiola et al., 2005). The association of c-Myc with the E3 ligase 
SCF
Skp2
 through the MBII domain is required for the transactivation of several target 
genes (Kim et al., 2003b, von der Lehr et al., 2003). c-Myc is also a substrate of Skp2 
which suggests a role for ubiquitylation in promoter activation possibly by allowing 
recruitment of proteasomal proteins with a role in gene expression (Gonzalez et al., 
2002, Muratani and Tansey, 2003). 
 
Myc can also regulate protein expression by an alternative mechanism involving RNA 
polymerase (pol) II. Myc mediates phosphorylation of the RNA pol II CTD by 
recruiting the P-TEFb (positive transcription elongation factor) kinase complex, through 
the MBI domain, to target promoters thereby stimulating transcriptional elongation and 
mRNA cap methylation (Price, 2000, Eberhardy and Farnham, 2002, Kanazawa et al., 
2003, Cowling and Cole, 2007). Myc can additionally promote transcription of 
ribosomal and small noncoding RNAs such as transfer RNAby RNA pol I and pol III 
(Gomez-Roman et al., 2003, Arabi et al., 2005, Grandori et al., 2005, Grewal et al., 
2005). More recently, a direct role for c-Myc in promoting initiation of S phase through 
activation of DNA replication has emerged from the observation of an interaction with 
components of the pre-replicative complex; the activity required integral N- and C-
terminal domains suggesting c-Myc binds directly to DNA to recruit factors that control 
the firing of replication origins (Dominguez-Sola et al., 2007). This study provided a 
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direct mechanism by which Myc proteins could contribute to generating genomic 
instability and accelerate tumorigenesis. 
 
The BR at the CTD is required for binding the DNA recognition sequence 
CAC(A/G)TG, called the E-box, present in the regulatory regions of activated target 
genes (Blackwell et al., 1990, Halazonetis and Kandil, 1991, Prendergast and Ziff, 
1991). Some differences have been observed though, regarding binding site preferences. 
For instance, flanking sequences can affect DNA binding affinity and non-canonical 
sites are also bound by Myc proteins (Blackwell et al., 1993, Fisher et al., 1993). 
Because the majority of the regulatory regions of known c-Myc targets have not been 
examined for N- and L-myc binding it is not clear how binding preferences affect 
differential transcriptional regulation by the various Myc proteins.  
 
The HLHZip region located in the CTD is responsible for interaction of Myc proteins 
with their primary partner protein, Max (Blackwood and Eisenman, 1991, Wenzel et al., 
1991, Blackwood et al., 1992). Heterodimerization with Max is required for binding to 
E-boxes and is necessary for some, but not all, Myc functions including transcriptional 
activation and repression by Myc, as well as for the ability of overexpressed Myc to 
transform cells, induce apoptosis and promote cell cycle progression (Amati et al., 
1992, Kretzner et al., 1992, Amati et al., 1993a, Amati et al., 1993b, Mao et al., 2003, 
Steiger et al., 2008). Nair and Burley determined the structure of the BRHLHZip 
domains of Myc/Max heterodimers and found this complex to form a bivalent 
heterotetamer (Nair and Burley, 2003). The Myc/Max dimer of heterodimers assembled 
head-to-tail bringing together the four leucine zippers that may provide a platform for 
recruitment of additional protein factors. Various Myc target genes have multiple E-
boxes widely separated and the identification of these complexes provides a model by 
which Myc/Max dimers can simultaneously engage several motifs (Grandori and 
Eisenman, 1997). Shim and colleagues observed complete abrogation of Myc-
dependent transactivation of the LDH-A gene when either of the two E-boxes present in 
this promoter were mutated demonstrating the relevance of simultaneous Myc/Max 
recruitment to various E-boxes in some regulatory regions (Shim et al., 1997).  
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Max can also form complexes with the Mad/Mnt proteins but unlike Myc/Max 
heterodimers, their binding to E-boxes leads to transcriptional repression through 
corepressor-mediated recruitment of histone deacetylase complexes (HDAC) (Ayer et 
al., 1993, Ayer et al., 1995, Schreiber-Agus et al., 1995, Laherty et al., 1997). The 
Max/Myc dimers usually prevail in proliferating cells whereas Max/Mad or Max/Mnt 
dimers are mostly observed in resting or differentiated cells. 
 
1.5.3 Transcriptional control by the Myc proteins 
The Myc proteins promote cell cycle progression and transformation by coordinated 
regulation of expression of a number of genes (Adhikary and Eilers, 2005). c-Myc 
suppresses expression of cell cycle/growth arrest genes including gas1 (growth arrest-
specific), p15, p21, p27, and various GADD (growth arrest and DNA damaging-
inducible) genes (Chen et al., 1996a, Lee et al., 1997, Marhin et al., 1997, Amundson et 
al., 1998, Staller et al., 2001, Yang et al., 2001, Seoane et al., 2002). In turn, it activates 
transcription of cell cycle promoting factors such as cdc25A, cdk4, cyclins D2, E and A, 
and E2F1-3 transcription factors (Jansen-Dürr et al., 1993, Galaktionov et al., 1996, 
Leone et al., 1997, Perez-Roger et al., 1997, Sears et al., 1997, Sears et al., 1999, 
Adams et al., 2000, Hermeking et al., 2000, Bouchard et al., 2001). Other 
transcriptional targets include genes involved in apoptosis and cell growth such as -
prothymosin and ornithine decarboxylase (ODC), respectively, and the catalytic subunit 
of telomerase (TERT) which contributes to the immortalization process (Eilers et al., 
1991, Bello-Fernandez et al., 1993, Dang, 1999, Wu et al., 1999); ODC, -prothymosin 
and TERT are activated by N-myc as well (Lutz et al., 1996, Mac et al., 2000, Nikiforov 
et al., 2002). The Myc proteins are also transcriptional regulators of microRNAs 
(miRNAs), small non-protein coding RNAs that negatively regulate gene expression by 
promoting RNA degradation through the RNAi pathway and sequence specific 
translational repression (Bartel, 2004, Mestdagh et al., 2010). Amplification of MYCN 
in neuroblastomas is associated with deregulated expression of miRNAs that control 
cell proliferation, adhesion, differentiation and survival and can therefore contribute to 
tumour pathogenesis (Chen and Stallings, 2007, Bray et al., 2009, Lovén et al., 2010, 
Ma et al., 2010).  
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The mechanisms for transcriptional repression by Myc are less well defined than for 
transactivation. Recruitment of Myc proteins to promoters by other transcription factors 
is thought to occur independently of DNA binding and results in inhibition of 
transactivation by these factors (Wanzel et al., 2003). Miz-1 (Myc-interacting zinc 
finger protein-1) is a transcription activator of the cell cycle arrest genes p21
Cip1
 and 
p15
INK4B
 whose activity is blocked through direct interaction with the BRHLHZip 
domain of Myc (Peukert et al., 1997, Seoane et al., 2001, Staller et al., 2001, Seoane et 
al., 2002, Wu et al., 2003b). Miz-1 inactivation by Myc also contributes to the ability of 
Myc to induce apoptosis by preventing expression of pro-survival genes such as BCL2 
(Patel and McMahon, 2006, Patel and McMahon, 2007). N-myc has also been shown to 
block activation of Miz-1 target genes involved in differentiation of neural cells (Zhang 
et al., 2006, Akter et al., 2011). Transcriptional repression by c- and N-myc can 
alternatively involve recruitment of histone deacetylases to target promoters (Jiang et 
al., 2007, Liu et al., 2007, Kurland and Tansey, 2008). 
 
Some studies indicate that for cell transformation, activation of transcription by c-Myc 
is less important than repression. This is based on the observation that a naturally 
occurring truncated form of c-Myc, c-MycS, lacking a region of the NTD that includes 
the highly conserved MBI region, retains the ability to repress expression of some target 
genes, stimulate proliferation and induce anchorage-independent growth (Spotts et al., 
1997, Xiao et al., 1998). Cowling and Cole constructed an artificial N-myc truncation, 
analogous to c-MycS, carrying a deletion of the N-terminus to the internal methionine 
located at residue 81 (Cowling and Cole, 2008). Similar to full-length N-myc, N-myc 
del80 was able to rescue the proliferative defect of MYC-null cells in a manner 
dependent on MBII. As observed for c-MycS, N-myc del80 retained the ability to 
repress most N-myc targets but exhibited a reduced transactivation potential. 
 
1.5.3.1 p21 regulation by the Myc proteins 
Transcriptional repression of p21 by c-Myc plays an essential role in overcoming 
growth arrest in response to a wide variety of circumstances and renders Myc-
overexpressing cells more sensitive to different stresses since it switches the cellular 
response from cell cycle arrest to apoptosis (Seoane et al., 2002, Arango et al., 2003). c-
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Myc can block expression of p21 in response to differentiation signals or DNA damage 
through interaction with Miz-1 at the core promoter thereby preventing transactivation 
by Miz-1, p53 and other cofactors; or it can alternatively sequester the transcription 
factors Sp1 and Sp3 which are positive regulators of p21 (Gartel et al., 2001, Herold et 
al., 2002, Seoane et al., 2002, Wu et al., 2003b). c-Myc may also induce p21 expression 
indirectly by activation of the p53 promoter or by inducing expression of the tumour 
suppressor p19
ARF
, an alternative reading frame protein encoded by the INK4b–ARF–
INK4a locus (Reisman et al., 1993, Ouelle et al., 1995, Kamijo et al., 1997, Zindy et al., 
1998). ARF interacts with the p53 inhibitor MDM2 and targets it for proteolysis leading 
to stabilized p53 and activation of its target genes (Kamijo et al., 1998, Zhang et al., 
1998, Weber et al., 1999). In agreement with this a study in c-Myc-null mouse cells 
reported reduced levels of p21 expression and a different study using c-Myc-
overexpressing fibroblasts described a p53- and p21-dependent G2 arrest in response to 
enhanced c-Myc (Mateyak et al., 1999, Felsher et al., 2000). 
 
1.6 Thesis 
N-myc and cyclin D1 are well-established human proto-oncogenes whose deregulated 
expression has been implicated in pathogenesis of several types of tumours (Croce, 
2008, Santarius et al., 2010). Cancer treatment commonly employs radiological as well 
as chemical agents that function by generating DNA damage; tumour cells often exhibit 
defects in DNA damage repair and are as a result more sensitive to such treatments than 
normal cells (Helleday et al., 2008, Jackson and Bartek, 2009). Understanding how N-
myc and cyclin D1 are regulated in response to genotoxic stress could uncover signaling 
pathways that mediate their oncogenesis and potentially provide novel or improved 
therapeutic strategies. 
 
1.6.1 Genotoxic agents 
Specific signalling pathways are activated depending on the type and extent of the DNA 
lesions induced by different genotoxic agents. However, some agents can inflict a 
variety of lesions that trigger parallel cascades and give rise to a complex cellular 
response (Hoeijmakers, 2001, Sancar et al., 2004, Jackson and Bartek, 2009). To better 
understand how the DNA damage response affects the regulation of N-myc and cyclin 
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D1, this study analysed the response of the two proteins to different damaging 
treatments (Table 2).  
 
Short-wavelength UV radiation (UVC) is absorbed by DNA very efficiently and the 
predominant lesions imposed by UVC exposure are CPDs and 6-4PPs formed between 
adjacent DNA bases (Cadet et al., 2005, Latonen and Laiho, 2005). These modifications 
induce distortions in the DNA helix that block DNA replication and transcription 
leading to activation of the ATR/Chk1 pathway (Guo et al., 2000b, Zhao and Piwnica-
Worms, 2001, Heffernan et al., 2002). Cisplatin is a widely used chemotherapeutic 
agent that binds directly to DNA and generates inter- and intra-strand crosslinks that 
perturb the helical structure of DNA and, similarly to UV radiation, activate an ATR-
dependent checkpoint (Jamieson and Lippard, 1999, Damia et al., 2001, Siddik, 2003). 
The chemical carcinogen 4NQO is considered a UV-mimetic due to its ability to 
generate bulky base adducts that are, similar to UV lesions, repaired by nucleotide 
excision (Zelle and Bootsma, 1980, Yang et al., 1991, Thoma, 1999). The metabolic 
activation of 4NQO into the active species can also generate reactive oxygen species 
(ROS) that lead to other DNA lesions such as single- and double-strand breaks (Nagao 
and Sugimura, 1976, Bailleul et al., 1989, Nunoshiba and Demple, 1993, Olive and 
Johnston, 1997). 
 
IR exposure can inflict DNA insults through direct ionization of DNA or through the 
generation of ROS such as hydroxyl radicals or peroxides; ROS account in large part 
for the genotoxic stress induced by this type of radiation and can give rise to a variety of 
lesions including base modifications, abasic sites, single-strand breaks (SSBs) and 
DSBs (Ward, 1988, Riley, 1994). H2O2 is a source of hydroxyl radicals and can 
therefore cause similar DNA lesions (Dahm-Daphi et al., 2000, Chatgilialoglu and 
O'Neill, 2001). DSBs resulting from IR or H2O2 treatment are strong activators of ATM 
and Chk2 and are repaired by homologous recombination (HR) or nonhomologous end-
joining (NHEJ) (Ward, 1988, Canman et al., 1998, Ahn et al., 2000, Khanna and 
Jackson, 2001). Etoposide is an anti-tumour drug that targets the DNA topoisomerase II, 
an enzyme that generates DSBs in the DNA in order to untangle the DNA helix. The 
drug binds to and stabilizes the complexes formed by the enzyme and the cleaved DNA 
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converting these transient cleavage complexes into single-strand gaps and DSBs that 
can simultaneously activate the ATR/Chk1 and ATM/Chk2 pathways (Caldecott et al., 
1990, Burden et al., 1996, Costanzo et al., 2003).  
 
1.6.2 N-myc and the DNA damage response 
Ectopic Myc expression strongly enhances cell sensitivity to stress stimuli such as 
serum deprivation and genotoxic damage through activation of the ARF–MDM2–p53 
tumour suppressor pathway (Reisman et al., 1993, Hermeking and Eick, 1994, Wagner 
et al., 1994, Zindy et al., 1998, Hoffman and Liebermann, 2008). To overcome these 
constraints, cancer cells with deregulated MYC frequently exhibit defects in p53-
dependent apoptosis (Eischen et al., 1999, Yin et al., 1999, Hemann et al., 2005). c-Myc 
is also a target for regulation by the ARF-p53 pathway. Both ARF and p21 have been 
shown to associate with c-Myc through the MBII domain and suppress transcriptional 
activation of target genes (Kitaura et al., 2000, Datta et al., 2004, Qi et al., 2004, 
Amente et al., 2006). The interaction between c-Myc and p21 also prevented binding of 
the latter to PCNA and therefore alleviated its inhibitory effect on DNA replication. 
Like c-Myc, N-myc has been demonstrated to transcriptionally activate p53 in NB cells 
and neuroblasts with MYCN amplification are thought to similarly require attenuation of 
apoptotic pathways or, alternatively, constitutive activation of survival pathways for 
malignant progression (Hogarty, 2003, Chen et al., 2010). 
 
As major regulators of cell proliferation, the Myc proteins have the potential to oppose 
the cell cycle arrest imposed by the DNA damage response machinery following 
genotoxic stress, particularly in cells with deregulated c- or N-myc expression. As 
observed for other cell cycle regulators, c-Myc is downregulated through different 
mechanisms following treatment with genotoxic agents such as IR, UVC and etoposide. 
(Sheen and Dickson, 2002, Britton et al., 2008, Cannell et al., 2010). IR- and etoposide-
induced downregulation of c-Myc was shown to permit cells to arrest in S phase thereby 
preventing replication of damaged DNA. Neuroblastoma cells, particularly those 
carrying amplified MYCN, are reported to have an altered response to IR as they fail to 
undergo G1 arrest following irradiation despite p53-dependent expression of p21 
(McKenzie et al., 1999, Tweddle et al., 2001a, Tweddle et al., 2001b). McKenzie and 
  A. Duarte 
45 
 
colleagues observed an impairment in the binding of ectopic p21 to cdk2 complexes in 
NB cells that could potentially explain these observations (McKenzie et al., 2003). 
More recently however, Bell and colleagues demonstrated that an attenuated induction 
of p21 could in part account for the altered G1 checkpoint exhibited by irradiated MNA-
NB cells but it remains unclear whether N-myc and p21 cooperate to permit 
proliferation of these cells under growth arresting conditions (Bell et al., 2006, Bell et 
al., 2007).  
 
This study attempted to understand the role of N-myc in the DNA damage response by 
pursuing the following objectives: 
 Determine if a physical interaction between N-myc and p21 exists and assess its 
functional consequence 
 Examine the cellular responses induced by ectopic p21 in Rat-1 fibroblasts 
expressing N-myc 
 Analyse the N-myc response to various genotoxic agents (UVC, IR, etoposide, 
cisplatin, 4NQO) in MYCN-amplified neuroblastoma cells 
 Investigate the upstream regulators of the N-myc response to UVC treatment 
 
1.6.3 Cyclin D1 and the DNA damage response 
The ubiquitin-dependent degradation of cyclin D1 by genotoxic stress is an essential 
element of the cellular response to DNA damage as it induces a G1 cell cycle arrest that 
prevents aberrant DNA replication (Agami and Bernards, 2000, Pontano et al., 2008, 
Santra et al., 2009). Distinct mechanisms however, are likely to be involved in the 
response to different genotoxic agents. In this study a possible role for NF-B 
transcription factor in regulating cyclin D1 following genotoxic insult was investigated 
as described: 
 Analysis of the effect of NF-B inhibition in the expression of cyclin D1 
following treatment with various DNA damaging agents (UVC, IR, 4NQO and 
H2O2) 
 Investigate the requirement for IKK and IKK in the cyclin D1 response to 
DNA damage 
 Examine the role of IKK and IKK in the cellular responses to DNA damage 
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Figure 1.1 – Regulation of cdks by cyclin subunits and cdk inhibitory proteins. 
Phosphorylation of Retinoblastoma protein (Rb) by cyclin-cdk complexes (the 
phosphate group is represented by an encircled letter P) leads to release of E2F and 
consequent transcriptional activation of target genes. G0, G1, S, G2 and M refer to the 
quiescence, gap1, DNA synthesis, gap2 and mitotic phases of the cell cycle, 
respectively. 
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Figure 1.2 – Mammalian cell cycle checkpoint Ppathways. In response to DNA 
damage, the ataxia telangiectasia mutated (ATM) and ATM-/Rad3-related (ATR) 
kinases are activated, leading to phosphorylation and activation of checkpoint kinase 1 
and 2 (Chk1/2). Phosphorylation of cdc25 phosphatases by Chk1/2 induces their 
degradation and/or cytoplasmic sequestration which prevent activation of cdk2- and 
cdk1-associated kinase activity and results in S or G2 arrest. Activated ATM/ATR also 
activates p53-dependent upregulation of p21 which can bind and inhibit cdk2 
complexes leading to G1 arrest. 
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Figure 1.3 – Signal transduction pathways of nuclear factor-B (NF-B) activation. 
Activation of the NF-B canonical pathway by tumour necrosis factor- (TNF), 
interleukin-1 (IL-1), lipopolysaccharide (LPS) and many other stimuli is dependent on 
phosphorylation of inhibitor of B- (IkB) by different kinases (the phosphate group 
is represented by an encircled letter P), leading to its ubiquitylation and subsequent 
degradation. In response to genotoxic stress, activation of NF-B is dependent on 
phosphorylation of IB kinase (IKK)  by ataxia telangiectasia mutated (ATM) kinase. 
Atypical pathways of NF-B activation include casein kinase 2 (CK2) and tyrosine-
kinase-dependent IkB phosphorylation. The non-canonical pathway is induced among 
other stimuli by lymphotoxin (LT) and results in IKK activation by the NF-B-
inducing kinase (NIK). Phosphorylation of the p100 subunit by IKK leads to its 
proteasomal processing into p52 and consequent activation of p52–Rel-B heterodimers. 
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Figure 1.4 – (A) Schematic representation of human N-myc with depiction of 
functional domains and conserved phosphorylation residues. I/II: Myc Boxes I/II; 
BRHLHZip: basic region/helix–loop–helix/leucine zipper domain. Alignment of N-myc 
with Max protein is also presented. (B) Myc-Max-Mad network and some interacting 
coactivators or corepressors such as the ATPase/helicases TIP48 andTIP49, the histone 
acetyl-transferases (HAT) CBP and p300 and the mSIN3-histone deacetylase complex 
(HDAC). 
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Table 1 – Correlation between MYCN amplification and neuroblastoma stage 
(International Neuroblastoma Staging System (Shimada et al., 1999b) 
 
 
 
 
 
 
 
 
 
 
 
Table 2 – Genotoxic agents used in this study, DNA lesions induced and 
most relevant repair mechanisms responsible for the removal of the lesions
1
 
 
 
 
 
 
 
 
 
 
 
 
1
Abbreviations: 4-NQO, 4-nitroquinoline-1-oxide; CPDs and 6-4PPs, 6-4 photoproducts 
and cyclobutane pyrimidine dimers, respectively; SSBs and DSBs, single- and double-
strand breaks, respectively; BER and NER, base- and nucleotide-excision repair, 
respectively; MMR, mismatch repair; HR, homologous recombination; NHEJ, non-
homologous end joining. 
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CHAPTER 2 - MATERIALS AND METHODS 
 
2.1 Reagents 
All reagents, including enzymes and antibodies, were purchased from Promega, 
Novagen, New England BioLabs, Fermentas, Roche, Sigma, Jackson ImmunoResearch, 
Millipore, Quiagen, Cancer Research UK, Cell Signaling Technology, Santa Cruz, GE 
Healthcare, BDH Prolabo, Invitrogen, PAA, Calbiochem, BD Biosciences and Stratech. 
 
2.2 Plasmid construction and preparation 
The cDNAs listed in Table 1 were generated by polymerase chain reaction (PCR) using 
the indicated oligonucleotide primers. The mouse Mycn (T58A) product was obtained 
by performing a 2-step amplification: the primers forward and reverse (mutated), and 
the primers forward (mutated) and reverse were first used to produce two distinct PCR 
products which then served as templates for an additional PCR reaction using the 
primers forward and reverse. PCR products were cloned into the pGEM-T vector 
(Promega) and then excised using the appropriate restriction enzymes for further 
cloning. For expression of fusion proteins, inserts were invariably introduced in the 
indicated vector downstream of the respective epitope generating N-terminally tagged 
proteins. The complete list of plasmids used in this study is presented in Table 3. All 
constructs obtained were confirmed by restriction digestion and sequencing. 
 
2.2.1 Polymerase Chain Reaction 
PCR reactions were performed in appropriate buffer using 1 unit of KOD DNA 
Polymerase (Novagen) and 1-5ng of plasmid DNA in a total volume of 50l; the 
reaction solution contained 2M of each primer, 0.2mM dNTPs (each) and 1mM 
MgCl2. Typically, PCR reactions consisted of 20-30 cycles of denaturing at 98°C for 15 
seconds (s), annealing at the lowest oligo melting temperature for 2s and extension at 
72°C for 20s.   
 
2.2.2 Digestion/Electrophoresis 
DNA digestions were carried out in appropriate buffer (New England BioLabs), using 
1g of DNA and 10 units of each enzyme in a total volume of 20l; the samples were 
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incubated at 37ºC for 1 hour (h). Tris acetate (TAE) loading buffer (40mM Tris 
acetate/1mM ethylenediamine tetraacetic acid (EDTA) pH8.0/2.5% (weight/volume) 
Ficoll/0.04% (weight/volume) bromophenol blue) was added and the samples were run 
at 80mA on a 1% (w/v) agarose gel containing 0.6μg/ml ethidium bromide. Bands were 
visualized under ultraviolet light and, when required, the relevant DNA was excised for 
purification. 
 
2.2.3 Gene Cleaning 
The samples were incubated in an equal volume of 6M NaI at 65ºC for 5min. The DNA 
was recovered by incubating with a silica suspension (100mg/ml) on ice for 5min. The 
suspension was prepared as previously described (Boyle and Lew, 1995). Briefly, silica 
powder (Sigma) was washed with PBS and allowed to settle for 2h. After discarding the 
supernatant, the procedure was repeated and the silica pellet was retrieved by 
centrifugation before ressuspending in 3M NaI for storage at -20ºC. The DNA was 
washed twice by brief centrifugation followed by resuspension in washing solution 
(50mM NaCl/10mM Tris pH7.5/2.5mM EDTA/50% (v/v) ethanol). Elution of the DNA 
from the silica was performed by resuspending in sterile water (dH2O) and incubating at 
60ºC for 5min. Following a brief centrifugation an aliquot of the supernatant was used 
for ligation reactions.  
 
2.2.4 Ligation 
Reactions were performed in 0.5M Tris-HCl pH7.6/10mM MgCl2/10mM DTT and 
50μg/ml BSA. 10ng of appropriately digested vector was incubated at room temperature 
for at least 1h with 10 units of T4 DNA Ligase (Fermentas) and the respective DNA 
sample. 
 
2.2.5 Transformation 
Ligation products were purified by gene cleaning and the eluates were added to 
electrocompetent Escherichia coli (E. coli) strain DH5α cells. Electrocompetent E. coli 
cells were obtained by washing exponentially growing cells three times with ice-cold 
dH2O and concentrating with 10% (v/v) glycerol; the cells were then stored at -80ºC. 
Electroporation (25μFD, 200Ω, 2.2kV) was performed using a BioRad Gene Pulser. 
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Luria Broth (LB) media (1% (w/v) bactotryptone/1% (w/v) NaCl/0.5% (w/v) bactoyeast 
extract pH7.0) was then added and the solution was plated onto LB plates supplemented 
with ampicillin (50μg/ml, Roche). The plates were incubated at 37ºC overnight. 
 
2.2.6 Small scale production of plasmid DNA - Miniprep 
Transformants were grown in 2ml LB/Amp media overnight at 37ºC with shaking. 
Aliquots from each sample were spun briefly and the supernatant was discarded. The 
cell pellets were resuspended by addition of 100μl of Solution I (50mM glucose/25mM 
Tris-HCl pH8.0/10mM EDTA pH8.0), followed by sequential addition of 200μl of 
Solution II (0.2M NaOH/1% (w/v) SDS) and 150μl of Solution III (3M potassium 
acetate/11.5% (v/v) glacial acetic acid). After mixing, the samples were centrifuged for 
3min at 13000 rotations per minute (rpm) and the DNA was precipitated from the 
supernatant solution by addition of absolute ethanol followed by centrifugation (as 
before). The supernatant was removed and the pellet was resuspended in dH2O by brief 
vortexing, and centrifuged for 1min at 13000rpm. 
 
2.2.7 Large scale production of plasmid DNA - Maxiprep 
Bacterial cultures were grown in 200ml of LB/Amp media at 37ºC overnight with 
shaking. The cultures were centrifuged at 5000rpm and 4ºC for 5min. The supernatants 
were removed and the pellets were resuspended in 10ml of Solution I. 20ml of Solution 
II and 15ml of Solution III were then added sequentially. After mixing, samples were 
centrifuged at 9000rpm for 5min and the supernatants were collected after filtering. The 
nucleic acids were precipitated by addition of 45ml of propan-2-ol and the solutions 
were spun as before. The supernatants were discarded and the precipitants were 
resuspended in 3ml of dH2O followed by 4ml of -20ºC 5M LiCl. After standing on ice 
for 5min, the solutions were spun at 13000rpm for 5min. The resulting supernatants 
were incubated on ice for 5min with two volumes of absolute ethanol and then 
centrifuged at 5000rpm and 4ºC for 5min. The pellets were resuspended in 500μl of 
dH2O and the RNA was degraded by incubating at 37ºC for 15min with 100g/ml 
Ribonuclease A (RNase A, Sigma). Plasmid DNA was precipitated by incubating on ice 
for 5min with 2.5M NaCl/20% (v/v) polyethylene glycol 6000 solution; the supernatant 
was discarded after spinning the solution for 5min at 13000rpm. After resuspension, 
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proteins were removed by phenol/chloroform extraction. The plasmid DNA was then 
precipitated by addition of 3M NaOAc, pH5.2 and absolute ethanol followed by 
centrifugation at 13000rpm. Plasmid DNA was resuspended at approximately 1mg/ml 
in dH2O. 
 
2.3 Protein Analysis 
2.3.1 SDS–Polyacrylamide Gel Electrophoresis (SDS-PAGE) Protein Gels  
SDS-PAGE protein separation was performed in 10 or 12% resolving gels (10 or 12% 
(w/v) acrylamide/0.4M Tris-HCl pH8.8/0.1% (w/v) Sodium Dodecyl Sulphate 
(SDS)/0.1% (w/v) ammonium persulphate (APS)/0.1% (v/v) TEMED) and 5% stacking 
gels (5% acrylamide/0.1M Tris-HCl pH6.8/0.1% SDS/0.1% APS/0.1% TEMED). 
Samples were resuspended in SDS-PAGE loading buffer (64mM Tris-HCl pH6.8/9.6% 
(v/v) glycerol/2% (w/v) SDS/5% (v/v) β-mercaptoethanol/0.1% (w/v) Bromophenol 
Blue) and run at 200V for 1-1.5h in running buffer (250mM glycine/0.1% (w/v) 
SDS/25mM Tris-HCl pH8.3). Gels were stained with Coomassie bluestaining solution 
(0.25% (w/v) Coomassie blue dye/10% (v/v) methanol/10% (v/v) acetic acid) or 
electrotransferred onto nitrocellulose membranes for immunodetection (see below). 
 
2.3.2 Immunoblotting 
Proteins were electrophoretically transferred from SDS-PAGE gels onto nitrocellulose 
membranes (Schleicher & Schnell) in electrotransfer buffer (25mM Tris/190mM 
glycine/0.01% (w/v) SDS/10% (v/v) methanol) or carbonate electrotransfer buffer 
(3mM disodium carbonate/10mM sodium hydrogen carbonate/0.01% (v/v) SDS/10% 
(v/v) methanol) at 400mA for 1h. The membranes were blocked at room temperature for 
1h in 5% (w/v) non-fat dried milk in phosphate buffer saline (PBS, 0.137M 
NaCl/3.4mM KCl/12mM Na2HPO4/1.8mM KH2PO4) with 0.1% (v/v) Tween 20 
(PBST). The primary antibody was then added and the membranes were incubated at 
room temperature for 2-3h or overnight at 4ºC. Blots were briefly rinsed in PBS and 
washed three times for 10min with PBST. Following a brief wash in PBS the 
membranes were incubated at room temperature for 1h with Horseradish Peroxidase 
(HRP)-conjugated secondary antibodies (Jackson ImmunoResearch) in 5% milk/PBST 
solution and then washed as before. The immunoblots were developed using the 
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chemiluminescent-HRP substrate system (Immobilon Western, Millipore) according to 
the manufacturer’s instructions and analysed using the Fujifilm Image Reader LAS–
3000. 
 
2.3.2.1 Protein quantification 
To determine the relative protein expression, the individual band intensities in the 
immunoblot images were quantified by densitometry using the Advanced Image Data 
Analyser (AIDA) software. The intensity profiles of the proteins of interest were 
normalized to the intensity of -tubulin (loading control) and normalized data was then 
expressed as percent of appropriate control. 
 
2.3.2.2 Antibodies 
The following antibodies were used in this study: mouse monoclonal anti-FLAG (M2, 
Sigma); rat monoclonal anti-HA (3F10, Roche); mouse monoclonal anti-His (Penta-His, 
Qiagen); mouse monoclonal anti-α-tubulin (TAT-1, Cancer Research UK); rabbit 
polyclonal (9405, Cell Signaling Technology; C-19, Santa Cruz) and mouse monoclonal 
anti-N-myc (NCM II 100 and 2, Santa Cruz); rabbit polyclonal anti-Max (C-124, Santa 
Cruz);  mouse monoclonal anti-cyclin D1 (72-13G and A-12, Santa Cruz); mouse 
monoclonal anti-cyclin D3 (D-7, Santa Cruz); mouse monoclonal anti-cyclin E1 (M-20, 
Santa Cruz); mouse monoclonal anti-cdk1 (17, Santa Cruz); rabbit polyclonal anti-cdk2 
(M2, Santa Cruz); mouse monoclonal anti-cdk4 (DCS-35, Santa Cruz); goat polyclonal 
anti-p21 (C-19, Santa Cruz); rabbit monoclonal anti-p27 (C-19, Santa Cruz); rabbit 
polyclonal anti-Phospho-Histone H2A.X (2577, Cell Signaling Technology); rabbit 
polyclonal anti-IKK (2682, Cell Signaling Technology); rabbit polyclonal anti-IKK 
(2684, Cell Signaling Technology); rabbit polyclonal anti-phospho-cyclin D1 (Thr286; 
2921, Cell Signaling Technology); mouse monoclonal cyclin A2 (E23-1, CRUK). For 
immunoblotting studies, primary antibodies were used at 1:500-1:1000 dilution. 
 
2.3.3 Expression and purification of Glutathione-S-Transferase (GST) fusion 
proteins 
The pGEX-KG vector (GE Healthcare) was used to express Glutathione S-Transferase 
(GST) fusion proteins in E. coli strain BL21. E. coli transformants were grown at 37ºC 
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overnight in 20ml cultures of LB/Amp. The cultures were scaled up by addition of 
LB/Amp to a total volume of 100ml and incubated for a further 1h. Expression was 
induced by the addition of 1mM isopropyl-beta-D-thiogalactopyranoside (IPTG; BDH 
Prolabo) and incubation at 37ºC for 4h. The cells were harvested by centrifugation at 
5000rpm and 4ºC for 5min and the pellets resuspended in lysis buffer (0.5% (v/v) 
NP40/20mM Tris-HCl pH8.0/100mM NaCl/1mM EDTA). The cells were lysed by 
sonication on ice and the lysate containing the GST fusion proteins was recovered by 
centrifugation as before. The resulting supernatant was mixed at 4ºC for at least 1h with 
glutathione-Sepharose beads (GE Healthcare) pre-equilibrated with lysis buffer. After 
binding, the beads were washed three times with lysis buffer and the samples were 
stored at -20ºC in 50% (v/v) glycerol. Fusion proteins were analysed by SDS-PAGE 
followed by Coomassie staining. 
 
2.3.3.1 Elution of GST-fused protein 
GST fusion proteins immobilized on glutathione-Sepharose beads were washed twice in 
100mM Tris pH8.0. GST-fused proteins were eluted in two volumes of 20mM reduced 
glutathione (BDH Biochemicals) in 100mM Tris-HCl pH8.0 at room temperature for 
10min, with occasional mixing. The eluted proteins were recovered from the 
supernatant after a brief centrifugation; the procedure was repeated as required to obtain 
adequate amounts of protein. 
 
2.3.4 Expression and purification of poly(Histidine) fusion proteins  
The pRSET-A vector (Invitrogen) was used to express poly(Histidine) fusion proteins in 
E. coli strain BL21. Bacterial culture and induction of protein expression was performed 
as described in section 2.3.3.  The cells were harvested as previously described and the 
pellets were resuspended in lysis buffer (20mM Tris-HCl pH8.0/0.5M NaCl). The cells 
were lysed by sonication on ice and the soluble protein fraction was recovered by 
centrifugation as before. Poly(His) fusions were isolated by incubating at room 
temperature for 30-45min with Chelating Sepharose Fast Flow (GE Healthcare) charged 
with nickel sulphate according to the manufacturer's instructions. The beads were 
washed three times with lysis buffer supplemented with 40mM imidazole. Fusion 
proteins were eluted from the beads with lysis buffer containing 0.5M imidazole for 
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5min followed by a brief centrifugation. The poly(His) fusion proteins present in the 
insoluble fraction were solubilised by incubating the pelleted material at 4ºC overnight 
in lysis buffer supplemented with 5mM imidazole and 6M urea. The insoluble fraction 
was recovered by centrifugation at 5000rpm and 4ºC for 10min and the fusion proteins 
present in the supernatant were isolated as previously described. Fusion proteins were 
analysed as before. 
 
2.3.5 In vitro expression of proteins 
Various proteins, cloned into the mammalian expression vector pcDNA3, were 
synthesized using a eukaryotic in vitro transcription/translation system (TNT Quick 
Coupled Transcription/Translation System, Promega) according to the manufacturer’s 
instructions. Template plasmid DNA (1g) was incubated with the provided Master 
Mix, which includes all of the reaction components (reticulocyte lysate solution, T7 
RNA polymerase, nucleotides, salt and RNase inhibitor) in the presence of 20M 
unlabelled or [
35
S]-labelled methionine. The reaction mixtures were incubated at 30ºC 
for 90min and stored at -20ºC in 50% (v/v) glycerol. 
35
S-radiolabelled products were 
resolved by SDS-PAGE and the gel was fixed in a 10% (v/v) acetic acid/10% (v/v) 
methanol solution for 10min. The gel was dried prior to autoradiography. Non-labelled 
translation products were detected by immunoblotting following SDS-PAGE.  
 
2.4 In vivo studies in mammalian cells 
2.4.1 Growth and maintenance of cell cultures 
Cell cultures were maintained at 37ºC under a humidified 5% CO2 atmosphere. Human 
embryonic kidney HEK293T and osteosarcoma U2OS cells and mouse 3T3 fibroblasts 
(wild-type, IKK-/-, IKK-/- and IKK/ double knockout) were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma) supplemented with 10% (v/v) fetal bovine 
serum (FBS, PAA); 1% Penicillin/Streptomycin (PAA) was also added to the growth 
media of 293T cells. Rat embryo fibroblasts (Rat-1) were grown in DMEM 
supplemented with newborn calf serum (NCS, Sigma). Human neuroblastoma SK-N-
DZ cells, a kind gift from Dr Denise Sheer at ICMS QMUL, London UK, and LAN-1, a 
kind gift from Dr Arturo Sala at UCL, London UK, were cultured in DMEM 
supplemented with 10% FBS and 1% non-essential amino acids (NEAA, Sigma). 
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Human neuroblastoma NB-1643 cells, a kind gift from Dr Peter Houghton at 
Nationwide Children's Hospital, Columbus USA, were cultured in Roswell Park 
Memorial Institute (RPMI, Sigma) supplemented with 10% FBS and 1% NEAA.  
 
2.4.2 DNA transfection of mammalian cells 
2.4.2.1 Lipofectin-mediated transfection 
One day before transfection cells were seeded at the confluence recommended by the 
manufacturer. 5g of DNA and 2-20l of Lipofectin reagent (Invitrogen) were 
separately added to 100l of serum-free DMEM and incubated at room temperature for 
30-45min. The reactions were combined and incubated for 10-15min as before. After 
washing the cells with DMEM the DNA/lipofectin solution was mixed with 0.8-1.8ml 
of DMEM and added to the cells. After 24h the media was replaced by normal growth 
medium; when appropriate, antibiotic selection was initiated a day later or the cells were 
collected for analysis. 
 
2.4.3 Establishment of stable cell lines 
Rat-1 cells were transfected with pBabepuro vector carrying FLAG-tagged mouse Mycn 
cDNA or empty vector and stable polyclonal cell populations were selected in 1-
10g/ml puromycin (Calbiochem). A stable polyclonal population of Rat-1 cells 
transfected with pBabepuro vector carrying FLAG-tagged mouse Mycn cDNA bearing a 
mutation (AG) at nucleotide position 172 resulting in a threonine-to-alanine amino 
acid change at residue 58 was selected in the same manner. Rat-1/pBabe and Rat-1/N-
myc cells were co-transfected with pCMVLacI vector and pOPRSVIMCS or 
pOPRSVICAT vector carrying HA-tagged human p21 or p27 cDNA, respectively. 
Stable clonal cell populations of Rat-1/pBabe/p21 and p27 and Rat-1/N-myc/p21 and 
p27 were selected in the presence of 300g/ml G418 Sulphate (Calbiochem) and 
150μg/ml hygromycin B (Calbiochem). Rat-1 cells were transfected with pcDNA3 
vector carrying FLAG-tagged mouse Mycn cDNA variants N-myc del63, del124, 
del177 or N-myc 1-370 and stable polyclonal cell populations were selected in 
300g/ml G418. 
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2.4.4 Fluorescent activated flow cytometry analysis 
2.4.4.1 Cell cycle synchronization and Propidium Iodide (PI) staining 
For M-phase arrest, Rat-1 cells were incubated for 18h with 0.21M nocodazole 
(Sigma). Following treatment, the cells were thoroughly washed with PBS and 
incubated with normal growth media. For flow cytometry analysis, cells were harvested 
from adherent cultures at the indicated time points by trypsinization followed by 
centrifugation at 1000rpm and 4ºC for 5min; when appropriate, floating dead cells were 
collected from culture media in the same manner. After washing with PBS and spinning 
as before, the cells were fixed in 70% (v/v) ethanol in PBS at 4ºC for at least 1h. Fixed 
cells were collected by centrifugation at 2500rpm for 3min and washed with PBS. After 
centrifuging as before the cells were ressuspended in 50g/ml PI (Calbiochem) in PBS 
for nucleic acids staining and treated with 100g/ml RNase. Cell cycle analyses were 
carried out on a FACSCalibur flow cytometer (BD Biosciences) using the laser 
excitation at 488nm. 10,000 events per sample were acquired using appropriate gates. 
Briefly, main cell populations were gated by forward light scatter versus side light 
scatter dual parameter plot; cell aggregates and debris were omitted by dot plotting the 
PI fluorescence pulse width (FL2-W) and area (FL2-A). When appropriate, cells with 
fragmented DNA that might be undergoing cell death were included in the analysis. 
Otherwise, cell cycle analysis was carried out on the live singlets gate using the FlowJo 
software (Tree Star) as exemplified in appendix IA; quantification of the percentage of 
cells with a DNA content below 2N (sub-G1, gated to the total number of cells) is 
exemplified in appendix IB.  
 
2.4.4.2 Bromodeoxyuridine (BrdU) incorporation assay 
For BrdU incorporation, cells were incubated for 30min with 10M BrdU (GE 
Healthcare) before harvesting and fixating as described above. Fixed cells were 
collected by centrifugation and washed with PBS as above; after centrifugation cells 
were ressuspended in 2M HCl/0.5% (v/v) Triton X-100 and incubated at room 
temperature for 30min. Cells were collected by centrifugation, washed in 1ml of 
neutralising solution (0.1M Tris pH8.5) and collected once more before addition of 1ml 
blocking solution (1% (w/v) BSA/0.5% (v/v) Tween 20 in PBS). Following 
centrifugation, cells were ressuspended directly in 20l FITC-conjugated anti-BrdU 
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antibody (347583, BD Biosciences) and incubated at room temperature for at least 
30min. Cells were then washed with blocking solution and centrifuged before 
performing PI staining as described above. Cell cycle profiles were analysed by plotting 
FI TC-fluorescence against PI fluorescence using the FlowJo software. BrdU positive 
cells were scored as the population of cells with FITC-fluorescence higher than that of 
the G1 or G2/M population. 
 
2.4.5 Immunofluorescence Microscopy 
For microscopy studies cells were seeded onto plates containing 10mm coverslips. Cell 
fixation was carried out in 4% (v/v) formaldehyde in PBS for 10min followed by three 
washes with PBS. Cells were permeabilised in ice-cold methanol for 10min, washed as 
before and blocked in 5% (w/v) bovine serum albumin (BSA) in PBS for 45-60min. 
After washing with PBS the coverslips were incubated with primary antibody (1:1000 
dilution) in PBS for 1h. Coverslips were washed as before and incubated with the Alexa 
Fluor-conjugated secondary antibody (Invitrogen; 1:3000 dilution) in PBS for 45min. 
After washing as before, the coverslips were mounted onto glass slides in a mountant 
solution (10% mowiol solution in 25% glycerol/100mM Tris-HCl pH8.5/1mg/ml DAPI, 
and 2.5% (w/v) DABCO). The preparations were examined on a Zeiss Axiovert 200M 
inverted microscope and the images were captured using the Axiocam software. For 
quantitation of the immunofluorescence in the Rat-1/N-myc cell population, 150–200 
cells in several random fields on each of three slides were scored for the presence of 
FLAG-N-myc in the nucleus. 
 
2.4.6 DNA damaging treatments 
For treatment with DNA damaging agents cells were plated in normal growth media 
24h before use. Cells were exposed to ultraviolet C (UVC) radiation (256nm) using a 
UVP CX-2000 Crosslinker, or ionizing radiation (-rays) delivered by a sealed 
Caesium-137 source (Gammacell 3000, MDS Nordion). For treatment with chemical 
agents (4-NQO, etoposide, cisplatin and H2O2), stock solutions were added to the 
culture medium for 30min, after which the cells were washed with PBS and fresh 
growth media was added. 
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2.5 In vitro analysis of protein interaction 
2.5.1 Binding assays 
GST or poly(His) fusion proteins bound to GSH-Sepharose or Ni-NTA beads, 
respectively, were incubated with in vitro-synthesized proteins in the respective lysis 
buffer (see sections 2.3.3 and 2.3.4 for details). Alternatively, poly(His) fusion proteins 
bound to Ni-NTA beads, were incubated with eluted GST fusion proteins. The mixtures 
were incubated at room temperature for 90min with occasional mixing. The beads were 
then washed three times with lysis buffer to remove unbound protein and the remaining 
bound proteins were separated by SDS-PAGE and detected by autoradiography or 
immunoblotting. 
 
2.5.2 Immunoprecipitation (IP) assay 
Cells were transiently transfected with
 
expression constructs encoding untagged, FLAG 
and/or HA-tagged proteins. The cells were scraped 48 hours after transfection using 1ml 
of PBS and harvested by centrifugation at 1500rpm and 4ºC for 5min. Alternatively, 
untransfected cells were cultured for analysis of endogenous proteins and harvested as 
described. The cells were ressuspended in 500l of lysis buffer (0.5% (v/v) 
NP40/20mM Tris-HCl pH8.0/250mM NaCl/1mM EDTA) and incubated on ice for 
30min with occasional vortex. Following centrifugation at 13000rpm and 4ºC for 5min, 
an aliquot of the cell lysate was separated for analysis of expression and the remaining 
volume was incubated with 0.5g of antibody raised against the appropriate epitope and 
20l of G-Sepharose beads (GE Healthcare) pre-equilibrated with lysis buffer. The 
samples were incubated with mixing at 4ºC for 2.5h. The beads were thoroughly 
washed in lysis buffer and ressuspended in SDS-PAGE loading buffer. The proteins 
were resolved by electrophoresis and detected by immunoblotting. 
 
2.6 Statistical analysis 
Experimental data is expressed as mean ± standard deviation calculated from three 
independent experiments. Statistical analysis was carried out by Student’s t test; a p 
value of <0.05 was considered statistically signiﬁcant. 
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Table 3 – cDNAs generated by PCR 
 
 
Primers notes: forward and reverse primer sequence indicated on top and below, 
respectively; mut, primers carrying the mutated codon; mutated codon is indicated in 
bold letters; linker sequences containing restriction sites for cloning are designated in 
lowercase letters. 
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Table 4 – List of constructs used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 Original construct by D. Mann, unpublished data  
2
 Original construct by L. Elphick, unpublished data 
3
 The carboxyl (C)-terminally truncated form of N-myc was generated by digesting the 
full-length cDNA with BamHI and SpeI, an internal restriction site at nucleotide 
position 661 (see appendix for details) 
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Table 4 – List of constructs used in this study (cont.) 
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CHAPTER 3 - INTERACTION BETWEEN N-MYC AND p21 
 
3.1. Introduction 
MYCN-amplified (MNA) neuroblastoma (NB) cell lines carrying wild type p53 fail to 
undergo G1 arrest following IR exposure, despite induction of the p53 target gene p21 
(McKenzie et al., 1999, Tweddle et al., 2001a, Tweddle et al., 2001b). McKenzie and 
colleagues suggested that lack of G1 arrest after DNA damage could be linked to 
an inability of p21 to bind Cdk2 complexes in NB cells, an essential event in the DNA 
damage response that prevents entry into S phase (Brugarolas et al., 1999, McKenzie et 
al., 2003). More recently, Bell and colleagues demonstrated that an attenuated induction 
of p21 might be responsible for the altered G1 checkpoint exhibited by irradiated MNA-
NB cells but it remains unclear how N-myc contributes to this phenotype (Bell et al., 
2006, Bell et al., 2007). Kitaura and colleagues identified and characterized a direct 
interaction between the transcription factor c-Myc and p21 (Kitaura et al., 2000). 
Binding of p21 to the Myc Box II (MBII) domain of c-Myc prevented its association 
with Max and the transcriptional activation of target genes. In turn, binding of c-Myc to 
the C-terminal region of p21 blocked the inhibitory interaction between p21 and PCNA 
thereby promoting DNA replication. The N-myc protein is closely related to c-Myc, 
both at the sequence and functional levels and common interaction partners have been 
described such as TRRAP and Miz-1 (Kohl et al., 1986, Peukert et al., 1997, McMahon 
et al., 1998, Malynn et al., 2000, Nikiforov et al., 2002, Zhang et al., 2006). 
 
This chapter describes the attempts to establish and characterize a novel interaction 
between N-myc and p21 as a mechanism by which the suppressive effect of p21 on cell 
proliferation could be physically attenuated in MNA-NB cells. 
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3.2 Results 
In order to investigate a possible association between N-myc and p21 analogous to the 
c-Myc/p21 interaction, several cDNA constructs were generated and used as described 
(Materials and Methods) for expression of heterologous proteins in different hosts, such 
as bacterial and mammalian cells, as well as cell-free protein synthesis. The 
identification of the N-myc domain(s) required for the putative interaction was 
performed simultaneously, as it could provide insight into the role of an interaction. 
Figure 3.1 schematically represents the proteins analysed in this study. The amino (N) 
terminal region of the Myc proteins is essential for the interaction with a wide variety of 
proteins (Sakamuro and Prendergast, 1999). To understand its relevance in a putative 
interaction with p21, different N-terminally truncated mutants of N-myc were expressed 
lacking: amino acids 1-63 (N-myc del63), a region encompassing the MBI domain; 1-
124 (N-myc del124), a region encompassing the MBI and MBII domains; and 1-177 
(N-myc del177). The mutants N-myc 1-124, which is restricted to the region 
encompassing MBI and MBII, and N-myc 1-220, 1-320 and 1-370, lacking regions that 
include the BRHLHZip domain, were later generated to address the observations made 
during this study. c-Myc and Max were included in the studies as controls when 
appropriate. 
 
3.2.1 In vitro binding assays 
Expression of GST fusion proteins was achieved by IPTG induction of E. coli 
transformants carrying mouse Mycn cDNA constructs cloned into the pGEX vector 
(Smith and Johnson, 1988). Recombinant N-myc proteins were isolated by affinity 
chromatography using GSH-Sepharose and analysed by SDS-PAGE followed by 
Coomassie staining (Figure 3.2A). Bacterial expression of N-myc fusion proteins 
yielded rather low amounts of products of the calculated molecular weight in all extracts 
(see figure). To determine the nature of the co-purified products, the samples were 
analysed by SDS-PAGE followed by immunoblotting using antibodies raised against 
the N- or the C-terminal region of N-myc as well as an antibody against GST. The latter 
showed a pattern of bands similar to that observed by gel staining indicating that the co-
purified proteins carry the GST tag and do not arise from unspecific binding to the 
beads (Figure 3.2B, top panel; compare to Figure 3.2A). Immunoblotting using an 
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antibody directed against the N-terminal region of N-myc only detected products in the 
sample for full-length N-myc (Figure 3.2B, middle panel) in agreement with the 
analysis that mapped the epitope of this antibody to the region that spans the MBI and 
MBII domains (see Figure 3.4). The band pattern observed was comparable to the GST 
immunoblot except the N-terminus antibody was practically unable to detect proteins 
exhibiting molecular weights lower than 37kDa, approximately, suggesting these 
products lack N-myc regions spanning the MBI and MBII domain. A distinct pattern 
was observed with the antibody directed against the C-terminus of N-myc: the GST-
fused proteins carrying the expected molecular weight were predominantly present in all 
samples with few additional bands detected. Thus, it appears that expression and 
purification of GST-fused N-myc resulted in isolation of significant amounts of 
truncated products with distinct C-terminus. 
 
The co-purification of cleavage products together with the expected fusion proteins 
makes the quantification of input protein difficult and interferes with the assessment of 
their binding ability to potential partner proteins in pull-down assays. To circumvent 
this problem, GST-fused N-myc proteins were eluted from GSH-Sepharose as described 
(Materials and Methods) and tested for their ability to bind immobilised p21 in vitro. 
The ability of the fusion proteins to interact with the Max protein was assayed in vitro 
prior to elution. For this purpose, the human cDNA sequence of Max was introduced 
into the pcDNA3 vector which was used to direct in vitro transcription/translation in the 
presence of 
35
S-labelled methionine. Equivalent amounts of the different GST fusion 
proteins immobilised on glutathione beads were incubated with radiolabelled Max 
protein as described (Materials and Methods). GST-fused N-myc 1-124 was also 
employed as a negative control for Max binding since it lacks the HLHZip domain. 
After washing, the bound proteins were separated by SDS-PAGE and detected by 
autoradiography. As shown in Figure 3.2C, all N-myc variants analysed except N-myc 
1-124 were able to bind Max in agreement with the reported requirement for an intact 
HLHZip domain for Myc/Max dimerization but not other regions of the protein 
(Blackwood and Eisenman, 1991, Wenzel et al., 1991). This observation demonstrates 
that N-myc GST fusions can interact specifically in vitro and suggests that partial 
deletions in the N-terminal region of the protein do not prevent proper folding of its C-
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terminus and therefore do not abolish association with other proteins, as shown with 
Max. It cannot be excluded, however, that the inverse is not true and that C-terminal 
deletions impair or abolish associations involving the N-terminus of N-myc. 
 
Human p21, previously cloned into the pRSET-A vector, was then expressed in E. coli 
as a poly(His) fusion protein and isolated by binding to nickel-charged Sepharose beads. 
The presence of the purified protein was confirmed by immunoblotting using anti-His 
antibody (Figure 3.3A). Equivalent amounts of immobilised His-tagged p21 were 
incubated with the eluted GST-fusion proteins to test their binding ability in vitro. After 
washing, the bound proteins were detected by immunoblotting. Full-length and N-
terminal N-myc mutants were detected using the C-terminal antibody to detect 
exclusively the products of the calculated molecular weight. The levels of input p21 
protein were also analysed by immunoblotting against the His-tag.  
 
As shown in Figure 3.3B, no binding was detected between the N-myc proteins and the 
Ni-Sepharose beads used as a negative control. Both full-length and N-terminal N-myc 
mutants efficiently associated with His-p21 indicating N-myc can associate with p21 in 
vitro and suggesting the region involved in the interaction is located downstream of 
residue 177. Additionally, the immunoblot analysed in Figure 3.3B was re-probed using 
a GST antibody in order to investigate whether the cleavage products present in these 
samples were also able to associate with p21. Although these products were clearly 
detected in the input samples, they failed to interact with His-p21 (Figure 3.3C), further 
suggesting a requirement for the C-terminal region of N-myc in the interaction. The 
binding ability of the N-myc mutants towards p21was determined in relation to the full-
length protein by quantifying the levels of bound protein using the AIDA software and 
normalising against the respective input levels. The three mutant proteins analysed were 
able to bind 3-4 times more p21 than the wild-type protein (Figure 3.3E).  
 
In order to define more precisely the region of N-myc required for the interaction with 
p21, the N-myc truncation mutants 1-124, 1-220, 1-320 and 1-370 were generated. 
Given the N-myc truncated products obtained with the bacterial expression constructs, 
an alternative expression system was used: N-myc proteins were synthesized using in 
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vitro transcription/translation. For this purpose, the mouse (N-myc) or human (c-Myc) 
cDNA sequences of all the proteins schematically represented in Figure 3.1 were 
introduced into the pcDNA3 vector downstream of a FLAG epitope. Protein products 
were detected by immunoblotting using antibodies raised against the FLAG epitope, 
and the C- or the N-terminus region of N-myc (Figure 3.4).  
 
As shown in Figure 3.4A, all proteins were detected by immunoblotting against FLAG; 
c-Myc was not recognized by either antibody directed against the C- or N-terminus of 
N-myc whereas full-length N-myc was detected by both antibodies as expected, 
indicating that this expression system does not give rise to widespread truncations and 
the expected proteins are therefore the predominant product in the samples. The N-myc 
antibody raised against the C-terminus of the protein, failed to detect the deletion 
mutant N-myc 1-370, or mutants carrying broader deletions within this region (Figure 
3.4B), indicating that its recognition site is likely located close to or within the 
BRHLHZip domain. The antibody raised against the N-terminus of the protein, on the 
other hand, detected poorly the N-myc mutants del63 and 1-124 (observable after long 
exposure of the immunoblot, Figure 3.4D), and failed to detect the del124 and del177 
mutants. The remaining mutants were efficiently detected.  
 
Human p21, cloned into the pGEX-KG vector, was expressed in E. coli as a 
recombinant GST-fusion protein and isolated by binding to GSH-Sepharose. This 
system was employed instead of the poly(His) fusion system as it allows expression of 
GST protein alone which provides a control for nonspecific binding to the beads and the 
tag moiety as well. Both products were analysed by SDS-PAGE followed by Coomassie 
staining (Figure 3.5A). The ability of p21 to interact with the various Myc proteins was 
tested in an in vitro assay as before. Equivalent amounts of immobilised GST-tagged 
p21 and GST protein were incubated with the in vitro expressed Myc proteins. Figure 
3.5B shows the immunoblotting analysis of bound proteins using anti-FLAG antibody. 
Little binding was detected between the Myc proteins and the GST protein alone. Full-
length N-myc and c-Myc appear to interact with p21 with similar efficiencies. Among 
the N-myc deletion mutants tested, those truncated within the C-terminal region failed 
to associate with p21, whereas deletions in the N-terminus of N-myc did not affect 
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binding to p21. These observations suggest that the interaction region of N-myc with 
p21 is located between amino acids 371 and 462 of N-myc, likely involving the 
BRHLHZip domain (residues 379-452) which is required for binding to the promoter 
region of target genes (BR motif) and associating with the Max (HLHZip motif). The 
amount of N-myc mutants bound to p21 was determined as before and compared to the 
full-length protein. All three N-myc mutants appear to bind more p21 in vitro than the 
wild-type protein (Figure 3.5C).  
 
3.2.2 Co-immunoprecipitation (IP) assays 
The interaction between N-myc and p21 was then studied through immunoprecipitation 
of the endogenous proteins from human NB SK-N-DZ cells (amplified MYCN, wild-
type p53) (Zaizen et al., 1993). Given that these cells exhibit upregulation of p21 
following IR irradiation (section 5.2.1, Figure 5.1) and high expression levels of p21 
could favour the observation of a putative N-myc/p21 association, both untreated and 
IR-treated cells were assayed. In light of the different responses observed for N-myc 
and p21 in SK-N-DZ cells exposed to IR and UVC radiation (see figure), it was also of 
interest to investigate the association in UVC-exposed cells. For this purpose, SK-N-DZ 
cells were cultured in normal growth media and either left untreated or exposed to 5Gy 
IR or 25J/m
2
 UVC. Cellular extracts were collected 3h following irradiation and 
subjected to immunoprecipitation using antibodies against N-myc or p21; the levels of 
the housekeeping protein α-tubulin were also assessed as a loading control. Whole cell 
lysates and immunoprecipitates were resolved by SDS-PAGE and analysed by 
immunoblotting against the indicated proteins (Figure 3.6).  
 
N-myc and p21 were both efficiently immunoprecipitated using the respective 
antibodies. However, neither p21 nor N-myc was present in the precipitates using anti-
N-myc or anti-p21 antibodies, respectively, and exposure of cells to IR or UVC prior to 
precipitation did not produce any observable changes in this regard. To confirm the 
ability of the assay to precipitate protein complexes through p21 and N-myc, the 
immunoblots presented in Figure 3.6A were additionally probed for the presence of the 
Myc-associated factor X, Max, and the p21 inhibitory target, Cdk2 (Wenzel et al., 1991, 
Harper et al., 1993). Max and cdk2 were specifically detected in the N-myc and p21 
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precipitates, respectively. IR and UVC irradiation resulted as before in accumulation or 
reduction of p21, respectively; the amount of protein precipitated varied accordingly. 
Although the levels of cdk2 were not affected by IR treatment, a greater proportion was 
co-precipitated through p21 in these cells. Two proteins of smaller molecular weight 
(indicated by arrowheads) were found to immunoprecipitate with the N-myc antibody in 
lysates obtained from both irradiated and non-irradiated SK-N-DZ cells (see figure). 
Proteins of identical molecular weights were also observed in N-myc and Max (Figures 
3.7-3.9) precipitates in subsequent assays using SK-N-DZ, NB-1643 and HEK293T 
cells (see below). Section 3.2.3 describes the studies carried out to identify and 
characterize these proteins.  
 
In their report, McKenzie and colleagues observed a limited association between cdk2 
and p21 following adenoviral-mediated overexpression of p21 in the NB-1643 
neuroblastoma cell line (amplified MYCN, wild-type p53), that was linked to a lack of 
G1 arrest (McKenzie et al., 2003). To investigate whether an N-myc/p21 interaction 
could be detected in this cellular context and elucidate these observations, the IP assay 
was performed using these cells. Unlike the mentioned study, however, this experiment 
examined the properties of endogenous p21. Cells were exposed to 5Gy IR or 25J/m
2
 
UVC 3h prior to immunoprecipitation of the lysates with N-myc or p21 antibodies, and 
the precipitates were analysed as before. As can be observed in Figure 3.7, these 
radiation doses elicited molecular responses equivalent to those observed for the SK-N-
DZ cell line: the levels of p21 were increased by treatment with IR and decreased in 
cells exposed to UVC. The amount of immunoprecipitated p21 varied according to 
changes in cellular levels and as above, the amount of co-precipitated cdk2 strongly 
increased in IR-treated cells demonstrating that endogenous p21 is able to associate 
with cdk2 in this cell line. Despite efficient immunoprecipitation of N-myc and p21, and 
respective co-precipitation of Max and cdk2, the results fail to show an association 
between the two proteins, as N-myc was not detected in the p21 immunoprecipitates or 
vice versa. 
 
The efficient immunoprecipitation of endogenous proteins requires, foremost, that the 
epitope on the target protein be exposed and thereby accessible to the antibody. 
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Additionally, binding of the antibody to a protein can prevent its association with other 
proteins. The antibodies used in this study effectively precipitated both p21 and N-myc 
(Figures 3.6-7). It is conceivable, however, that, as a complex, neither protein is 
recognized by their respective antibodies. The results from the in vitro binding 
experiments (section 3.2.1) demonstrated the requirement for the C-terminal region of 
N-myc for the interaction with p21, which coincides with the recognition site of the N-
myc antibody used in the IP assays (amino acids 327-339). Furthermore, the p21 
antibody used recognizes the C-terminus of the protein, a region distinct from the cdk-
binding motif of p21, which is located at the amino terminus, but overlapping the 
domain involved in the interaction with c-Myc (Chen et al., 1995a, Kitaura et al., 2000). 
 
In an attempt to address this possible limitation, SK-N-DZ and NB-1643 cells were 
transiently transfected with a pcDNA3 construct directing the expression of 
Hemagglutinin (HA)-tagged human p21 (Field et al., 1988). The human Max cDNA 
was similarly cloned for use as a control. Transfection was carried out as described 
(Materials and Methods) and the cell lysates were subjected to immunoprecipitation 48h 
later using anti-HA antibody; precipitated proteins were analysed as before (Figure 3.8). 
p21 and Max were expressed with similar efficiencies in the two cell lines, albeit at 
lower levels in NB-1643 cells, and as a result comparable amounts of p21 and Max 
were immunoprecipitated in the two lines. N-myc, however, was only co-precipitated in 
cells expressing HA-Max but not HA-p21. 
 
Expression of exogenous proteins for the purpose of immunoprecipitation was also 
tested in human HEK293T cells transiently transfected with pcDNA3 constructs 
expressing HA-tagged human p21 or Max, either alone or in combination with a 
construct expressing mouse N-myc. Cell lysates were subjected to immunoprecipitation 
48h later using anti-HA antibody; precipitated proteins were analysed as before (Figure 
3.9). All proteins were expressed at good levels and both p21 and Max were efficiently 
precipitated through the HA tag. N-myc was strongly present in the Max precipitates 
but was undetected in the p21 precipitates. 
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3.2.3 Short forms of N-myc 
The immunoblotting analysis carried out following immunoprecipitation of endogenous 
N-myc from MNA-NB cellular lysates consistently detected two proteins of smaller 
molecular weights (~40/50kDa approximately), in addition to the N-myc protein of the 
calculated molecular size (Figures 3.6-7). For the IP assays, immunoblotting of N-myc 
was invariably performed using a polyclonal antibody raised against its C-terminal 
region (Figure 3.4), whereas protein immunoprecipitation was performed using a 
monoclonal antibody that recognizes residues 327-339 of N-myc. Importantly, the same 
proteins were also co-precipitated with Max in two NB cell lines suggesting these cells 
express polypeptides that differ significantly from N-myc in molecular weight but carry 
a region sharing a common epitope at the C-terminus of the protein (Figure 3.8). 
Moreover, transfection of HEK293T cells with a construct carrying the complete mouse 
Mycn cDNA expressed two polypeptides with similar electrophoretic motilities to the 
endogenous proteins; the two polypeptides also co-precipitated with Max indicating the 
presence of an intact HLHZip domain (Figure 3.9). 
 
To determine if the two polypeptides are exclusively detected in MNA-NB cells but not 
cell lineages which do not express N-myc, whole cell lysates of HeLa (human cervical 
carcinoma), HEK293T (human embryonic kidney) and NIH3T3 (mouse fibroblasts) 
cells were analysed by immunoblotting (Kohl et al., 1984, Malynn et al., 1995, Chayka 
et al., 2009). SK-N-DZ, LAN-1 and NB-1643 human MNA-NB cell lysates were 
analysed in parallel using the previously characterized antibody raised against the N-
terminus of N-myc and an antibody whose epitope maps to residues surrounding lysine 
351 within the C-terminus. As can be observed in Figure 3.10, N-myc (60-65kDa band) 
was detected in NB cells using the two antibodies specific for this protein. The two 
polypeptides of lower molecular weights (indicated by arrowheads) were also detected 
using the C-terminus antibody but failed to be detected by the N-terminus antibody. N-
myc and the additional polypeptides were not detected in the non-NB cell lines analysed 
using either antibody indicating expression of the short polypeptides is restricted to NB 
cells similar to N-myc. Together with the data obtained in the immunoprecipitation 
studies, these observations suggest MNA-NB cells express two polypeptides that share 
an epitope found in the C-terminus region of N-myc, including the HLHZip domain 
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(amino acids 396-455 in human N-myc) since they efficiently associated with Max. 
These polypeptides lack however, the N-terminus region of N-myc; considering the 
mapping analysis performed for the N-terminus antibody, the region missing could span 
approximately residues 1-124.  
 
The expression of a splice form of the MYCN transcript has been reported (van 
Bokhoven et al., 2005, Jacobs et al., 2009). However, as described above, introduction 
of the N-myc cDNA into cells gave rise to two polypeptides with molecular weights 
approximate to the endogenous proteins suggesting the latter may not arise through 
alternative mRNA splicing. Shorter forms of the c-Myc protein (c-MycS) have been 
described; these isoforms result from translational initiation at downstream start (AUG) 
codons in the MYC mRNA (Spotts et al., 1997). The two full-length human N-myc 
proteins (464 and 456 amino acids) also arise from translation at alternative start sites 
(Mäkelä et al., 1989). Analysis of the coding sequence of human N-myc revealed the 
presence of three in-frame start codons at the 5’ end, corresponding to internal 
methionines at residues 12, 81 and 116 in the protein (see appendix V) (Stanton et al., 
1986). In order to investigate if translational initiation at these start sites could originate 
products exhibiting similar electrophoretic motilities to the endogenous polypeptides, 
the N-terminally truncated variants hN-myc del80 and del115 were generated using 
human N-myc cDNA. Initiation of translation at Met12 would be expected to give rise 
to a protein similar in molecular weight to the full-length N-myc and this residue was 
therefore not examined. 
 
Full-length and truncated human N-myc sequences were introduced into the pcDNA3 
vector and expressed using in vitro transcription/translation. Protein extracts were 
analysed by immunoblotting as before alongside lysates from NB cell lines. As shown 
in Figure 3.11A, in vitro expressed full-length protein and the two mutants exhibited 
molecular weights that closely resembled endogenous N-myc and smaller proteins, 
respectively, suggesting the latter could be truncated forms of N-myc lacking those 
regions investigated. Low-percentage SDS-PAGE separation of the cellular extracts 
produced multiple bands of full-length N-myc (indicated by an asterisk). To determine 
if the slower migrating bands corresponded to N-myc proteins carrying post-
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transcriptional phosphorylations, SK-N-DZ and LAN-1 cellular lysates were treated 
with alkaline phosphatase and analysed as before. The treatment suppressed expression 
of the bands exhibiting higher molecular weights demonstrating these constituted 
phosphorylated forms of the full-length proteins and not additional isoforms (Figure 
3.11B). To determine if the human N-myc cDNA could direct cellular expression of the 
two short variants by alternative translation initiation, as observed for the mouse 
sequence, HEK293T cells were transiently transfected with the construct described 
above and cellular lysates were analysed as before. The constructs encoding hN-myc 
del80 and del115 were also employed for reference. As can be observed in Figure 
3.11C, two polypeptides exhibiting electrophoretic motilities similar to hN-myc del80 
and del115 were detected in cells transfected with the complete N-myc sequence. 
Transfection with the hN-myc del80 sequence appeared to result in expression of both 
hN-myc del80 and del115 suggesting translation initiation occurred concurrently from 
positions 81 and 116 in these cells. Together, these observations suggest MNA-NB cells 
express short variants of N-myc protein with distinct N-terminal regions that may result 
from translation initiation at downstream start codons. 
 
3.2.3.1 IP assays 
The in vitro binding assays showed a stronger association between the N-terminally 
truncated forms of N-myc compared to the full-length protein (Figures 3.3 and 3.5). 
Given that N-terminally deleted N-myc variants may occur naturally in MNA-NB cells 
it was of interest to investigate if, in contrast to wild-type N-myc, an interaction 
between the N-terminal mutants employed in section 3.2.2 and p21 could be observed 
by immunoprecipitation. For this purpose, HEK293T cells were transiently transfected 
with a pcDNA3 construct expressing human p21, alone or in combination with 
constructs expressing different HA-tagged mouse N-myc variants or human Cdk2. Cell 
lysates were subjected to immunoprecipitation 48h later using anti-HA antibody and 
precipitated proteins were analysed as before (Figure 3.12). Although Cdk2 was 
expressed and precipitated at lower levels than the remaining HA-tagged proteins, p21 
was nevertheless successfully precipitated through it, thus providing a positive control. 
Endogenous Max was detected by re-probing the IP immunoblot and was clearly 
associated with full-length N-myc and both N-terminally truncated mutants under 
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analysis. The assay failed to detect p21 in the precipitates from both N-myc, as 
previously observed, and N-myc del63. Notably, p21 was found to interact with the N-
myc mutant lacking amino acids 1-124. The association was weaker than that observed 
between p21 and Cdk2, considering the precipitated amount of the HA-tagged proteins, 
but it was nevertheless readily detected.  
 
The analysis was then further extended to include the C-terminally truncated N-myc 
mutant, N-myc 1-370, and c-Myc. As before, HEK293T cells were transiently 
transfected to express human p21, alone or simultaneously with different HA-tagged 
mouse N-myc variants, human c-Myc or human Cdk2. Cell lysates were subjected to 
immunoprecipitation 48h later using anti-HA antibody; precipitated proteins were 
analysed as before. As can be observed in Figure 3.13, cdk2 and c-Myc were transfected 
at rather low efficiencies, compared to the remaining proteins, and the former was in 
fact almost undetectable in the whole cell lysates (input) and weakly detected in the 
precipitate; p21 was nevertheless readily detected in the cdk2 precipitate. p21 was also 
present in the c-Myc precipitate, supporting a previous observation of the c-Myc/p21 
association (Kitaura et al., 2000). Among the N-myc variants, p21 was only precipitated 
through N-myc del124. This N-terminal deletion appears to destabilize the C-terminal 
region of N-myc as evidenced by the detection and immunoprecipitation of smaller 
products that have retained the HA epitope. All Myc proteins were found to associate 
with endogenous Max except N-myc 1-370 which lacks the HLHZip domain required 
for this interaction. 
 
3.3 Discussion 
This chapter describes the studies undertaken to identify and characterize a putative 
interaction between N-myc and p21. In vitro pull-down assays were initially carried out 
using heterologous fusion proteins expressed in E. coli; GST-fused N-myc has been 
widely used to characterize interactions through the N- or C-terminus of the protein and 
was therefore employed (Gross-Mesilaty et al., 1998, Sjostrom et al., 2005, Liu et al., 
2007, Zhao et al., 2008). Importantly, the N-myc variants were able to bind Max (Figure 
3.2C) demonstrating the integrity of the C-terminal region where the HLHZip domain 
required for this interaction lies (Wenzel et al., 1991). Expression and purification of 
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recombinant N-myc proteins yielded predominantly proteins of smaller molecular 
weight than predicted due to C-terminal deletions (Figures 3.2A and 3.2C). Protease 
inhibitors were not employed and it is therefore possible that these by-products arose 
from protein cleavage during either expression or purification of the fusion proteins. 
The presence of a number of rare codons in the mouse Mycn cDNA may have also 
impaired protein expression by generating translational problems, as previously 
described (Robinson et al., 1984, DePinho et al., 1986, Kurland and Gallant, 1996, 
Nakamura et al., 2000). 
 
Elution of GST-fused N-myc proteins from GSH-Sepharose allowed specific detection 
of the full-length N-myc variants by immunoblotting against the C-terminus thus 
minimizing interference by the truncated proteins in assessing binding to p21. Pull-
down assays using eluted proteins and immobilised His-tagged p21 indicated the two 
proteins are able to bind in vitro with no apparent requirement for the N-terminus 
(Figure 3.3). These observations were then confirmed through a distinct pull-down 
assay using in vitro expressed Myc proteins and GST-fused p21 (Figure 3.5). The 
results suggested N-myc binds p21 through the BRHLHZip domain. The strength of 
interaction of the N-terminal N-myc mutants was reproducibly higher than that of the 
full-length protein. Studies on the isolated transactivation domain of c-Myc (amino 
acids 1-143 of human protein) encompassing the MBI and MBII domains has shown it 
to be mostly unstructured in solution (McEwan et al., 1996, Flinn et al., 1998, Fladvad 
et al., 2005). Secondary structure is induced by interaction with target factors and 
promotes protein folding and stronger associations (Hermann et al., 2001, Ferreira et al., 
2005). This mechanism of cofactor recruitment is thought to allow for specific 
interactions to occur with a wide variety of structurally distinct target. The BRHLHZip 
domain however, exhibits a prestructured form in solution, particularly the Zip domain, 
likely to promote rapid and specific binding to its primary partner Max (Fieber et al., 
2001). Thus, it is possible that full-length N-myc and N-terminal mutants will exhibit 
distinct overall conformations in vitro that may explain the differences observed in the 
ability to bind p21 and most importantly, Max. 
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Consistent with previous reports, IR exposure resulted in accumulation of p21 in MNA-
NB cells, SK-N-DZ and NB-1643 (Figures 3.6A and 3.7, respectively) (Canman et al., 
1994, El-Deiry et al., 1994, Goldman et al., 1996). The classic IR-induced G1 arrest is 
thought to be attenuated in MNA-NB cells due to weak upregulation of p21 in response 
to this genotoxic agent (McKenzie et al., 1999, Bell et al., 2006, Bell et al., 2007). p21 
blocks G1 progression by direct inhibition of cdk2 thus promoting the 
 repressive effect of pRb on E2F-mediated transcription required for entry into S phase 
(Waldman et al., 1995, Brugarolas et al., 1999). Although the levels of cdk2 were not 
affected in IR-treated cells, upregulation of p21 led to an increase in the amount of co-
precipitated cdk2 suggesting a greater fraction of the cdk2 cellular pool is associated 
with p21 following irradiation and likely inhibited as a consequence. These results 
demonstrate that p21 is functional in these cells and challenges the observations by 
McKenzie and colleagues of impaired binding between p21 and cdk2 in the NB-1643 
cell line which was responsible for lack of G1 arrest. Treatment of both cell lines with 
UVC resulted in decreased levels of p21. Previous studies have reported distinct 
responses by p21 to UV radiation. Several groups demonstrated p53-dependent and 
independent induction of p21 following treatment leading to G1 arrest (Poon et al., 
1996, Loignon et al., 1997, Haapajärvi et al., 1999, Jabbur et al., 2000). Others reported 
a dose-dependent downregulation of p21 in response to this agent (Allan and Fried, 
1999, Bendjennat et al., 2003, Lee et al., 2006, Lee et al., 2007). N-myc, on the other 
hand, appeared unaffected by either IR or UV radiation, consistent with observations 
described in section 5.2.1 which demonstrated a relatively weak effect by the UVC dose 
tested (25J/m
2
) on N-myc expression.  
 
Immunoprecipitation of endogenous N-myc and p21 using both cell lines failed to show 
binding between the two proteins, although Max was efficiently precipitated through N-
myc. To exclude a possible interference in the interaction by the antibodies used in 
these assays which were raised against internal regions of the proteins, p21 and Max 
proteins carrying an N-terminal hemagglutinin epitope were expressed in MNA-NB or 
HEK293T cells to test binding to endogenous or ectopic N-myc, respectively. Co-
precipitation of N-myc through the epitope was observed with Max but not p21 
suggesting these proteins do not associate in vivo. Immunoprecipitation of Max and N-
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myc in MNA-NB or transfected HEK293T cells led to co-precipitation of two 
polypeptides detected by immunoblotting against the C-terminus of N-myc (Figures 
3.6-3.9). These polypeptides exhibited lower molecular weights than N-myc and could 
not be detected by an antibody raised against its N-terminal region; further studies 
suggested they are only present in N-myc-expressing NB cells (Figure 3.10). Different 
isoforms have been described for N-myc as well as c-Myc and L-myc (Kaye et al., 
1988, Ikegaki et al., 1989, Spotts et al., 1997, van Bokhoven et al., 2005, Jacobs et al., 
2009). The MNA-NB cell lines SK-N-DZ and LAN-1 do not express c- or L-myc thus 
excluding any cross-reactivity with these family members by the antibody in these cells 
(Nisen et al., 1986, Yazawa et al., 2002). Furthermore, the epitope mapping analysis of 
the N-myc C-terminus antibody used in the IP assays (Figure 3.4) has established the 
specificity of this reagent. Given that the short polypeptides appear to have identical 
molecular weights in all NB lines analysed it is highly unlikely that cross-reactivity with 
c- or L-myc accounts for the observations in the remaining cells analysed, NB-1643.  
 
In vitro expression of human N-myc using two downstream start codons located in the 
N-terminus of the protein gave rise to polypeptides very similar in size (~40/50 kDa 
approximately) to the endogenous proteins (Figure 3.11). The MYC transcript gives rise 
to two full-length protein isoforms, c-Myc 1 and 2, which are inefficiently translated 
due to a non-AUG initiation codon and an AUG codon located in a suboptimal context, 
respectively (Marilyn, 1986, Hann et al., 1988). As a result of ribosomal leaky scanning 
at these sites, shorter isoforms, c-MycS, are translated from downstream start codons 
(Spotts et al., 1997). The sequences of the putative downstream initiation sites 
investigated here are perfectly conserved in the mouse Mycn transcript (DePinho et al., 
1986). In agreement with this, transfection of HEK293T cells with constructs containing 
the mouse or human cDNA sequence (Figures 3.9 and 3.11C, respectively) led to 
expression of N-myc and two shorter polypeptides suggesting that the truncations are 
conserved between mouse and human. 
 
Bokhoven and colleagues demonstrated the existence of two splice forms of the MYCN 
transcript, the full-length consisting of three exons and a smaller transcript (MYCN) 
that lacks exon 2. The MYCN transcript gives rise to a truncated form of N-myc (253 
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amino acids) that lacks the N-terminal 263 amino acids present in N-myc but carries  52 
amino acids encoded by exon 1 of the gene which are not present in the full-length 
protein. These studies additionally reported the expression of two polypeptides of 
approximately 42 and 45kDa that were detected by immunoblotting against the C-
terminus of N-myc in various fetal tissues and a NB cell line. The 45kDa protein was 
described as the product of the MYCN transcript although no further analyses were 
performed to assert this. The two proteins reported in these studies are consistent with 
the observations described above. However, both polypeptides were able to bind Max 
indicating neither was detected due to cross-reactivity of the N-myc C-terminal 
antibodies in NB lysates and are hence specific N-myc protein products. Expression of 
two polypeptides with molecular weights approximating to the endogenous proteins was 
also observed with transfected N-myc cDNA suggesting a post-transcriptional 
mechanism regulates expression of these proteins. Moreover, in vitro expression of N-
myc proteins carrying N-terminal deletions of 80 or 115 amino acids yielded products 
exhibiting electrophoretic motilities equivalent to the endogenous proteins. Thus, the 
extensive truncation in the N-myc sequence reported in these studies to result from 
alternative splicing (211 and 203 amino acids in comparison to the full-length isoforms) 
would be expected to generate a protein of lower molecular weight than those reported 
here. Together, the data presented here supports the likelihood that NB cells express 
short isoforms of N-myc protein that are unlikely to result from expression of a short 
MYCN transcript as previously described. Further studies are however, required to 
establish unequivocally the identity of the short polypeptides described above and the 
mechanism by which they arise. These include mutation of the putative downstream 
initiation sites in the context of the full-length MYCN/Mycn sequence to determine if 
expression of the two short polypeptides is prevented. 
 
To determine if truncated forms of N-myc could bind p21, various mouse N-myc 
mutants were expressed in HEK293T cells and analysed by immunoprecipitation. 
Interaction with p21 was only observed with N-myc del124 even though all N-myc 
variants carrying an intact C-terminus exhibited a similar association with Max (Figures 
3.12 and 3.13). To enable detection of more weakly N-myc-bound proteins, 
immunoprecipitation was performed under less stringent conditions using lower salt 
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conditions (100mM NaCl) but full-length N-myc and p21 still failed to precipitate under 
these conditions. The human N-myc del80 protein carries a deletion similar to the 
mouse N-myc del63 tested here; since no interaction was observed between the latter 
and p21 it is likely that the human mutant is equally unable to do so. The human N-myc 
del115 also resembles the mouse N-myc del124, shown here to interact with p21, and 
would be expected to similarly bind p21. Despite this, p21 binding was not observed 
with the human or mouse truncation mutants expressed endogenously in NB cells or 
ectopically from alternative translation of the complete N-myc cDNA sequence in 
HEK293T cells, respectively. The conflicting observations could result from the modest 
difference in their N-terminus but unlike the C-terminus this region seemed to be 
dispensable for p21 binding in the in vitro pull-down assays. Given that all truncated 
forms of N-myc appeared to bind Max as efficiently as the full-length protein, 
accounting for the marked differences in expression levels, it is reasonable to assume 
these proteins carry an intact C-terminus. Furthermore, the stability and specificity of 
Myc and Max heterodimerization can be abrogated by subtle structural alterations 
supporting the notion that the N-terminal mutants described here retain a regular C-
terminus (Littlewood et al., 1992, Estojak et al., 1995, Nair and Burley, 2003).  
 
The natural isoform that exhibits a molecular weight comparable to N-myc del115 was 
expressed at much lower levels than N-myc del124 which may account for the inability 
to detect the former in p21 precipitates and vice-versa. Indeed, both putative N-myc 
isoforms were expressed at lower levels than the full-length proteins and were weakly 
detected even in immunoprecipitates using N-myc or Max antibodies. This observation 
could challenge the relevance of a putative interaction between an N-myc isoform and 
p21 in MNA-NB cells. However, cellular signaling through N-myc could result in 
distinct regulation of full-length and truncated isoforms given their likely structural 
differences at the N-terminus. Indeed, c-MycS as well as full-length c-Myc 1 appear to 
be upregulated under conditions of methionine deprivation whereas expression of the 
predominant c-Myc 2 isoform is decreased in response to limiting levels of this nutrient 
(Hann et al., 1992, Hann, 1995). Overexpression of c-Myc 1 can inhibit cell growth and 
activate transcription through an additional binding site of Myc/Max heterodimers 
suggesting c-Myc isoforms are functionally distinct and the same may apply to N-myc. 
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N-myc stability is regulated by sequential phosphorylation of two conserved residues 
located within the MBI domain: at Ser62 by the cdk1 complex and at Thr58 by GSK3, 
resulting in its ubiquitylation and consequent degradation by the proteasome (Bonvini et 
al., 1998, Kenney et al., 2004, Sjostrom et al., 2005, Yaari et al., 2005, Chesler et al., 
2006). Despite the well characterized regulation of these residues, studies on the role of 
the N-terminal region in regulating the stability of Myc proteins have been rather 
puzzling. Several groups have shown that c-MycS proteins exhibit short half-lives 
comparable to full-length c-Myc despite lacking the N-terminal ~100 amino acids 
where the MBI region lies; others have implicated this domain in c-Myc ubiquitylation 
and proteolysis (Spotts et al., 1997, Flinn et al., 1998, Salghetti et al., 1999, Chen et al., 
2000, Gregory and Hann, 2000). More recently, Herbst and colleagues demonstrated 
that different domains in c-Myc can regulate protein stability in a cell type-specific 
manner (Herbst et al., 2004). This observation suggests certain mutations may confer 
stability in some but not all cell types as a result perhaps, of the multiple ubiquitin 
ligases involved in regulating Myc proteins. Phosphorylation of N-myc at Thr58 and 
Ser62 is required for binding and ubiquitylation by the SCF
Fbxw7
 ligase and promotes N-
myc degradation during cell cycle (Welcker et al., 2004, Otto et al., 2009). The putative 
N-myc isoforms described here failed to be detected using an N-terminal antibody 
indicating the MBI domain (amino acids 44-63) is likely to be absent in these proteins 
and suggesting they are regulated independently of phosphorylation at Thr58 and Ser62. 
The TRUSS protein also regulates N-myc stability but binds instead to its C-terminus to 
promote ubiquitylation by the DDB1-Cul4A ligase (Choi et al., 2010). Deletion of both 
MBI and MBII was required to prevent N-myc turnover subsequent to ubiquitylation by 
DDB1-Cul4A
TRUSS
 and this regulatory pathway could therefore be preserved in both 
putative isoforms. 
 
The shorter isoform of N-myc detected in MNA-NB cells appears to carry a more 
extensive deletion at the N-terminus that possibly affects the integrity of the MBII 
domain, in contrast to the longer isoform or c-MycS, and could therefore have different 
biological activities. Deletion of this domain reduces the transactivation potential of 
Myc and the ability to induce proliferation but does not abolish either completely (Bush 
et al., 1998, Nikiforov et al., 2002, Oster et al., 2003, Cowling et al., 2006). Various 
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groups have demonstrated MBII is additionally required for Myc-induced 
transformation and apoptosis as well as its ability to block differentiation (Stone et al., 
1987, Freytag et al., 1990, Kato et al., 1990, Evan et al., 1992). Studies on the properties 
of c-MycS are again confounding since the effect of these isoforms on cell survival 
seems to depend on cellular background. c-MycS was shown to trigger apoptosis similar 
to c-Myc in immortalized Rat-1 fibroblasts cultured under low-serum conditions 
whereas expression of this isoform in c-Myc null Rat-1 cells was unable to do so (Xiao 
et al., 1998, Oster et al., 2003). Others have similarly reported a failure by the short 
isoform to trigger apoptosis in quiescent primary cells or in vivo (Hirst and Grandori, 
2000, Benassayag et al., 2005). An artificial N-myc truncation mutant analogous to c-
MycS (N-myc del80) has been shown to retain the ability to stimulate proliferation and 
repress expression of most N-myc targets (Cowling and Cole, 2008). Given that these 
biological activities were dependent on MBII, it is possible they have been partially 
abolished in the shorter putative isoform. 
 
Together, the findings described above suggest that, unlike c-Myc, full-length N-myc 
does not interact with p21 in vivo. The putative N-myc del115 isoform may however, be 
able to associate with p21 in MNA-NB cells and future studies are required to determine 
the functional consquences of this interaction. In contrast to c-Myc which was shown to 
require the MBI and MBII domains to bind p21, the results suggest a role for the 
BRHLHZip domain in the putative N-myc/p21 interaction (Kitaura et al., 2000). 
Interestingly, p21 has been previously shown to interact with the Zip domain of the 
CCAAT/enhancer binding protein  (C/EBP) transcription factor (Timchenko et al., 
1997, Harris et al., 2001). The c-Myc/p21 interaction was also observed in this study by 
in vitro pulldown assays (Figure 3.5) and immunoprecipitation of ectopic proteins 
(Figure 3.13) but the region involved was not investigated. Kitaura and colleagues 
demonstrated that p21 prevented Myc-Max dimerization, despite the apparent 
involvement of distinct domains, and therefore impaired c-Myc-dependent 
transactivation; the interaction was however, not shown for the endogenous proteins as 
here with N-myc. Unlike c-Myc, overexpression of p21 did not abolish the interaction 
between N-myc del124 and Max as the latter co-precipitated with the N-myc variant as 
efficiently as with the full-length or N-myc del63 proteins. Divergences between the 
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regions of N- and c-Myc required for binding to the tumour suppressor ARF and 
transcriptional cofactor Yaf2 have also been reported (Bannasch et al., 2001, Mädge et 
al., 2003, Datta et al., 2004, Qi et al., 2004, Amente et al., 2007). In the case of ARF the 
interaction is mediated by the N- and C-terminus of c-Myc and the central region 
(amino acids 140 and 300) of N-myc; ARF appears nevertheless to similarly inhibit the 
transcriptional activity of the two Myc proteins. In contrast, binding to Yaf2 blocks or 
enhances transcriptional activation by c-Myc or N-myc, respectively suggesting certain 
factors may regulate the balance between the activities of the different Myc proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  A. Duarte 
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 - Schematic representation of the full-length and truncation mutants of 
mouse N-myc protein under study and human c-Myc. Some functional domains are 
depicted as grey boxes. I/II: Myc Boxes I/II; BRHLHZip: basic region/helix–loop–
helix/leucine zipper domain.  
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Figure 3.2 - SDS-PAGE analysis of the proteins expressed for studying in vitro the 
interaction between p21 and N-myc. (A) Full length and truncated forms of mouse N-
myc fused to a GST tag were expressed in E. coli and immobilized on glutathione-
Sepharose beads. The proteins were resolved by SDS-PAGE and analysed by 
Coomassie staining. (B) GST-tagged full length and truncated forms of N-myc were 
resolved by SDS-PAGE and analysed by immunoblotting using antibodies against GST 
(top panel), the N-terminus region of N-myc (middle panel), or the C-terminus region of 
N-myc (bottom panel). The bands corresponding to the GST-fused proteins of the 
correct molecular weight are indicated. (C) 
35
S-labelled human Max protein was 
synthesized using the in vitro transcription/translation system, and incubated with 
different GST-tagged N-myc proteins immobilized on glutathione-Sepharose beads. 
After washing of the beads, the bound proteins were resolved by SDS-PAGE and 
detected by autoradiography; the experiment was carried out a single time. MW: Protein 
Molecular Weight Marker.  
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Figure 3.3 - In vitro study of the interaction between p21 and N-myc. (A) Human p21 
fused to a His tag was expressed in E. coli and immobilized on chelating Sepharose. 
The protein was resolved by SDS-PAGE and analysed by immunoblotting using an 
antibody against the His tag. (B) His-tagged p21 immobilized on chelating Sepharose 
(p21) or chelating Sepharose (S) was incubated with eluates of GST-tagged mouse N-
myc and truncation mutants. After washing, the bound proteins were resolved by SDS-
PAGE and detected by immunoblotting using an antibody against the C-terminal region 
of N-myc. 10% of the protein input was analysed in parallel as a reference. Results are 
representative of three independent experiments. (C) The immunoblot analysed in (B) 
was re-probed using a GST antibody. (D) As a loading control, 10% of the His-p21 
protein used in the pull-down assays was analysed by immunoblotting against the His 
tag. (E) The amount of p21-bound protein was quantified for each N-myc variant using 
the AIDA software and normalised against the respective input levels. Relative protein 
binding was determined in relation to full-length N-myc. MW: Protein Molecular 
Weight Marker.  
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Figure 3.4 - SDS-PAGE analysis of the proteins expressed for studying in vitro the 
interaction between p21 and N-myc. Full length human c-Myc, mouse N-myc and 
truncated forms of the latter were cloned downstream of a FLAG epitope and expressed 
using in vitro transcription/translation. The proteins were resolved by SDS-PAGE and 
analysed by immunoblotting using antibodies against FLAG (A), the C-terminus region 
of N-myc (B), or the N-terminus region of N-myc (C-D, the two images are from the 
same immunoblot subjected to different exposures). The analysis was carried out a 
single time. MW: Protein Molecular Weight Marker. 
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Figure 3.5 – In vitro study of the interaction between p21 and N-myc. (A) GST and 
GST-p21 proteins were expressed in E. coli and immobilized on glutathione-Sepharose 
beads. The proteins were resolved by SDS-PAGE and analysed by Coomassie staining. 
(B) Analysis of two independent experiments (B.1 and B.2). GST and GST-p21 
immobilized on Sepharose beads were incubated with FLAG-tagged Myc proteins 
expressed using in vitro transcription/translation. After washing, the bound proteins 
were resolved by SDS-PAGE and detected by immunoblotting using anti-FLAG 
antibody. 10% of the protein input was analysed in parallel as a reference. (C) The 
amount of p21-bound protein was quantified for each N-myc variant using the AIDA 
software and normalised against the respective input levels. Relative protein binding 
was determined in relation to full-length N-myc. MW: Protein Molecular Weight 
Marker.  
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Figure 3.6 - Analysis of the interaction between N-myc and p21 by protein co-
immunoprecipitation using human neuroblastoma SK-N-DZ cells. Cells were exposed 
to the indicated dose of ionizing radiation (IR, A) or ultraviolet C (UVC, B) and lysed 
3h post-exposure. Whole cell extracts were immunoprecipitated with anti-p21 or anti-N-
myc antibodies and immunoprecipitates (IP) were resolved by SDS-PAGE and analysed 
by immunoblotting against N-myc, p21, cdk2 and -tubulin (loading control). The p21 
immunoblot was reprobed against Max; the position of residual p21 is indicated. 10% 
of the protein input was analysed in parallel as a reference. Two additionally 
immunoprecipitated peptides are indicated by black and white triangles. Results are 
representative of three independent experiments. MW: Protein Molecular Weight 
Marker.  
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Figure 3.7 - Analysis of the interaction between N-myc and p21 by protein co-
immunoprecipitation using human neuroblastoma NB-1643 cells. Cells were exposed to 
the indicated dose of ionizing radiation (IR) or ultraviolet C (UVC) and lysed 3h post-
exposure. Whole cell extracts were immunoprecipitated with anti-p21 or anti-N-myc 
antibodies and immunoprecipitates (IP) were resolved by SDS-PAGE and analysed by 
immunoblotting against N-myc, p21, cdk2 and -tubulin (loading control). The p21 
immunoblot was reprobed against Max; the position of residual p21 is indicated. 10% 
of the protein input was analysed in parallel as a reference. Two additionally 
immunoprecipitated peptides are indicated by black and white triangles. Results are 
representative of two independent experiments. MW: Protein Molecular Weight 
Marker.  
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Figure 3.8 - Analysis of the interaction between N-myc and p21 by protein co-
immunoprecipitation using human neuroblastoma SK-N-DZ (A) and NB-1643 (B) cells. 
Cells were transfected with increasing amounts (1 or 2g plasmid DNA per 6cm dish) 
of constructs directing the expression of HA-tagged human p21 or Max, as indicated. 48 
hours after transfection, cells were lysed and whole extracts were immunoprecipitated 
with anti-HA antibody. Immunoprecipitates (IP) were resolved by SDS-PAGE and 
analysed by immunoblotting against N-myc, HA and -tubulin (loading control). 10% 
of the protein input was analysed in parallel as a reference. Two additionally 
immunoprecipitated peptides are indicated by black and white triangles. Results are 
representative of three independent experiments. MW: Protein Molecular Weight 
Marker.  
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Figure 3.9 - Analysis of the interaction between N-myc and p21 by protein co-
immunoprecipitation in HEK293T cells. Cells were transfected with different constructs 
encoding HA-tagged human p21 or Max and mouse N-myc, as indicated. 48 hours after 
transfection, cells were lysed and extracts were immunoprecipitated with anti-HA 
antibody. Immunoprecipitates (IP) were resolved by SDS-PAGE and analysed by 
immunoblotting against N-myc, HA and -tubulin (loading control). 10% of the protein 
input was analysed in parallel as a reference. Two additionally immunoprecipitated 
peptides are indicated by black and white triangles. Results are representative of three 
independent experiments. MW: Protein Molecular Weight Marker.  
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Figure 3.10 – Analysis of N-myc expression in various cell lines. Human non-
neuroblastoma HeLa, HEK293T and NIH3T3, and MYCN-amplified neuroblastoma 
SK-N-DZ, LAN-1 and NB-1643 whole cell lysates were resolved by SDS-PAGE and 
analysed by immunoblotting using antibodies against the N-terminus (top panel) or C-
terminus (middle panels, the two images are from the same immunoblot subjected to 
different exposures) of N-myc and -tubulin (loading control). Two additionally 
detected peptides are indicated by black and white triangles. MW: Protein Molecular 
Weight Marker.  
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Figure 3.11 – Analysis of N-myc expression in various cell lines and protein extracts. 
(A) Human MYCN-amplified neuroblastoma SK-N-DZ, LAN-1 and NB-1643 whole 
cell lysates and human (h) N-myc variants expressed using in vitro 
transcription/translation. (B) MYCN-amplified neuroblastoma SK-N-DZ and LAN-1 
cells were lysed and whole extracts were incubated in the absence or presence of 
alkaline phosphatase (AP). (C) HEK293T cells were transfected with different 
constructs encoding human N-myc variants, as indicated, and whole extracts were 
collected 48 hours later. Results are representative of two independent experiments. (A-
C) Cellular and protein extracts were resolved by SDS-PAGE and analysed by 
immunoblotting against the N-terminus (N-term) or C-terminus (C-term) region of N-
myc as indicated, and -tubulin (loading control). Bands corresponding to full-length 
N-myc are indicated by an asterisk; two additionally detected peptides are indicated by 
black and white triangles. MW: Protein Molecular Weight Marker. 
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Figure 3.12 - Analysis of the interaction between N-myc and p21 by protein co-
immunoprecipitation in HEK293T cells. Cells were transfected with different constructs 
encoding human p21 and HA-tagged mouse N-myc variants or human cdk2, as 
indicated. 48 hours after transfection, cells were lysed and whole extracts were 
immunoprecipitated with anti-HA antibody. Immunoprecipitates (IP) were resolved by 
SDS-PAGE and analysed by immunoblotting against HA, p21 and -tubulin (loading 
control). The p21 immunoblot was reprobed against Max; the position of residual p21 is 
indicated. 10% of the protein input was analysed in parallel as a reference. Results are 
representative of two independent experiments. MW: Protein Molecular Weight 
Marker.  
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Figure 3.13 - In vitro analysis of the interaction between N-myc and p21 by protein co-
immunoprecipitation in HEK293T cells. Cells were transfected with different constructs 
encoding human p21 and HA-tagged human cdk2, human c-Myc or mouse N-myc 
variants, as indicated. 48 hours after transfection, cells were lysed and whole extracts 
were immunoprecipitated with anti-HA antibody. Immunoprecipitates (IP) were 
resolved by SDS-PAGE and analysed by immunoblotting against HA, p21 and -
tubulin (loading control). The p21 immunoblot was reprobed against Max; the position 
of residual p21 is indicated. 10% of the protein input was analysed in parallel as a 
reference. HA-cdk2 was only weakly detected on the immunoblots and the protein band 
is therefore indicated. Results are representative of two independent experiments. MW: 
Protein Molecular Weight Marker.  
 
 
 
 
 
  A. Duarte 
98 
 
CHAPTER 4 - CELLULAR RESPONSES TO N-myc AND p21 IN RAT-1 CELLS 
 
4.1 Introduction 
Expression of c-Myc in quiescent Rat-1 fibroblasts is sufficient to promote re-entry into 
and progression through the cell cycle (Eilers et al., 1991). c-Myc overexpression can 
render these cells resistant to growth arrest by anti-proliferative signals such as serum 
withdrawal, but cell proliferation is limited by the induction of apoptosis (Evan et al., 
1992, Fulda et al., 1999). Conditional expression of N-myc was also shown to promote 
cell cycle entry of quiescent SH-EP neuroblastoma cells and accelerate progression into 
S phase, while conferring a higher susceptibility to drug-induced apoptosis (Lutz et al., 
1996). Like c-Myc, ectopic N-myc can by itself drive cellular transformation of Rat-1 
fibroblasts (Small et al., 1987). Induction of c-Myc results in elevated p53 gene 
expression through direct activation of the p53 promoter and several reports have 
demonstrated a role for p53 in mediating apoptosis in cells with deregulated expression 
of c-Myc  (Reisman et al., 1993, Hermeking and Eick, 1994, Tavtigian et al., 1994, 
Wagner et al., 1994, Sakamuro et al., 1995, Zindy et al., 1998). The usual cell cycle 
arrest observed following p53 accumulation however, is attenuated in cells expressing 
ectopic c-Myc likely through direct repression of genes involved in the p53-dependent 
proliferation block such as GADD45A,  p21 and gas1 (Hermeking et al., 1995, Lee et 
al., 1997, Marhin et al., 1997, Seoane et al., 2002). 
 
MNA-NB cell lines carrying wild type p53 also fail to undergo G1 arrest following IR 
exposure, despite induction of the p53 target gene p21 (McKenzie et al., 1999, Tweddle 
et al., 2001a, Tweddle et al., 2001b). Is it unclear however, if this is due to a weaker 
expression of p21 or whether this protein is functionally impaired in NB cells with 
deregulated N-myc (Bell et al., 2006, Bell et al., 2007). The cellular responses of Rat-1 
fibroblasts to ectopic N-myc and p21 were then analysed under normal and stress 
growth conditions in order to understand if N-myc overexpression can suppress a p21-
induced proliferation arrest. 
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4.2 Results 
4.2.1 Establishment of a Rat-1/N-myc cell line 
To determine if exogenous N-myc can induce similar cellular events as c-Myc, the Rat-
1 cell line was transfected with the vector pBabepuro (Morgenstern and Land, 1990) 
directing the constitutive expression of the mouse N-myc cDNA fused N-terminally to a 
FLAG epitope. A stable polyclonal population of cells expressing FLAG-tagged N-myc 
(referred hereafter as Rat-1/N-myc) was selected in puromycin. A control population of 
Rat-1 cells (Rat-1/pBabe), transfected with the empty vector alone, was established in 
parallel. The expression of N-myc in the pooled cell population was analysed by 
immunoblotting using an antibody raised against the FLAG epitope. As shown in Figure 
4.1A, a protein of approximately 70kDa was specifically detected in Rat-1/N-myc cells. 
To confirm the identity of this protein, these cells were further analysed by 
immunoblotting against N-myc and three human MNA-NB cell lines were examined in 
parallel as a positive control. N-myc protein was readily detected in all samples tested, 
albeit at slightly different molecular weights (Figure 4.1B). Ectopic N-myc expressed in 
Rat-1 cells migrated somewhat slower than endogenous N-myc in NB cells due to the 
presence of the FLAG epitope as well as it being of mouse origin. 
 
The cellular localization of FLAG-N-myc was also examined by immunofluorescence 
microscopy using anti-FLAG antibody. Rat-1 cells were simultaneously stained using 
DAPI to give a clear indication of the nucleus boundary under the fluorescent 
microscope and allow an assessment of the total number of cells in the field. The Alexa 
Fluor-conjugated secondary antibody used gave a red fluorescent signal. As can be 
observed in Figure 4.1C, some background signal, apparent by the red staining, was 
observed in the control cell line. However, the signal was diffuse and cytoplasmic likely 
resulting from non-specific binding of the anti-FLAG antibody. Rat-1/N-myc cells, on 
the other hand, show a strong nucleic signal that co-localizes with the DAPI-stained 
nuclei, in agreement to the established nuclear role of N-myc as a transcription factor 
with DNA-binding properties (Ramsay et al., 1986, Dang and Lee, 1989). 
Immunostaining for FLAG was positive in >90% of cells in the Rat-1/N-myc 
population, as determined as described (Materials and Methods). 
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Interaction of the Myc proteins with Max is essential for activation of target genes and 
consequently to many of their biological effects on cell proliferation and apoptosis. It 
was therefore of importance to establish the ability of FLAG-N-myc to associate with 
endogenous Max. For this purpose, Rat-1 cellular extracts were subjected to 
immunoprecipitation using antibodies against Max or FLAG; whole cell lysates and 
immunoprecipitates were then resolved by SDS-PAGE and analysed by immunoblotting 
against the indicated proteins. As shown in Figure 4.1D, Max was efficiently 
precipitated through its antibody in both cell lines tested and FLAG-N-myc was found 
to co-precipitate with Max in Rat-1/N-myc cells. However, Max was only precipitated 
by anti-FLAG antibody in Rat-1/N-myc cells demonstrating the specificity of the 
interaction and the reagents.  
 
4.2.2 Effect of N-myc on cell cycle progression 
To test if ectopic expression of N-myc can accelerate progression through the cell cycle, 
Rat-1 cultures were synchronized by treatment with nocodazole and their cell cycle 
distribution following release from this agent was determined by flow cytometric 
analysis. Nocodazole causes cells to arrest in G2/M phase by blocking the 
polymerization of tubulin into microtubules and therefore preventing the correct 
segregation of chromosomes during mitosis (Jordan et al., 1992). For cell cycle 
profiling, cells were plated under normal conditions 24h before treatment. Cultures were 
then incubated for 18h in media supplemented with nocodazole after which the cells 
were washed with PBS and incubated with normal growth media. At the indicated time 
points the cells were collected in PBS and fixed in 70% ethanol at 4ºC. The cells were 
ressuspended in propidium iodide for staining of nucleic acids and treated with RNase 
before analysis. 
 
In order to determine the most suitable concentration of nocodazole to use in further 
experiments, a dose-response experiment was performed. Rat-1 cell lines were exposed 
to a range of concentrations and the cells were collected at 0 and 24h following release 
from nocodazole block. As shown in Figure 4.2, at a concentration of 0.21M (see 
square C), nocodazole induced only minor levels of cell death (≤4% for both cell lines) 
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yet exerted a strong mitotic block (≥80% of cells at G2/M phase). Higher concentrations 
of nocodazole did not improve the cell cycle arrest and increased cell loss. 
 
For analysis of cell cycle progression, Rat-1/pBabe and N-myc cells were synchronized 
by treatment with 0.21M nocodazole. Cells were collected at various time points after 
treatment and analysed by flow cytometry after PI staining. Figure 4.3 illustrates the cell 
cycle distribution of asynchronous cells and synchronized cells collected at 0 and 24h 
post-release. Incubation with nocodazole led to the accumulation of approximately 85% 
of cells in G2/M phase in both lines. Following removal of the inhibitor, the mitotic 
arrest was reversed and both cell lines entered and progressed through interphase as 
observed by the accumulation of cells in the G1 and S phases. However, 24h after 
release, a significantly higher proportion of Rat-1/N-myc cells was observed in S phase, 
as determined from three independent experiments. This observation indicates that N-
myc can accelerate entry into S phase in Rat-1 fibroblasts. 
 
4.2.3 Effect of N-myc on expression of cell cycle regulators 
To gain initial insight into the molecular basis underlying N-myc-mediated cell cycle 
progression, expression of cell cycle regulators was investigated in Rat-1/pBabe and N-
myc cells. Whole cell lysates of asynchronous cell cultures were analysed by 
immunoblotting using antibodies specific for the proteins of interest; a representative 
data set is shown in Figure 4.4. Expression of cyclin D1, A and E, cdk2 and PCNA were 
modestly increased in Rat-1/N-myc cells whereas cdk1 and p27 were slightly decreased 
in these cells. The remaining regulators increased more strongly as in the case of cdk4 
and cdc25A. Nevertheless, the increase in expression relative to control cells was found 
to be approximately twofold at maximum, as quantified using the AIDA software and 
normalised against -tubulin levels.  
 
Together, analysis of the Rat-1 cell lines demonstrates the functionality of the N-myc 
expression system and the suitability for studying its effect on cell proliferation and 
survival in response to different growth conditions. 
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4.2.4 IPTG-inducible expression of p21 and p27 in Rat-1 cells 
To investigate a possible role for N-myc in suppressing the growth arrest activity of 
p21, Rat-1/pBabe and Rat-1/N-myc cells carrying Isopropyl β-D-1-
thiogalactopyranoside (IPTG) inducible p21 or p27 constructs were established. The 
LacSwitch II system (Stratagene) used consists in introducing two vectors into the 
mammalian cells. The coding sequence of the target proteins are inserted downstream of 
the Lac operator sequence in the Lac operator vector. The Lac repressor protein, 
expressed from the second vector, specifically binds to the Lac operator blocking 
transcription of the target sequences. Addition of IPTG prevents binding of the Lac 
repressor to the Lac operator thus allowing transcription to occur.  
 
Stable clones of both Rat-1/pBabe and Rat-1/N-myc cells conditionally expressing HA-
tagged p21 were isolated. In order to evaluate the specificity of the observations with 
p21, stable clones expressing IPTG-inducible p27, also a member of the Cip/Kip family 
of cdk inhibitors, were also selected. For each cell line described, a set of 10-12 clones 
was isolated by plating the cells at low density to allow selection of individual colonies. 
To analyse expression of the IPTG-inducible proteins, cells were plated under normal 
conditions and allowed to attach overnight. Cultures were then incubated for 48h in 
media supplemented with 1mM IPTG and whole cell lysates were analysed by 
immunoblotting using an antibody raised against the HA epitope. Figure 4.5 shows the 
analysis performed for two clones of each cell line selected for use in further studies 
based on IPTG inducibility and level of expression of p21 or p27. These clones were 
again tested in an independent experiment and expression of ectopic N-myc was found 
not to be affected by induction of p21 or p27 (see appendix VII). 
 
In order to determine through protein immunoprecipitation if an association between N-
myc and p21, analogous to the c-Myc/p21 interaction, occurs in Rat-1 cells, the Rat-
1/N-myc clones D and H expressing inducible p21 and p27 (as a control), respectively, 
were employed (Kitaura et al., 2000). For this purpose, cells were incubated in normal 
growth media for 48h in the presence or absence of 1mM IPTG to induce protein 
expression. Cellular extracts were collected and subjected to immunoprecipitation using 
anti-HA antibody. Whole cell lysates and immunoprecipitates were resolved by SDS-
  A. Duarte 
103 
 
PAGE and analysed by immunoblotting against HA and FLAG. As can be observed in 
Figure 4.6, both p27 and p21 were effectively precipitated by anti-HA antibody in 
IPTG-treated cells, although small amounts of the exogenous proteins were also present 
in precipitates from untreated cells revealing minor promoter leakage in this system. 
FLAG-N-myc, although strongly detected in whole cell lysates, was not present in the 
precipitated fraction. 
 
4.2.5 Effect of p21 and p27 on cell cycle progression 
For analysis of cell cycle progression, Rat-1/pBabe and N-myc cells carrying an IPTG-
inducible p21 or p27 gene were incubated for 48h in normal growth media in the 
presence or absence of 1mM IPTG. Cells were collected at this time and analysed by 
flow cytometry after PI staining. Figure 4.7 illustrates the cell cycle distribution of the 
different clones under study. For each of the treatments carried out, the protein levels of 
p21 and p27 were examined by immunoblotting against the HA epitope and the levels 
of expression in three independent experiments were found to be consistent with the 
data shown in Figure 4.5 (not shown). The IPTG treatment was performed on 
asynchronously growing cell cultures; as a result, the untreated samples of the various 
clones show a slight variation in the distribution among cell cycle phases. This 
divergence is more accentuated for the Rat-1/N-myc clones C and D which show a 
moderate difference in the G1 fraction (42.1±3% and 52.3±6.8%, respectively). The 
latter was previously demonstrated to express modest levels of exogenous p21 in the 
absence of IPTG induction (Figure 4.6). Ectopic expression of p21 has been reported to 
induce a cell cycle arrest at the G1/S transition and it is therefore reasonable to speculate 
that the low but steady levels of p21 expression in clone D are responsible for a G1 
delay in these cells and account for the difference observed (El-Deiry et al., 1994). 
 
Induction of p21 in Rat-1 lines induced an accumulation of cells in G1 phase 
accompanied by the loss of cells in the S-phase in both control and N-myc clones 
(Figure 4.7A). The Rat-1/pBabe clones A and B underwent an increase of 
approximately 10 and 12%, respectively, and N-myc clones C and D showed an 
increase of approximately 17 and 11%, respectively. The average reduction in S-phase 
cells ranged 5 and 10% for all clones. The G1 enrichment and the S-phase fraction 
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decrease observed for clones B and C was found to be significant, as determined from 
three independent experiments. A role for p21 in promoting a G2 arrest has also been 
consistently observed (Bunz et al., 1998, Cayrol et al., 1998, Ando et al., 2001). None 
of the cell lines under study showed accumulation of cells with a G2/M-phase DNA 
content; in fact, the data for the IPTG-treated cultures shows a small reduction in the 
G2/M population relative to what is observed for the respective untreated cultures. 
However, in the Rat-1/pBabe clones, the decrease in the G2/M population does not 
accompany the decrease in the S population (on average, 1-2% and 9-10%, 
respectively), whereas the reduction in the G2/M population in both Rat-1/N-myc clones 
was approximately 7%, similar to the changes observed in the S-phase fraction. In 
support of this, the decrease in the G2/M fraction observed for clone C (Rat-1/N-myc) 
was found to be significant whereas the decrease observed for clone B (Rat-1/pBabe) 
was not. These observations suggest that Rat-1/pBabe and N-myc cells are similarly 
susceptible to p21-induced G1 arrest; however, control cells but not N-myc-expressing 
cells undergo in addition a G2 delay as a result of p21 expression. 
 
p27 induction was also accompanied in both Rat-1/pBabe clones and N-myc clones by a 
moderate enrichment in G1-phase cells (on average, 6-7% and 13%, respectively) and a 
decrease in S- and G2/M-phase cells (3-5% and 5-8%, respectively; Figure 4.7B), which 
is in agreement with previous reports by several groups of a G1 arrest triggered by 
increased levels of p27 (Kato et al., 1994, Toyoshima and Hunter, 1994, Niculescu III et 
al., 1998, Gardner et al., 2001). Unlike p21-expressing clones, Rat-1/pBabe/p27 clones 
show similar reductions in S and G2/M populations (4-5% and 3%, respectively). 
However, p27 expression produced a weaker effect on the cell cycle distribution of all 
clones, being more variable in the case of N-myc clones, making the observation of a G2 
delay more difficult. 
 
Further experiments were conducted to examine the p21 dose/response relationship in 
the Rat-1/N-myc cell system. To identify the IPTG dose range that gave rise to different 
levels of promoter induction (as determined by protein expression), control and N-myc 
cells were treated with various concentrations of IPTG and lysates collected 24 or 36h 
post-treatment were analysed by immunoblotting against HA. Through the inducibility 
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studies it was determined that using 2.5-10M IPTG generates increasing levels of 
protein expression within this time frame. For analysis of cellular proliferation, clones 
B, D, E and H, one of each cell line selected based on the observation that they express 
similar levels of ectopic protein, were employed. Cultures were treated with 0-10M 
IPTG and incubated for 24 or 36h before collecting for flow cytometry or 
immunoblotting analysis. Figures 4.8A and 4.8D show a dose-dependent increase in the 
expression of p21 and p27, respectively, in IPTG-treated cultures. IPTG induction 
produced slightly higher levels of protein expression in Rat-1/N-myc clones compared 
to control clones. 
 
Figures 4.8B-C and 4.8E-F illustrate the cell cycle distribution of Rat-1/p21 or p27 
cultures, respectively. Expression of p21 resulted in a marked accumulation of cells in 
G1 as early as 24h post-induction. In both clones, the increase in the G1 population was 
accompanied by a reduction in the S- and G2/M-phase populations. However, in control 
cells this effect was only obvious at higher IPTG doses (5-10M), whereas N-myc cells 
were responsive to the lowest dose tested (2.5M). The immunoblotting and 
quantitative analysis suggests this difference may have resulted from a slightly stronger 
expression of p21 in Rat-1/N-myc cells. The proportion of cells undergoing a G1 delay 
in Rat-1/N-myc cells correlated at both times very clearly with the IPTG dose-
dependent expression of p21; at 36h this effect was also observable in control cells. 
Both clones responded poorly to induction of p27, except for Rat-1/N-myc cells treated 
with 10M IPTG which exhibited a clear accumulation of cells in G1 with a 
concomitant decrease in the S- and G2/M cell fractions. This difference could also be 
partly attributed to a stronger expression of p27 in N-myc cells. 
 
Taken together, these results give no evidence that N-myc can suppress p21 function at 
the protein level and suggest other mechanisms of regulation are involved in the bypass 
to the ionizing radiation-induced G1 arrest in MNA-NB cells. 
 
4.2.6 Effect of p21 and p27 on N-myc-induced cell death 
Overexpression of c-Myc in Rat1 fibroblasts results in a failure to arrest under 
conditions of serum deprivation and other growth-arresting signals, which sensitizes 
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these cells to apoptotic cell death (Evan et al., 1992). To determine if N-myc has a 
similar effect in these cells, the cell cycle progression of the Rat-1 clones examined in 
the previous section was analysed in the presence or absence of serum. The ability of 
p21 and p27 to protect cells from undergoing cell death in cultures maintained in 
conditions of serum starvation was also examined. Cells were seeded under normal 
conditions and allowed to attach overnight. At day 1, cultures were washed with PBS 
incubated in complete growth medium (10% serum) or low serum medium (0.5% 
serum). At day 2, p21 and p27 expression was induced by addition of 1mM IPTG to 
cultures maintained in low serum medium. Cells were harvested every 24h for 5 days 
for flow cytometry analysis. 
 
As illustrated in Figures 4.9A and 4.9C, the G1 population in the control clones 
maintained in complete media showed a moderate increase (approximately 10%) at later 
times. Under these conditions, the Rat-1/N-myc clones also exhibited an increase both 
in the proportion of cells with G1 (5-10%) and sub-G1 DNA content (approximately 6%) 
(Figures 4.9B and 4.9D). During the 4-day incubation under serum-deprived conditions, 
the G1 population of non-IPTG-induced control cultures increased by approximately 
10% for both clones and the S and G2/M-phase populations decreased by approximately 
20 and 10%, respectively (Figures 4.10A and 4.10C). Induction of either p21 or p27 
expression caused a sharp increase in the G1 population 24h following IPTG addition 
(approximately 15% and 20%, respectively). Over the same period, p27 induction 
decreased both the S-and the G2/M-phase populations by half; expression of p21 had a 
similar effect on the proportion of cells in S-phase, but the G2/M-phase population was 
reduced by no more than 20% in these cells. The cell cycle distribution of IPTG-treated 
cultures remained relatively constant at later times.  
 
In Rat-1/N-myc clones maintained in the absence of IPTG, the G1 population was only 
weakly affected by serum withdrawal, remaining constant even at later times (Figure 
4.10B and 4.10D). In both clones analysed, the S- and G2/M-phase populations 
sustained reductions of 25-50% during the 4-day incubation under serum-deprived 
conditions. Induction of p21 or p27 by IPTG addition resulted in a strong cell cycle 
block in G1 (this fraction increased by approximately 30%), accompanied by a decrease 
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in the S- and G2/M-phase populations. Unlike control cells, however, both Rat-1/N-myc 
lines appear to regain proliferative capacity at later times as suggested by the decrease 
in the G1 population and the increase in the S- and G2/M-phase fractions. In serum-
deprived control cells expressing p21 or p27, the proportion of dead cells, as assessed 
by the sub-G1 fraction, remained constant throughout the experiment, whereas in non-
IPTG-treated cells this population had, by day 4, increased by approximately 10%. In 
N-myc cells, expression of p21 greatly suppressed within the 4-day incubation the cell 
death observed in serum-deprived cultures; this cell fraction decreased from 
approximately 25% to 8% of the total cell population. A very similar increase in the 
sub-G1 population was observed in N-myc/p27 cells but p27 induction only partly 
suppressed the accumulation of dead cells, from approximately 25% to 15%.  
 
These observations suggest that both p21 and p27 can to some extent protect cells from 
cell death under conditions of serum starvation. In control cells this appears to result by 
enforcing an earlier cell cycle arrest that prevents cells from entering the cell cycle 
under conditions that would otherwise result in death. Expression of N-myc renders 
Rat-1 cells more susceptible to stressful growth conditions such as serum starvation, at 
least in part through the repression of the G1 arrest observed in control cells. Enforced 
expression of p21 or p27 in serum-starved Rat-1/N-myc restores the normal G1 delay 
and blocks aberrant progression through the cell cycle. 
 
4.3 Discussion 
This chapter describes the analyses undertaken to understand if N-myc and p21 can 
functionally interact to regulate cell proliferation and survival. To this aim, the 
individual or combined effect of their expression was studied in Rat-1 cells. This model 
system is especially suitable as it has been widely employed in the study of Myc 
functions in proliferation, transformation and apoptosis (Small et al., 1987, Evan et al., 
1992, Amati et al., 1993b, Conzen et al., 2000). For this purpose, Rat-1 cells were 
initially transfected with a construct carrying the mouse cDNA fused N-terminally to a 
FLAG epitope. Immunoblotting analysis of Rat-1/N-myc cell lysates using anti-FLAG 
antibody demonstrated expression of a polypeptide exhibiting the molecular weight 
predicted for the FLAG-N-myc fusion protein (Figure 4.1A). The identity of this 
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polypeptide was further confirmed by immunoblotting directed against an N-myc 
epitope located at the N-terminus (Figure 4.1B). This analysis also revealed that ectopic 
N-myc was expressed in Rat-1 cells at levels equivalent to endogenous N-myc in NB 
cells. Cellular immunostaining against the FLAG epitope demonstrated a specific 
nuclear signal in Rat-1/N-myc cells (Figure 4.1C) in agreement with previous 
observations and its role as a transcriptional regulator (Ramsay et al., 1986, Slamon et 
al., 1986). Furthermore, the FLAG signal was detected in most cells and appeared to be 
consistent among cells. These observations are of particular importance given the 
polyclonal nature of this cell population and they predict strong and homogeneous 
responses to the treatments. Ectopic N-myc was also shown to associate efficiently with 
endogenous Max protein (Figure 4.1D), an essential property for the activity of Myc 
proteins (Wenzel et al., 1991, Amati et al., 1992, Amati et al., 1993a, Amati et al., 
1993b, Wenzel and Schwab, 1995). 
 
Expression of ectopic N-myc resulted in accelerated entry into S phase as determined by 
flow cytometry analysis (Figure 4.3), indicating it can promote progression through G1 
in Rat-1 cells as previously described for neuronal cells (Bourhis et al., 1991, Lutz et 
al., 1996, Knoepfler et al., 2002, Wartiovaara et al., 2002, Kenney et al., 2003). A 
number of positive regulators of cell cycle progression were modestly upregulated in 
Rat-1/N-myc cells (Figure 4.4). This observation is consistent with previous analyses on 
c-Myc that demonstrated a relatively weak ability by Myc-Max heterodimers to 
transactivate target genes (Kretzner et al., 1992, Bush et al., 1998). In agreement with 
previous reports, cdk4 expression was increased in Rat-1/N-myc cells possibly 
reflecting direct gene transactivation by N-myc since the cdk4 promoter carries Myc-
responsive E-boxes (Guo et al., 2000a, Hermeking et al., 2000, Menssen and 
Hermeking, 2002). Unlike cyclin D3, cyclin D1 was not strongly affected by N-myc 
expression. Reports on the role of Myc in cyclin D1 regulation have been rather 
conflicting with observations of both positive and negative effects on cyclin D1 gene 
expression as well as a post-transcriptional increase in cyclin D1 levels in response to c-
Myc (Daksis et al., 1994, Philipp et al., 1994, Solomon et al., 1995, Perez-Roger et al., 
1999). The same study suggested a direct role for c-Myc in cyclin D2 transactivation 
whereas the protein levels of cyclin D3 appeared unaffected. N-myc was similarly 
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shown to drive proliferation of neuronal precursors through upregulation of cyclin D1 
and D2 but not cyclin D3 (Ciemerych et al., 2002, Knoepfler et al., 2002, Kenney et al., 
2003). Cyclin D2 expression could not be detected in Rat-1 cells in this study, 
consistent with a previous report (Quelle et al., 1993). The cyclin D3 promoter carries 
an E-box but this motif has so far only been shown to mediate promoter activation by 
muscle-specific transcription factors of the MyoD family in order to promote cell 
differentiation (Kiess et al., 1995, Skapek et al., 1995, Wang et al., 1996b, Cenciarelli et 
al., 1999). However, ectopic expression of c-Myc in HeLa cells was shown to induce a 
marked increase in cyclin D3 levels; conversely, downregulation of endogenous c-Myc 
led to decreased cyclin D3 expression (Jänicke et al., 1996). Similar findings were 
described by Qi and colleagues using human erythroleukemia cells or lung carcinoma 
cells for analysis of overexpressed or silenced c-Myc, respectively (Qi et al., 2007). 
They demonstrated a direct correlation between the levels of c-Myc and expression of 
cyclin A, D3 and E as well as cdk2 and cdk4; p21 and p27 levels on the other hand were 
inversely proportional to c-Myc expression and cyclin D1 was not affected.  
 
The concerted increase in cdk4 and cyclin D3 in Rat-1/N-myc cells possibly contributed 
to G1 progression by relieving inhibition of E2F transcription factors by Rb. The modest 
increase in the levels of cyclin E1 and A2 and cdc25A observed in these cells are in 
agreement with previous reports and likely aided E2F activation and consequent S-
phase entry as well as progression through this stage (Jansen-Dürr et al., 1993, Hanson 
et al., 1994, Barrett et al., 1995, Galaktionov et al., 1996, Mateyak et al., 1999, Murphy 
et al., 2011). Interestingly, expression of p21 was upregulated in Rat-1/N-myc cells. 
Deregulated c-Myc can block transactivation of p21 in response to DNA damage or 
differentiation signaling in order to suppress its growth-arresting potential (Gartel et al., 
2001, Herold et al., 2002, Seoane et al., 2002, Wu et al., 2003b, Gartel and 
Radhakrishnan, 2005). However, c-Myc-null Rat-1 cells were shown to exhibit reduced 
levels of p21 and overexpression of c-Myc can trigger G2 arrest in normal human 
fibroblasts in a p53- and p21-dependent way (Mateyak et al., 1999, Felsher et al., 2000). 
Furthermore, c-Myc was shown to directly transactivate the p53 promoter suggesting it 
may indirectly induce p21 expression (Reisman et al., 1993). N-myc can similarly 
activate transcription of p53 in NB cells; the p21 upregulation observed in Rat-1/N-myc 
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cells is likely p53-independent since the p21 promoter region was reported to be 
hypermethylated in these cells which possibly accounts for the low p21 expression 
observed in Rat-1/pBabe cells (Allan et al., 2000, Chen et al., 2010). Serum stimulation 
of quiescent cells can however, induce p21 expression independently of p53 (Michieli et 
al., 1994, Macleod et al., 1995, Parker et al., 1995, Alpan and Pardee, 1996). Myc genes 
are also responsive to mitogen stimulation and promote in turn expression of E2F1/2 
proteins (Kelly et al., 1983, Dean et al., 1986, Murphy et al., 1987, Leone et al., 1997, 
Sears et al., 1997, Beier et al., 2000, Misawa et al., 2000, Oliver et al., 2003). E2F1 was 
shown to activate expression of p21 during G1 thus suggesting a possible explanation 
for the increased expression of p21 in Rat-1/N-myc cells (Hiyama et al., 1998). 
 
The repressive effect of c-Myc over p21 transcriptional activation as a mechanism of 
blocking growth arrest has been well established (Mitchell and El-Deiry, 1999, Claassen 
and Hann, 2000, Gartel et al., 2001, Wu et al., 2003b, Li and Wu, 2004). The 
relationship between N-myc expression and regulation of p21 is however, less clear; 
MNA-NB cells fail to undergo G1 arrest following exposure to IR despite induction of 
p21 but this response appears however, to be dependent on attenuation of p21 levels 
(McKenzie et al., 1999, Tweddle et al., 2001b, Bell et al., 2006, Bell et al., 2007). To 
investigate if N-myc can regulate the cellular responses triggered by ectopic p21, 
namely cell cycle arrest, independently of transcriptional control, a p21 or p27 (as a 
control) construct was introduced into the Rat-1 cell lines described above. In the 
experimental system used, induction of ectopic p21, and p27,  was controlled by an 
IPTG regulated foreign promoter to exclude any effect of N-myc on p21, or p27, at the 
transcriptional level and achieve equivalent protein expression in Rat-1/pBabe and N-
myc cells (Figure 4.5). These cells were also employed in the investigation of an 
interaction between N-myc and p21 by immunoprecipitation but consistent with the data 
described above (section 3.2.2) no association was observed (Figure 4.6). Cell cycle 
distribution of the different lines isolated was analysed by flow cytometry under 
different growth and IPTG stimulation conditions. Cells were first analysed 48h after 
IPTG addition to observe the cellular response to maximum protein synthesis. 
Expression of p21 appeared to induce a similar accumulation of cells in G1 phase in 
control and N-myc cells with a concomitant loss of S- and G2/M-phase cells (Figure 
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4.7). Rat-1/pBabe cells retained however, a proportionally higher G2/M fraction 
compared to N-myc cells. Further studies analysing the cellular response to increasing 
p21 doses at 24 and 36h after IPTG addition yielded compatible observations. The G1 
cell fraction of both control and N-myc Rat-1 lines increased in proportion to p21 
expression and a decrease was observed in the remaining cell cycle populations (Figure 
4.8B-C). 
 
Various studies have described the induction of both G1 and G2 arrest in response to 
ectopic p21, and p27 in a number of different cell lines including Rat-1 fibroblasts 
(Bates et al., 1998, Cayrol et al., 1998, Medema et al., 1998, Niculescu III et al., 1998). 
The observations made in this study are consistent with a role for p21 and p27 in G1/S 
transition and seem to indicate that N-myc cannot abolish the G1 block triggered by 
expression of ectopic p21 in Rat-1 cells as observed for IR-treated MNA-NB cells hence 
suggesting a requirement for transcriptional or translational control of p21 in order to 
bypass the radiation-induced arrest. Previous reports suggest distinct mechanisms that 
could prevent efficient induction of p21 in cells expressing N-myc. C-myc can actively 
block expression of p21 in response to DNA damage by preventing promoter activation 
by the Miz-1 transcription factor (Herold et al., 2002, Seoane et al., 2002). N-myc can 
similarly inhibit Miz-1-dependent transcriptional activation of target genes but the p21 
promoter has not been investigated (Zhang et al., 2006, Akter et al., 2011). p53, the key 
regulator of p21 expression following DNA damage, is transcriptionally activated by N-
myc in NB cells and neuroblasts with MYCN amplification (Chen et al., 2010). 
However, expression of the E3 ligase MDM2, a negative regulator of p53, is also 
directly activated by N-myc in NB cells suggesting p53 function and expression of 
downstream target genes could be attenuated in cells carrying amplified MYCN (Slack 
et al., 2005). 
 
Although no accumulation of cells in G2/M was observed following p21 or p27 
induction in the Rat-1 control cells, a more marked decrease in the G2/M fraction 
occurred in Rat-1/N-myc cultures. Possibly, this effect illustrates the latter’s ability to 
progress through G2/M at an accelerated rate in comparison to control cells which could 
then have given rise to a more pronounced increase in the G1-phase population. In 
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support of this hypothesis, c-Myc null cells exhibit significantly prolonged G1 and G2 
phases of the cell cycle and c-Myc depletion in various cell lines can lead to 
accumulation in S or G2/M phases (Mateyak et al., 1997, Wang et al., 2007). Shibuya 
and colleagues demonstrated that stimulation of hematopoietic cells with cytokines that 
induce c-Myc expression promoted progression through S-phase and correlated with 
induction of cell cycle genes critical for entry into G2/M such as cyclins A and B and 
cdk1 (Shibuya et al., 1992). The S phase arrest exhibited by cells stimulated with a 
cytokine that failed to induce c-Myc could be rescued by expression of ectopic c-Myc 
clearly indicating a role for this protein in the S to G2/M transition. Conditional 
expression of N-myc in NB or 3T3 cells has also been shown to increase the rate of 
DNA synthesis whereas targeted deletion in neuronal progenitor cells led to a marked 
decrease in S-phase and mitotic cells (Cavalieri and Goldfarb, 1988, Lutz et al., 1996, 
Knoepfler et al., 2002). A role for c-Myc in promoting DNA synthesis has also been 
long noted with direct and indirect mechanisms having been described so far, including 
association with the pre-replicative complex at replication origins and transcriptional 
activation of nucleotide metabolic genes, respectively (Studzinski et al., 1986, Iguchi-
Ariga et al., 1987, Dominguez-Sola et al., 2007, Liu et al., 2008).  
 
The Rat1 cell lines carrying IPTG-inducible expression of p21 and p27 were further 
employed to study the potential of N-myc in inducing cell death in response to serum 
deprivation and examine whether p21 (or p27) could influence the cellular outcome 
under these conditions. Fragmentation of nuclear DNA due to enzymatic degradation is 
one of the hallmarks of eukaryotic cell death (Williams et al., 1974, Umansky, 1982). 
Although cleavage of chromosomal DNA is an earlier and more characteristic feature of 
programmed cell death (apoptosis) it is also a component of  necrotic cell death 
(Compton, 1992, Darzynkiewicz et al., 1997). Flow cytometry analysis of cell cultures 
undergoing cell death through either pathway can therefore similarly reveal a sub-
population of cells (sub-G1) with reduced PI-stained DNA compared to the G0/G1 
population (Afanas'ev et al., 1986, Nicoletti et al., 1991, Darzynkiewicz et al., 1997). 
However, a substantial body of work has shown that c- and N-myc expression in serum-
deprived Rat-1 fibroblasts promotes apoptotic cell death and analysis of the sub-G1 
population in this study could therefore be used as an indicative and simple method of 
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assessing apoptosis (Evan et al., 1992, Fanidi et al., 1992, Harrington et al., 1994, 
Littlewood et al., 1995, Aubry and Charron, 2000). Consistent with these studies, the 
findings described above demonstrate a higher rate of cell death in Rat-1/N-myc 
cultures maintained under conditions of serum starvation compared to control cultures 
(Figures 4.10A-D).  
 
Although serum-starved Rat-1 control cells accumulated in G1, there was no marked 
protection from apoptosis suggesting serum deprivation prevented S-phase entry 
through induction of p27 and not p21. This observation is consistent with previous 
reports that failed to detect p21 induction in quiescent cells (Michieli et al., 1994, 
Macleod et al., 1995, Alpan and Pardee, 1996). Accumulation of p27 on the other hand 
also promotes G1 block and is associated with a quiescent state in many cell types (Poon 
et al., 1995, Coats et al., 1996, Carrano et al., 1999, Iyer et al., 1999). Thus, it appears 
that N-myc, similar to c-Myc, can overcome the cell cycle arrest imposed by elevated 
but physiological levels of p27 (Vlach et al., 1996). c-Myc was shown to affect p27 
protein levels by promoting ubiquitin-dependent proteolysis by the SCF
Skp2
 ligase, 
whose Skp2 and Cul1 members are upregulated by c-Myc (Carrano et al., 1999, 
Tsvetkov et al., 1999, O'Hagan et al., 2000, Bretones et al., 2011). Constitutive c- or N-
myc induce cdk2-cyclin E kinase activity leading to phosphorylation and consequent 
degradation of p27 by the proteasome (Steiner et al., 1995, Müller et al., 1997, Sheaff et 
al., 1997, Montagnoli et al., 1999, Nakamura et al., 2003). Myc activation of D cyclins 
is also thought to lead to sequestration of p27 from the cdk2 complexes thus 
contributing to cell cycle progression (Bouchard et al., 1999, Perez-Roger et al., 1999). 
Regarding transcriptional control of p27 by Myc, conflicting results have emerged with 
some studies reporting a role for c-Myc in p27 gene repression whereas others did not 
observe such an effect suggesting it may depend on cell type or growth conditions 
(Steiner et al., 1995, Yang et al., 2001, Chandramohan et al., 2004). The G1 block 
induced by overexpression of p27 observed in this study in contrast, is not bypassed by 
N-myc expression in agreement with previous observations (Müller et al., 1997, Acosta 
et al., 2008). Müller and colleagues showed that phosphorylation and consequent 
release of p27 from cdk2-cyclin E complexes was required for activation of these 
complexes (Müller et al., 1997). It is therefore reasonable to argue that under conditions 
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of continuous p27 expression, these complexes are permanently associating with 
unphosphorylated p27 molecules and will therefore lack catalytic activity towards other 
substrates required for S-phase entry.  
 
N-myc appears to render Rat-1 cells more susceptible to serum deprivation at least in 
part by preventing the physiological G1 arrest observed in control cells. This hypothesis 
is supported by the ability of ectopic p21, and p27 to a lesser extent, to suppress the 
increase in the sub-G1 fraction and induce proliferative block in G1. Thus, induction of 
p21 expression does partly protect N-myc-expressing cells from undergoing cell death 
following serum deprivation but only at the expense of proliferative potential by 
blocking aberrant cell cycle progression. Furthermore, while unclear for p27, various 
direct pro-survival functions have been demonstrated for p21 including the ability to 
interact and block procaspase-3 activation, which is promoted by ectopic expression of 
c-Myc, thereby protecting against Fas-mediated cell death (Kangas et al., 1998, Suzuki 
et al., 1998, Suzuki et al., 1999, Suzuki et al., 2000, Coqueret, 2003). These activities by 
p21 possibly account for the differences observed in p21- and p27-expressing cells 
regarding their ability to suppress N-myc-dependent cell death independently of their 
effect on cell cycle progression. 
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Figure 4.1 – Analysis of FLAG-N-myc expression in Rat-1 fibroblasts transfected with 
pBabepuro-FLAG-N-myc (mouse cDNA) or empty vector. 
For legend, see following page. 
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Figure 4.1 (cont) – Analysis of FLAG-N-myc expression in Rat-1 fibroblasts 
transfected with pBabepuro-FLAG-N-myc (mouse cDNA) or empty vector. (A) Whole 
cell lysates of Rat-1/pBabe and Rat-1/N-myc cultures were analyzed by immunoblotting 
against FLAG and -tubulin (loading control). (B) Whole cell lysates of Rat-1/N-myc 
and the human neuroblastoma cell lines SK-N-DZ, LAN-1 and NB-1643 were analyzed 
by immunoblotting against N-myc and -tubulin. (C) Immunofluorescence analysis of 
Rat-1/pBabe and Rat-1/N-myc cells using anti-FLAG antibody. Stained cells were 
visualised on a Zeiss Axiovert 200M inverted microscope and the images were captured 
using the Axiocam software. Scale bar equals 20m. (D) Rat-1/pBabe or N-myc whole 
cell extracts were immunoprecipitated with anti-Max or anti-FLAG antibodies and the 
immunoprecipitates (IP) were resolved by SDS-PAGE and analysed by immunoblotting 
against FLAG, Max and -tubulin (loading control). 10% of the protein input was 
analysed in parallel as a reference. MW: Protein Molecular Weight Marker.  
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Figure 4.2 – Analysis of cell cycle distribution of Rat-1 fibroblasts transfected with 
pBabepuro-FLAG-N-myc (mouse cDNA) or empty vector treated with nocodazole. Rat-
1/pBabe and Rat-1/N-myc cell cultures were incubated for 18h in normal growth media 
supplemented with 0 (A), 0.03 (B), 0.21 (C), 0.43 (D), 0.85 (E), 1.7 (F), 3.4 (G) or 
17M (H) nocodazole; cells were then incubated under normal growth conditions and 
collected following 0 or 24h. PI staining was performed prior to flow cytometry 
analysis. For each sample, 10,000 events were acquired and DNA profiles were 
analysed using the FlowJo software; cell death was determined based on the presence of 
the sub-G1 population. 
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Figure 4.3 – Analysis of cell cycle distribution of Rat-1 fibroblasts transfected with 
pBabepuro-FLAG-N-myc (mouse cDNA) or empty vector submitted to mitotic arrest 
treatment. Rat-1/pBabe and Rat-1/N-myc cell cultures were incubated for 18h in normal 
growth media supplemented with 0.21M nocodazole; cells were then incubated under 
normal growth conditions and collected at the indicated times. PI staining was 
performed prior to flow cytometry analysis. For each sample, 10,000 events were 
acquired and DNA profiles were analysed using the FlowJo software; error bars 
represent standard deviations calculated from three independent experiments (see 
appendix VI for data). Asterisk represents p<0.01, Student’s t test. 
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Figure 4.4 – Analysis of protein expression in Rat-1 fibroblasts transfected with 
pBabepuro-FLAG-N-myc (mouse cDNA) or empty vector. Whole cell lysates of Rat-
1/pBabe and Rat-1/N-myc cultures were analyzed by immunoblotting against the 
indicated proteins. Protein levels were quantified using the AIDA software and 
normalised against -tubulin levels. The relative protein expression (%) is displayed at 
the bottom of the respective panel and was determined in respect to the Rat-1/pBabe 
sample. Results are representative of two independent experiments. 
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Figure 4.5 – Analysis of HA-p21 and HA-p27 expression in Rat-1/pBabe and Rat-1/N-
myc (mouse cDNA) cells. Rat-1/pBabe (clones A-B, E-F) and Rat-1/N-myc (clones C-
D, G-H) cells carrying an IPTG-inducible HA-tagged human p21 (A, clones A-D) or 
p27 (B, clones E-H) were incubated for 48h in normal growth media in the presence or 
absence of 1mM IPTG. Whole cell lysates were resolved by SDS-PAGE and analysed 
by immunoblotting against HA and -tubulin (loading control). MW: Protein Molecular 
Weight Marker. 
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Figure 4.6 – Analysis of the interaction between mouse N-myc and human p21 by 
protein co-immunoprecipitation in Rat-1 cells. Rat-1/N-myc/HA-p27 and HA-p21 cells 
were incubated for 48h in normal growth media in the presence or absence of 1mM 
IPTG. Whole cell extracts were immunoprecipitated (IP) with anti-HA antibody. The 
immunoprecipitates were resolved by SDS-PAGE and analysed by immunoblotting 
against HA and FLAG. 10% of the protein input was analysed in parallel as a reference. 
The experiment was carried out a single time. MW: Protein Molecular Weight Marker. 
 
 
 
 
 
 
 
 
  A. Duarte 
122 
 
 
Figure 4.7 – Analysis of cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
(mouse cDNA) cells carrying an IPTG-inducible human p21 (A) or p27 (B) construct. 
Rat-1 cell cultures were incubated for 48h in normal growth media in the presence or 
absence of 1mM IPTG. PI staining was performed prior to flow cytometry analysis. For 
each sample, 10,000 events were acquired and DNA profiles were analysed using the 
FlowJo software; error bars represent standard deviations calculated from three 
independent experiments (see appendix VIII for data). Asterisk represents p<0.01, 
Student’s t test. 
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Figure 4.8 – Analysis of cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
(mouse cDNA) cells carrying an IPTG-inducible HA-tagged human p21 (A-C) or p27 
(D-F) construct. 
For legend, see following page. 
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Figure 4.8 (cont) – Analysis of cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
(mouse cDNA) cells carrying an IPTG-inducible HA-tagged human p21 (A-C) or p27 
(D-F) construct. 
For legend, see following page. 
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Figure 4.8 (cont) – Analysis of cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
(mouse cDNA) cells carrying an IPTG-inducible HA-tagged human p21 (A-C) or p27 
(D-F) construct. Rat-1 cell cultures were incubated for 24 or 36h in normal growth 
media supplemented with 0-10M IPTG. Cells were analysed by immunoblotting 
against HA and -tubulin (loading control) (A, D) or flow cytometry following PI 
staining (B-C, E-F). For each sample, 10,000 events were acquired and DNA profiles 
were analysed using the FlowJo software. Results are representative of two independent 
experiments (see appendix IX for data). Protein levels were quantified using the AIDA 
software and normalised against -tubulin levels. The relative protein expression is 
displayed at the bottom of the respective panel and was determined in respect to the 
untreated sample. The experiment was carried out a single time. 
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Figure 4.9 – Analysis of cell cycle distribution of Rat-1/pBabe (A, C) and Rat-1/N-myc 
(mouse cDNA) (B, D) cells carrying an IPTG-inducible human p21 (A, B) or p27 (C, 
D) construct. Rat-1 cell cultures were incubated for 1-5 days in growth media 
supplemented with 10% serum. Cells were analysed by flow cytometry following PI 
staining. For each sample, 10,000 events were acquired and DNA profiles were 
analysed using the FlowJo software. Results are representative of two independent 
experiments (see appendix X for data). 
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Figure 4.9 (cont) – Analysis of cell cycle distribution of Rat-1/pBabe (A, C) and Rat-
1/N-myc (mouse cDNA) (B, D) cells carrying an IPTG-inducible human p21 (A, B) or 
p27 (C, D) construct. 
For legend, see previous page. 
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Figure 4.10 – Analysis of cell cycle distribution of Rat-1/pBabe (A, C) and Rat-1/N-
myc (mouse cDNA) (B, D) cells carrying an IPTG-inducible human p21 (A, B) or p27 
(C, D) construct. Rat-1 cell cultures were incubated at day 1 in growth media 
supplemented with 0.5% serum and 1mM IPTG was added 24h later (indicated with a 
―+‖). Cells were analysed by flow cytometry following PI staining. For each sample, 
10,000 events were acquired and DNA profiles were analysed using the FlowJo 
software. Results are representative of two independent experiments (see appendix XI 
for data). 
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Figure 4.10 (cont) – Analysis of cell cycle distribution of Rat-1/pBabe (A, C) and Rat-
1/N-myc (mouse cDNA) (B, D) cells carrying an IPTG-inducible human p21 (A, B) or 
p27 (C, D) construct. 
For legend, see previous page. 
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CHAPTER 5 - N-MYC AND THE DNA DAMAGE RESPONSE 
 
5.1 Introduction 
Cell cycle regulators are primary targets of the DNA damage response to allow 
coordination of the DNA repair process with cell cycle progression. These targets 
include: p53, which is activated and stabilized after DNA damage, and activates, in turn, 
the expression of p21 to promote cell cycle arrest (Dulić et al., 1994, Banin et al., 1998); 
cdc25A phosphatase, which is degraded following DNA damage to prevent cdk 
dephosphorylation and consequent activation (Mailand et al., 2000); and cyclin D1, 
which is degraded after treatment with both ultraviolet and ionising radiation (Pagano et 
al., 1994, Agami and Bernards, 2000). Furthermore, c-Myc is also negatively regulated 
following treatment with various genotoxic agents such as UVC and etoposide; in the 
latter case this effect was shown to block cell cycle progression and prevent replication 
of damaged DNA (Britton et al., 2008, Cannell et al., 2010). Amplification and 
consequent overexpression of N-myc in NB cells appears to correlate with a failure to 
arrest in G1 following IR exposure and sensitization of cells to DNA damage-induced 
apoptosis (Tweddle et al., 2001b, Bell et al., 2006). These reports suggest that N-myc 
levels may play a decisive role in regulating the cellular events after DNA damage is 
inflicted. 
 
To dissect the role of N-myc in the DNA damage response, molecular changes in MNA-
NB cells treated with UV, IR, etoposide, cisplatin and 4NQO were investigated. In 
addition to N-myc, the responses by cyclin D1 and p21, key components of the cell 
cycle machinery, were also examined in some instances to evaluate the integrity of the 
DDR in NB cells. Histone H2AX is rapidly phosphorylated on serine 139 at sites of IR-
induced DSBs, as well as in response to UV-induced replicational stress (Rogakou et 
al., 1998, Burma et al., 2001, Ward and Chen, 2001). Formation of phosphorylated 
H2AX (H2AX) was therefore also examined as it provides a useful marker for 
monitoring activation of DDR signaling. 
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5.2 Results 
5.2.1 Effect of ultraviolet and ionising radiation on N-myc and cyclin D1 
expression 
To investigate if the expression of N-myc, like c-Myc, is regulated following exposure 
to ultraviolet C (UVC) radiation, the MYCN-amplified neuroblastoma line, SK-N-DZ 
(wild-type p53) was employed. The effect of IR in these cells was also tested as it gives 
rise to distinct DNA lesions and can therefore activate different effectors of the DDR. 
Cells were plated in normal growth medium and allowed to attach overnight. Cultures 
were irradiated with a range of UVC and IR doses and collected 3h post-exposure. 
Figure 5.1A shows a representative immunoblotting analysis of N-myc, cyclin D1 and 
p21 protein expression in response to the treatments. 
 
UVC irradiation suppressed drastically the expression of cyclin D1 and p21, including 
in cells exposed to the lowest dose tested (25J/m
2
) in which cyclin D1 becomes 
undetectable and p21 levels are strongly reduced in comparison to the untreated control. 
Contrastingly, N-myc is only moderately affected by 25J/m
2
 UVC but is strongly 
reduced following exposure to higher doses. Expression of N-myc appears to decline in 
a dose-dependent manner in response to UVC irradiation, an effect that is not observed 
for cyclin D1 or p21. Exposure of cells to IR also promoted downregulation of cyclin 
D1, although less dramatically than UVC since the protein was still detectable by 
immunoblotting at the highest dose tested (25Gy). N-myc expression was only modestly 
affected by this treatment whereas p21 levels were strongly increased in irradiated cells 
in line with previous studies that reported a p53-dependent upregulation of p21 
following exposure to -radiation (Dulić et al., 1994, El-Deiry et al., 1994). 
 
A possible role for p53, a downstream target of ATM/ATR that regulates cell cycle 
progression following DNA damage was then investigated (Kastan et al., 1991, Kastan 
et al., 1992, Agarwal et al., 1995, Tibbetts et al., 1999). For this purpose, the expression 
of N-myc after UV and IR irradiation was examined in the MNA-NB LAN-1 cell line 
which lacks p53 expression (Kohl et al., 1984, Davidoff et al., 1992). Cells were 
exposed to the dose ranges used previously and analysed by immunoblotting as before. 
As shown in Figure 5.1B, the levels of N-myc in LAN-1 cells were downregulated in all 
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UVC-treated samples compared to the untreated control, and the effect was also dose-
dependent, similar to that observed for the SK-N-DZ line. In IR-treated cells, the levels 
of N-myc remained relatively constant at all doses tested. Expression of cyclin D1 was 
strongly reduced after treatment with UVC or IR, independently of the dose used. LAN-
1 cells, which lack p53 protein expression, show a very low basal expression of p21 
which prevents adequate analysis of its response to either treatment. Nevertheless, in 
cells irradiated with 50-200J/m
2
 UVC, the levels of p21 become undetectable in the 
immunoblot, while in IR-treated cells p21 expression does not appear to be affected. 
 
5.2.2 N-myc response to low UVC doses 
The decrease in N-myc, cyclin D1 and p21 appeared to exhibit distinct kinetics in 
response to lower doses of UVC. To further analyse the effect of this type of radiation 
on their regulation, SK-N-DZ and LAN-1 cells were exposed to a lower range of UVC 
doses and collected 3h post-exposure. Expression of phosphorylated H2AX (H2AX) 
was examined to monitor accumulation of DNA damage. As shown in Figure 5.2, the 
levels of H2AX increased in a dose-dependent manner in both NB cell lines, albeit at 
higher levels in LAN-1 cells, indicating accumulation of DNA damage in response to 
the treatment. Both cell lines responded very similarly regarding N-myc and cyclin D1; 
N-myc expression was unaffected in cells treated with 5-10J/m
2
 UVC and moderately 
or strongly decreased following irradiation with 25 or 50J/m
2
 UVC, respectively. The 
levels of cyclin D1 were drastically reduced in cells treated with 10J/m
2
 or higher UVC 
doses. A low dose of UVC (5J/m
2
) induced p21 expression in SK-N-DZ whereas higher 
doses led to a dose-dependent decrease as observed above. As before, expression of p21 
was mostly undetectable in LAN-1 cells. 
 
5.2.3 Long-term response to UVC and IR exposure 
In order to better understand the effect of UVC and IR on N-myc expression, NB cells 
were treated with the same dose ranges as in section 5.2.1 and collected at later times 
(up to 24h) for immunoblotting analysis. Treatment of SK-N-DZ cells with high doses 
of IR and other genotoxic agents used below consistently reduced cell viability at later 
times. For this reason, the LAN-1 cell line was primarily employed in the analyses 
presented in this chapter. 
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As shown in Figure 5.3A, H2AX was undetectable in untreated LAN-1 cells but 
accumulated following irradiation in a dose-dependent way, signalling an increase in the 
amount of DNA damage induced that was sustained up to 24h post-exposure. The levels 
of N-myc were decreased in irradiated cells as early as 3h after treatment, as previously 
observed, and by 6h the dose-dependent effect of UVC on N-myc expression was clear. 
In cells treated with 25J/m
2
 UVC, the levels of N-myc returned to normal within 12h of 
exposure and remained comparable to the untreated control at later times. The response 
to the higher doses of UVC, however, was maintained up to 24h following exposure. 
Expression of cyclin D1 exhibited a dose-dependent decrease at 3-6h post-treatment; at 
later times however, the protein was undetectable in all UV irradiated cells. In cultures 
treated with medium or high UVC doses (50-200J/m
2
), there was a marked decline in 
the levels of the housekeeping protein α-tubulin (monitored as a loading control) at later 
time points (12-24h) that suggests loss of protein content likely as a result of cell death. 
The time- and dose-dependent regulation of N-myc in SK-N-DZ cells was found to be 
consistent with that observed for LAN-1 cells (Figure 5.3B). These results demonstrate 
that the UVC-induced changes in N-myc and cyclin D1 levels in NB cells represent 
long-term effects on protein regulation that potentially affect the global cellular 
response to UVC treatment.  
 
As presented in Figure 5.4, exposure of LAN-1 cells to ionizing radiation induced 
accumulation of H2AX and a dose-dependent decrease in cyclin D1 expression that 
resembles the observations made above. This effect was maintained up to 24h after 
treatment demonstrating that IR exposure also has long-term effects on cyclin D1 levels. 
Expression of N-myc did not appear to be affected as a result of the treatment. SK-N-
DZ cells were also examined at later times (up to 12h) following exposure to the same 
IR dose range but despite clear accumulation of H2AX in irradiated cells, the levels of 
N-myc were not affected by the treatment (data not shown). Increasing the IR dose up to 
60Gy did not produce any changes in the levels of N-myc in LAN-1 cells (data not 
shown).  
 
Taken together, these results suggest that expression of N-myc in MNA-NB cell lines is 
distinctly regulated following exposure to UVC or IR. The observed differences do not 
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appear to arise from a failure to respond to IR-induced damage as both cyclin D1 and 
p21 responded as previously reported, and accumulation of the DNA damage marker 
H2AX was observed following exposure to both genotoxic agents. The observations 
also appear to exclude a role for p53 in the UVC-dependent downregulation of N-myc. 
 
5.2.4 Effect of other DNA damaging agents on N-myc expression 
c-Myc is also downregulated in response to genotoxic stress. Various inhibitors of 
topoisomerase II and IR, which induce DSBs, can suppress expression of MYC mRNA 
(Ward, 1988, Caldecott et al., 1990, Fornari Jr et al., 1996, Watson et al., 1997, Magnet 
et al., 2001). The decrease in c-Myc levels following exposure to UV or the DNA 
damaging agent tripchlorolide occurs instead through accelerated proteolysis (Jiang et 
al., 2003, Britton et al., 2008). Tripchlorolide is thought to activate the nucleotide 
excision repair (NER) pathway, the same mechanism that removes UV-induced lesions, 
suggesting it similarly generates base adducts (Thoma, 1999, Cadet et al., 2005). A 
possible relation between the type of DNA lesion induced and regulation of N-myc was 
therefore investigated. For this purpose the chemotherapeutic drugs etoposide and 
cisplatin were employed; etoposide induces DSBs as a result of topoisomerase II 
inhibition whereas cisplatin generates DNA adducts that can be removed by the NER 
pathway as well as the mismatch repair (MMR) pathway (Burden et al., 1996, Jamieson 
and Lippard, 1999, Chaney et al., 2005). The carcinogenic agent 4NQO is considered a 
UV-mimetic since it introduces lesions repaired by nucleotide excision and was 
therefore also tested (Zelle and Bootsma, 1980). 
 
5.2.4.1 Etoposide 
To investigate if N-myc expression is regulated in neuroblastoma lines, LAN-1 cells 
were treated with a range of etoposide doses as described (Materials and Methods) and 
collected at the indicated time points for immunoblotting analysis. As shown in Figure 
5.5A, treatment with 2.5-25M etoposide did not induce any detectable changes in the 
levels of N-myc, despite accumulation of H2AX. The levels of cyclin D1 were slightly 
reduced at 6h post-exposure in treated cells, particularly at the highest dose tested, but at 
12h protein expression was drastically abolished at all doses tested. The cyclin D1 
response to etoposide was sustained up to 24h after treatment displaying a dose-
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dependent behaviour that was not obvious at earlier times. This observation is consistent 
with previous reports on the etoposide-induced downregulation of cyclin D1 (Lan et al., 
2002, Santra et al., 2009). Treatment with higher doses of etoposide (25-200M) did not 
induce changes in the expression of N-myc, unlike cyclin D1 which, as observed before, 
was downregulated in a dose-dependent manner up to 24h after treatment (Figure 5.5B). 
Thus, it appears that activation of the DNA damage response by etoposide, as 
determined by H2AX accumulation, does not affect regulation of N-myc, in clear 
contrast to cyclin D1. 
 
5.2.4.2 Cisplatin 
For analysis of the N-myc expression following exposure to cisplatin, LAN-1 cells were 
treated with a range of doses as described (Materials and Methods) and collected at the 
indicated time points for immunoblotting. As shown in Figure 5.6A, treatment with 
cisplatin resulted in accumulation of H2AX, particularly at later times, but the levels of 
N-myc were not affected in these cells.  
 
Direct comparison of cells treated with cisplatin and UVC showed a much lower 
genotoxic potential, as determined by H2AX accumulation, for the cisplatin doses 
tested above, in comparison to the other agent (data not shown). To determine if higher 
concentrations of cisplatin could affect N-myc expression, LAN-1 cells were treated 
with 200-500M cisplatin and collected at the indicated times for analysis as before. As 
can be observed in Figure 5.6B, cisplatin treatment did not change the levels of N-myc; 
contrastingly, cyclin D1 was strongly downregulated by the lowest dose tested (200M) 
as early as 3h following treatment. Both responses were sustained up to 12h post-
exposure; at this time, cultures treated with 300-500M cisplatin exhibited a reduced -
tubulin signal likely resulting from loss of protein content due to cell death.  
 
5.2.4.3 4-nitroquinoline-1-oxide (4NQO) 
To determine the effect of 4NQO in NB cells, LAN-1 and SK-N-DZ cells were treated 
with a range of 4NQO doses as described (Materials and Methods) and collected 6h 
after treatment. As presented in Figure 5.7, immunoblotting analysis revealed 
accumulation of H2AX in cells treated with 4NQO. Expression of N-myc decreased in 
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a dose-dependent manner in both cell lines and a similar response was observed for 
cyclin D1. In LAN-1 cells the levels of N-myc were strongly reduced by 2.5M 4NQO, 
whereas SK-N-DZ cells were only similarly responsive to a higher dose (25M). A loss 
of -tubulin signal was observed for both cell lines treated with 25M 4NQO, likely a 
result of cell death.  
 
These observations demonstrate that neither etoposide nor cisplatin, like IR, were able 
to induce, at the doses tested, the changes in N-myc expression observed following 
UVC and 4NQO exposure. Still, in the case of etoposide and cisplatin a requirement for 
p53 activity in the regulation of N-myc levels cannot be excluded since only the p53-
null LAN-1 cell line was tested. Nevertheless the signaling pathway activated by UVC 
and 4NQO is preserved in these cells and will therefore be the focus of this study. The 
data described suggests N-myc regulation could be related to the type of DNA lesion 
introduced by UVC radiation and the repair pathway activated as a consequence. The 
observation that cisplatin did not appear to exert an equivalent effect on N-myc despite 
generating bulky lesions that can, similar to UV light, activate the NER pathway, seems 
to implicate different or additional signaling pathways in the response to the damage 
induced by this agent thus accounting for the distinct effect. 
 
5.2.5 Molecular mechanisms regulating the N-myc response to UVC 
5.2.5.1 Upstream regulators of the N-myc response to UVC 
ATR is the primary kinase activated in response to a variety of agents that generate 
replication stress such as UV light and it would be thus of interest to investigate its role 
in the N-myc response to UVC (Guo et al., 2000b, Ward et al., 2004). However, unlike 
ATM, the development of a specific ATR inhibitor has yet to be reported. Furthermore, 
the study which described the CGK733 compound as an inhibitor of both kinases was 
subsequently retracted (Won et al., 2006). Given that ATM is also activated following 
UV irradiation, through direct phosphorylation by ATR, a possible role for ATM was 
then investigated by employing the ATM specific inhibitor KU-55933 (Hickson et al., 
2004, Stiff et al., 2006). LAN-1 cells were incubated with 10M KU-55933 for 30min 
prior to exposure to 50J/m
2
 UVC and collected 3h post-irradiation. The phosphorylation 
and consequent activation of checkpoint kinase 2 (Chk2) at threonine 68, although 
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ATR-dependent in cells exposed to UV radiation, is catalysed by ATM (Stiff et al., 
2006).This event should thus be blocked by the inhibitor and expression of phospho-
Chk2 was then analysed by immunoblotting to evaluate its activity. As shown in Figure 
5.8A, N-myc was downregulated in cells exposed to UVC, and phospho-Chk2 was 
readily detected in these cells. Incubation with KU-55933 reduced the accumulation of 
phospho-Chk2 in irradiated cells by approximately 50% but expression of N-myc 
exhibited a similar decline in both untreated and UV-treated cells suggesting ATM in 
not required for UV-dependent downregulation of N-myc.  
 
Prolonged incubation of LAN-1 cells with KU-55933 prior to UV irradiation (3h) did 
not improve ATM inhibition as assessed by the levels of phospho-Chk2 (data not 
shown) and a higher concentration of KU-55933 was then tested. For this purpose, 
LAN-1 cells were treated with 50M KU-55933 for 30min before exposure to 50J/m2 
UVC and collected 3h post-irradiation. As shown in Figure 5.8B, phosphorylation of 
Chk2 following UVC exposure was almost completely abolished by treatment with KU-
55933. Expression of N-myc however, was severely reduced in cells treated with KU-
55933; exposure to UVC did not induce further changes in the levels of N-myc. In order 
to determine if the effect of KU-55933 on the basal expression of N-myc was specific to 
the LAN-1 cell line, SK-N-DZ cells were treated in the same manner and analysed by 
immunoblotting. Treatment with KU-55933 strongly blocked accumulation of phospho-
Chk2 in UV-treated SK-N-DZ cells and reduced the protein levels of N-myc, 
independently of UV irradiation, indicating that the latter is not a cell line-specific effect 
(Figure 5.8C). 
 
Treatment with ATM/ATR inhibitors has been shown to induce downregulation of 
cyclin D1 in the absence of DNA damage (Alao and Sunnerhagen, 2009, Li and Yang, 
2010). In agreement with these reports, analysis of cyclin D1 levels in LAN-1 and SK-
N-DZ cells treated with KU-55933 revealed complete abrogation of protein expression 
by this treatment in both cell lines (Figures 5.8B and 5.8C, respectively). The ATM 
specific inhibitor KU-55933 exerted similar effects on N-myc levels suggesting a role 
for ATM in regulating N-myc, and possibly cyclin D1, expression in normal 
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proliferating NB cells. Alternatively, the responses observed with either inhibitor could 
result from off-target effects.  
 
5.2.5.2 Level of N-myc regulation in response to UVC 
Britton and colleagues (2008) demonstrated that the downregulation of c-Myc following 
UVC exposure occurred post-transcriptionally as a result of accelerated proteasomal 
degradation. To determine if N-myc is similarly regulated by this agent, the Rat-1 cell 
line expressing ectopic FLAG-tagged mouse N-myc (described in section 4.2.1) was 
used. Rat-1/N-myc cells were treated with a range of UVC doses and lysed 6h after 
exposure. Lysates were analysed by immunoblotting against the FLAG epitope, as well 
as cyclin D1 in order to analyse the UV effect on the levels of an endogenous protein 
demonstrated above to be regulated under these conditions. As shown in Figure 5.9, 
UVC exposure resulted in accumulation of H2AX indicating activation of DDR 
signaling in Rat-1 cells at the doses tested. Expression of FLAG-N-myc was 
downregulated in irradiated cells in a dose-dependent manner similar to that observed 
for endogenous N-myc in the NB cell lines, albeit with a lower sensitivity. This 
observation seems to indicate that UVC-dependent regulation of N-myc occurs at least 
in part through a post-transcriptional mechanism that is conserved in different cell types 
and species. 
 
Regulation of N-myc protein turnover is mediated by the ubiquitin-proteasome pathway 
(Bonvini et al., 1998, Gross-Mesilaty et al., 1998). To determine the role of this 
pathway in the UVC-dependent decrease in N-myc expression, LAN-1 and SK-N-DZ 
cells were incubated with the proteasome-specific inhibitor MG132 (Calbiochem) prior 
to exposure to a range of UVC doses (Rock et al., 1994). Cell lysates were collected 3h 
following UVC irradiation and analysed as before. As shown in Figure 5.10, treatment 
with MG132 inhibitor prevented the decrease in N-myc expression following UVC 
irradiation, indicating that the downregulation of N-myc in NB cells is likely mediated 
by the ubiquitin-proteasome pathway. 
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5.2.5.3 Role of DDB2 in the N-myc response to UVC 
The DDB1-DDB2 complex participates in the NER pathway and is particularly efficient 
in the recognition of UV photolesions (Keeney et al., 1993, Dualan et al., 1995, 
Fujiwara et al., 1999). This complex forms part of a Cul4A ubiquitin ligase that 
regulates the stability of a number of proteins involved in DDR signaling and repair by 
promoting ubiquitin-dependent proteasome degradation (Groisman et al., 2003, 
Stoyanova et al., 2008, Stoyanova et al., 2009). DDB2 has been shown to serve as the 
substrate receptor for the DDB1-Cul4A
DDB2
 complex (Lee and Zhou, 2007, Stoyanova 
et al., 2008, Stoyanova et al., 2009). In light of the specific regulation of N-myc 
observed following UVC and 4NQO treatment and the apparent requirement for 
proteasome activity in this response it was of interest to investigate a possible physical 
association between N-myc and the DDB2 receptor. For this purpose, HEK293T cells 
were transiently transfected with a pcDNA3 construct expressing FLAG-tagged human 
DDB2, either alone or in combination with a construct expressing HA-tagged mouse N-
myc. To confirm the ability of the assay to precipitate DDB2, the interaction between 
DDB2 and p21, a previously described target of the DDB1-Cul4A
DDB2
 complex, was 
used as a positive control by co-transfection of cells with constructs encoding FLAG-
DDB2 and HA-tagged human p21 (Stoyanova et al., 2008). 48h after transfection, cell 
cultures were incubated in the presence or absence of 10M MG132 for 30min to block 
proteasomal degradation. Whole cell lysates were collected and subjected to 
immunoprecipitation using anti-HA antibody; precipitated proteins were analysed by 
immunoblotting against FLAG or HA epitope. As can be observed in Figure 5.11A, 
DDB2 associated specifically with p21; inhibition of proteasome activity did not affect 
the basal levels of either protein but increased the amount of DDB2 that co-precipitated 
through p21 consistent with previous observations. DDB2 was also detected in N-myc 
precipitates, although only in cells incubated with MG132, suggesting it can interact 
specifically with N-myc (Figure 5.11B). The lack of detectable DDB2 in N-myc 
precipitates from untreated cells could be due to the markedly lower level of protein 
present in this sample as MG132 treatment strongly increased the basal levels of N-myc 
and proportionally raised the amount of precipitated protein. This is in contrast with p21 
whose precipitation was similarly efficient in the two samples when compared to the 
amount of protein present in the total cell lysates. This observation appears to exclude 
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the requirement for UVC-induced signaling in mediating N-myc/DDB2, or p21/DDB2, 
association. 
 
The putative N-myc/DDB2 interaction was then assayed in the NB cell line SK-N-DZ 
to determine if the endogenous proteins can also associate. To investigate a possible 
relationship between induction of DNA damage by UVC irradiation and the association 
of DDB2 to N-myc, cells were exposed to 50J/m
2
 UVC and collected 3h following 
treatment; UVC-treated cells were additionally incubated with 10M MG132 for 30min 
prior to lysis to stabilize N-myc. Cell lysates were immunoprecipitated using anti-
DDB2 antibody and precipitated proteins were analysed as before (Figure 5.12). As 
observed before, UVC exposure induced accumulation of H2AX, indicative of DDR 
activation, and a strong decrease in the levels of N-myc; treatment with proteasome 
inhibitor prevented UVC-induced downregulation of N-myc. Although DDB2 was 
present in cell lysates, the precipitated protein could not be discriminated in the 
immunoblot due to severe cross-reactivity of the secondary antibody with the 
immunoprecipitated lysates. N-myc was however weakly detected in the DDB2 
precipitate from UVC-irradiated cells in which proteolysis was inhibited by MG132 
treatment, but not in untreated cells. Given that ectopically expressed N-myc and DDB2 
were shown to associate without a requirement for UVC exposure (Figure 5.11) this 
observation could reflect the presence of slightly higher levels of N-myc and&or DDB2 
in MG132-treated cells which allowed detection of N-myc in DDB2 precipitates. 
Together, these observations suggest N-myc can associate with DDB2 in vivo but the 
role of the interaction in the N-myc response to UVC radiation is unclear. The evidence 
indicating the DDB complex is the NER factor with the highest affinity for UV-induced 
lesions together with the role of DDB2 as a substrate receptor for the DDB1-Cul4A 
ligase raises the possibility that DDB regulates N-myc stability following UVC 
exposure in NB cells and could explain the distinct response of N-myc to this genotoxic 
agent. 
 
5.2.5.4 Mapping of the region of N-myc involved in the response to UVC 
Identification of the N-myc domain(s) required for degradation following UVC 
exposure could provide insight into the mechanism of regulation or the cellular 
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mediators of the N-myc response. The role of the well-characterized Myc Boxes I and II 
and the BRHLHZip domain were therefore first investigated. For this purpose, Rat-1 
fibroblasts were transfected with the vector pcDNA3 directing the constitutive 
expression of three N-terminal mutants, N-myc del63, del124 and del177, and a C-
terminal mutant, N-myc 1-370, fused N-terminally to a FLAG epitope (see section 3.2.1 
for details). Stable polyclonal cell populations were selected as described (Materials and 
Methods) and expression of the FLAG-tagged mouse N-myc variants was analysed by 
immunoblotting against the FLAG epitope. The Rat-1/N-myc cell line was also 
included in the analysis as a positive control. As shown on Figure 5.13A, all N-myc 
mutants, apart from N-myc del63, were expressed at levels equivalent to the wild-type 
protein. 
 
Rat-1 lines were then employed to study the response by the various N-myc mutants to 
UVC irradiation. Cells were treated with 200J/m
2
 UVC and collected 6h after exposure 
for immunoblotting using an anti-FLAG antibody; a representative immunoblot is 
shown in Figure 5.13B. As observed before, the levels of wild-type N-myc decreased by 
approximately 50% in UVC-exposed cells (Figure 5.13C). In contrast, the three mutants 
carrying deletions in the N-terminus region responded weakly to irradiation, with 
protein levels decreasing by less than 15% in treated cells. The effect of UVC on N-myc 
1-370 was comparable to that observed for the wild-type protein with expression 
declining by approximately 50%. This data implies a role for the N-terminal region of 
N-myc in the response to UVC radiation, more specifically residues 1-63, and appears 
to exclude the need for an intact C-terminus in this response. 
 
5.2.5.5 Role of phospho-residue Thr58 in the N-myc response to UVC 
In cycling cells, phosphorylation at threonine 58 by GSK3 targets N-myc for 
proteasomal degradation (Kenney et al., 2004, Welcker et al., 2004, Sjostrom et al., 
2005, Yaari et al., 2005, Chesler et al., 2006). To determine if this residue is also 
involved in UVC-dependent downregulation of N-myc, a Rat-1 cell line was established 
expressing a FLAG-tagged mutant N-myc bearing a threonine-to-alanine mutation at 
this position (N-myc (T58A)) to prevent phosphorylation. Expression of the mutant 
protein was confirmed by immunoblotting against the FLAG epitope (Figure 5.14A). 
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The effect of UVC radiation on N-myc expression in the two Rat-1 lines was then 
examined by anti-FLAG immunoblotting in lysates collected 6h post-exposure to 
200J/m
2
 UVC. As shown in Figure 5.14B, both wild-type and T58A mutant N-myc 
were downregulated in irradiated cells; however, expression of the latter was 
significantly less decreased following treatment, as determined from three independent 
experiments (Figure 5.14C). The changes in cyclin D1 and H2AX levels were similar 
in both cell lines indicating that the distinct responses do not arise from differences in 
the treatment. Additionally, treatment of cells with MG132 inhibitor prior to UVC 
exposure blocked downregulation of N-myc in both cell lines indicating the response is 
dependent on proteasome activity as observed in NB cells. This observation supports 
the findings described above regarding the requirement for an intact N-terminus in the 
UVC-dependent regulation of N-myc and suggests phosphorylation at Thr58 may be 
necessary for this response.  
 
5.2.6 Cellular response to UVC treatment in Rat-1 lines 
Enhanced expression of N-myc can sensitize cells to apoptosis following exposure to 
cytotoxic agents by impairing the cell cycle arrest normally triggered under these 
conditions (Fulda et al., 1999, Paffhausen et al., 2007). In light of the observations 
described above regarding the negative regulation of N-myc by UVC radiation, it was of 
interest to determine if ectopic N-myc could affect the cellular response or increase 
susceptibility to this type of radiation in the Rat-1 line. For this purpose, Rat-1 control 
and N-myc cells were exposed to a range of UVC doses and collected for flow 
cytometry analysis 24h after irradiation. Figure 5.15A illustrates the cell cycle 
distribution of the two lines as determined from three independent experiments; the cell 
fraction exhibiting fragmented DNA (sub-G1) indicative of cell death is also presented 
(Figure 5.15B). Irradiation of Rat-1 control cells with increasing UVC doses did not 
induce marked changes in cell cycle distribution but caused a small decrease in cell 
viability. Rat-1/N-myc cells exhibited in comparison, a stronger increase in cell death 
(approximately 20%). The increased UV sensitivity observed in Rat-1/N-myc may have 
resulted from an N-myc-mediated attenuation of the DNA damage-induced cell cycle 
arrest since a sharp reduction in the G2/M-phase population was observed in UV-treated 
cultures. 
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The truncated variants of N-myc were shown to be distinctly regulated following 
exposure to UVC radiation (Figure 5.13). In order to compare the effect of UV-resistant 
or sensitive N-myc variants on cell cycle progression following irradiation, the various 
Rat-1 lines were exposed to a range of UVC doses and collected for flow cytometry 
analysis 24h after treatment (Figure 5.16). UVC-treated Rat-1 control cultures showed a 
dose-dependent accumulation of cells in S phase accompanied by a decrease in the G1 
fraction; the G2/M population remained relatively stable at all UVC doses tested. Rat/1-
N-myc cultures showed a small depletion of G1 cells at higher UVC doses (100-
200J/m
2
); as previously observed, UV treatment resulted in a strong decrease in the 
G2/M fraction and in cell viability. Apart from the Rat-1/N-myc del124 cell line which 
exhibits an enriched S-phase population even in the untreated control and does not show 
changes in cell cycle distribution following UVC irradiation, the remaining N-myc 
mutant lines under study showed following treatment an increased S-phase fraction and 
a decreased G1 population as observed for control cells. Furthermore, none of the 
mutants showed a clear reduction in the G2/M population following exposure nor 
exhibited a drastic increase in cell death in response to the treatment. Thus, it appears 
that the ability of wild-type N-myc to sensitize Rat-1 cells to radiation, possibly through 
suppression of an UVC-induced cell cycle arrest, requires an intact N- and C-terminus. 
Deletion of the N-terminal residues 1-63, encompassing the MBI domain, or the C-
terminal residues 371-462, where the BRHLHZip domain lies, is sufficient to abolish 
the N-myc-dependent cell death. Although N-myc mutant 1-370 was shown to be 
degraded following UVC treatment the same as the wild-type protein, the response to 
irradiation by cells carrying this variant is distinct from Rat-1/N-myc cells suggesting 
the cellular effect is not dependent on UV regulation of N-myc. 
 
5.3 Discussion 
This chapter presents the investigation on N-myc regulation in response to DNA 
damage. Analysis of N-myc expression in neuroblastoma SK-N-DZ cells following 
treatment with IR and UVC revealed a distinct response to these genotoxic agents. 
Treatment with UVC resulted in a dose-dependent decline in the levels of N-myc 
whereas IR had little effect on protein levels (Figure 5.1A). Consistent with previous 
reports, exposure to UVC or IR induced a dramatic downregulation of cyclin D1 at all 
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doses tested (Agami and Bernards, 2000, Miyakawa and Matsushime, 2001, Santra et 
al., 2009). As described above, progression through G1 phase of the cell cycle is 
blocked by the inhibitory binding of pRb to E2F proteins (Flemington et al., 1993, Helin 
et al., 1993). Cyclin D1 associates with cdk4/6 and mediates phosphorylation and 
inactivation of pRb leading to transcriptional induction of genes required for entry into 
S phase (Ewen et al., 1993, Connell-Crowley et al., 1997, Dyson, 1998, Black and 
Azizkhan-Clifford, 1999). As observed above, the levels of p21 were reduced by UVC 
treatment but accumulated in IR-treated cells. Phosphorylation of p53 by ATM in 
response to IR increases its transcriptional activity and may render it more resistant to 
inhibition by MDM2 (Shieh et al., 1997, Banin et al., 1998, Canman et al., 1998, 
Lambert et al., 1998, Dumaz and Meek, 1999, Zhang and Xiong, 2001). Upregulation of 
p21 in response to IR is dependent on p53 transcriptional activation thus suggesting p53 
and its upstream activating kinase ATM are functional in these cells (Canman et al., 
1994, Dulić et al., 1994, El-Deiry et al., 1994). The downregulation of p21 following 
exposure to UVC is therefore not due to a failure by p53 to activate the p21 gene. This 
response is instead mediated by ATR and appears to be partly UV dose-dependent 
(Cotton and Spandau, 1997, Reinke and Lozano, 1997, Allan and Fried, 1999, 
Bendjennat et al., 2003, Zhong et al., 2005, Lee et al., 2007). In agreement with this, 
treatment of SK-N-DZ cells with a low dose (5J/m
2
) of UVC radiation led to p21 
accumulation whereas higher doses (10-200J/m
2
) resulted in its downregulation (Figure 
5.2).  
 
As shown in Figure 5.1B, the response by N-myc to both UVC and IR was readily 
reproducible in human LAN-1 cells which do not express p53 (Kohl et al., 1984). These 
observations imply that the specific response to UVC is independent of p53 activity in 
NB cells. Downregulation of cyclin D1 as a result of UVC or IR irradiation was also 
observed in these cells. The cyclin D1 response to DNA damage observed in both NB 
lines suggests the failure by MNA-NB cells to arrest in G1 following IR exposure 
reported in a number of studies is not due to aberrant D1 regulation under these 
conditions (McKenzie et al., 1999, Tweddle et al., 2001b, Bell et al., 2006). In 
agreement with a requirement for p53 in the p21 response to IR, no accumulation of p21 
was observed in LAN-1 cells treated with this agent. Although induction of p21 during 
  A. Duarte 
145 
 
cell proliferation and differentiation appears to be independent of p53, the low basal 
levels of p21 in LAN-1 cells are likely due to lack of p53 activity (Michieli et al., 1994, 
Macleod et al., 1995, Parker et al., 1995). The p21 response to UVC was for this reason 
difficult to assess. The analysis shown in Figure 5.2 is consistent with the observations 
described above but seems to indicate the involvement of different mechanisms in the 
UV-dependent regulation of N-myc, cyclin D1 and p21 since these proteins exhibited 
rather distinct responses to this genotoxic agent suggesting they perform different roles 
in the response to UVC-induced DNA damage. 
 
Negative regulation of the related c-Myc protein in response to UVC has been reported 
as well and the effect was also found to be independent of p53 activity (Britton et al., 
2008). Other DNA damaging agents were found to induce changes in the levels of c-
Myc. Similar to UV, the genotoxic drug tripchlorolide was shown to promote 
accelerated c-Myc proteolysis (Jiang et al., 2003, Ren et al., 2003). IR triggered instead 
a decrease in c-Myc mRNA and consequently protein levels, an effect that was not 
observed for N-myc protein in this study (Watson et al., 1997, Sheen and Dickson, 
2002, Rieger and Chu, 2004). Treatment with the DNA topoisomerase II inhibitors 
teniposide, doxorubicin and amsacrine also suppressed transcriptional expression of c-
Myc (Bunch et al., 1994, Orr et al., 1995, Fornari Jr et al., 1996, Magnet et al., 2001). 
Etoposide, which similarly targets this enzyme, seems to decrease c-Myc protein levels 
through translational repression (Burden et al., 1996, Cannell et al., 2010). Analysis of 
the N-myc response to etoposide in LAN-1 cells did not suggest this protein is regulated 
in a similar manner (Figure 5.5). Cyclin D1 on the other hand exhibited a strong dose-
dependent decrease in response to this drug. Cannell and colleagues found the c-Myc 
response to be both p53-dependent and independent suggesting the absence of p53 
expression in LAN-1 cells cannot alone account for the distinct effects of this drug in 
the two Myc proteins (Cannell et al., 2010). Treatment with the DNA crosslinking agent 
cisplatin likewise induced downregulation of cyclin D1 in these cells without any 
visible effect on N-myc protein levels (Figure 5.6). In contrast to these agents, treatment 
with the UV-mimetic 4NQO resulted in a marked reduction in N-myc as well as cyclin 
D1 expression in LAN-1 and SK-N-DZ cells, although the latter exhibited a limited 
response to lower 4NQO doses (Figure 5.7). The effects of etoposide and cisplatin on 
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cyclin D1 levels in NB cells are consistent with previous reports and support the notion 
that the decrease in cyclin D1 levels triggered by various genotoxic stresses is a 
universal component of the DNA damage response to promote cell cycle arrest (Lan et 
al., 2002, Santra et al., 2009). Despite the multiple functions of N-myc in promoting cell 
cycle progression, the distinct effects of the various genotoxic agents tested suggest its 
specific downregulation by UVC radiation, and 4NQO, does not directly participate in 
the induction of proliferative block mediated by the DDR machinery. 
 
Similarly to IR, etoposide and the remaining topoisomerase II inhibitors mentioned 
generate DSBs which can be repaired by HR or NHEJ (Ward, 1988, Caldecott et al., 
1990, Sancar et al., 2004). UV-induced photo-adducts are removed by the NER 
pathway which is also thought to be involved in the response to tripchlorolide (Thoma, 
1999, Jiang et al., 2003, Cadet et al., 2005). Expression of c-Myc thus seems to be 
equally suppressed by different genotoxic stresses. The type of DNA lesion and the 
repair pathway activated as a consequence may determine the mechanism by which this 
protein is downregulated. In the case of N-myc, no effect was observed on protein levels 
following treatment with agents that induce DSBs. As described above, several studies 
have reported a failure by MNA-NB cells to arrest in G1 following IR treatment but the 
regulation of N-myc levels following treatment was not examined in either MNA or 
non-MNA cells (McKenzie et al., 1999, Bell et al., 2006, Bell et al., 2007). Similarly, 
ectopic expression of c-Myc was shown to attenuate the IR-induced G1/S checkpoint in 
human mammary epithelial cells (Sheen and Dickson, 2002). In this study, the IR-
induced downregulation of endogenous c-Myc in control cells was not inhibited by 
ectopic c-Myc but protein levels remained abnormally high and prevented G1 arrest 
nevertheless. 
 
5.3.2 Molecular mechanisms regulating the N-myc response to UVC 
To investigate the molecular mechanisms regulating the specific UVC-induced 
reduction in N-myc levels, the Rat-1 cell line expressing constitutive mouse N-myc 
described above (section 4.2.1) was employed. Exposure of Rat-1/N-myc cells to UVC 
demonstrated the N-myc response to this agent involved a post-transcriptional control 
mechanism (Figure 5.9). The kinetics at which N-myc, but not cyclin D1, was decreased 
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following treatment appeared to vary from that observed for NB cells. Still, UVC-
induced downregulation of N-myc in NB cells (SK-N-DZ and LAN-1) was prevented 
by treatment with a proteasome inhibitor (Figure 5.10) indicating that destabilization of 
N-myc protein is likely the dominant mechanism involved in the response to irradiation. 
This observation is consistent with the findings by Britton and colleagues regarding the 
regulation of c-Myc by UVC irradiation (Britton et al., 2008). 
 
The DDB1-Cul4A
DDB2
 ligase was shown to direct proteasomal degradation of p21 and 
p53 following UV exposure (Shiyanov et al., 1999b, Groisman et al., 2003, Stoyanova 
et al., 2008, Stoyanova et al., 2009). As an initial approach to determine whether N-myc 
is similarly regulated by this E3 ligase, a possible interaction between N-myc and 
DDB2, the substrate receptor, was investigated by immunoprecipitation of ectopically 
expressed proteins in HEK293T cells or endogenous proteins in SK-N-DZ cells. N-
myc/DDB2 binding was clearly shown using HEK293T cell lysates (Figure 5.11B) and, 
consistent with previous reports, DDB2 was also found to interact with p21 (Figure 
5.11A) (Stoyanova et al., 2008, Stoyanova et al., 2009). Endogenous N-myc also 
precipitated through DDB2 in NB cells exposed to UVC in which proteasome activity 
had been inhibited to prevent N-myc degradation (Figure 5.12). However, this 
observation could have resulted from the presence of slightly increased levels of N-myc 
in these cells given that UVC exposure was not required for ectopic N-myc and DDB2 
to associate (Figure 5.11B). Alternatively, this requirement may have been bypassed in 
HEK293T cells due to overexpression of both N-myc and DDB2. These observations 
could suggest a role for DDB2, in association with DDB1 and Cul4, in the specific N-
myc response to this type of radiation but further studies are required to confirm these 
observations and determine if this putative interaction mediates ubiquilylation by the 
DDB1-Cul4A
DDB2
 ligase and consequent proteolysis of N-myc. 
 
In human cells, p53 transactivation of DDB2 is important for efficient repair of UV-
induced CPDs (Ford and Hanawalt, 1995, Ford and Hanawalt, 1997, Hwang et al., 
1999). However, basal expression of DDB2 is not solely dependent on p53 and its gene 
contains additional binding sites for Sp1 and E2F transcription factors, among others, 
which suggests it may be expressed in a cell cycle-regulated manner (Nichols et al., 
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2003, Prost et al., 2006). In agreement with this, DDB2 expression was detected in 
LAN-1 cells which lack p53 expression, albeit at lower levels than in SK-N-DZ cells 
(data not shown). Furthermore, the mouse DDB2 gene does not contain a functional p53 
response element and other factors appear to contribute to expression of mouse DDB2, 
as demonstrated for E2F (Tan and Chu, 2002, Lin et al., 2009). Rodent ﬁbroblasts were 
shown nevertheless, to have decreased DDB activity than human fibroblasts due to 
lower DDB2 expression (Bohr et al., 1985, Tang et al., 2000). This may account for the 
distinct kinetic in the UVC-dependent downregulation of N-myc observed in Rat-1 
fibroblasts expressing ectopic N-myc (Figure 5.9) compared to NB cells (Figure 5.1). 
Consistent with this, UVC-dependent decrease in c-Myc levels was also less 
pronounced in mouse embryo fibroblasts and CHO cells in comparison to human U2OS 
osteosarcoma cells (Britton et al., 2008). 
 
As described above, the DDB complex participates in the GG-NER pathway by acting 
as an initial sensor of UV-induced DNA lesions, a role which is likely to involve 
chromatin remodeling to allow access to transcriptionally inactive DNA and efficient 
repair (Chu and Chang, 1988, Payne and Chu, 1994, Hwang et al., 1999, Tang et al., 
2000). In agreement with this hypothesis, the DDB complex was shown to bind the 
HAT CBP/p300 (Datta et al., 2001). This finding suggests DDB might stimulate DNA 
repair in part by recruiting histone-modifying enzymes and altering chromatin structure 
at sites of damage, a mechanism analogous to that used in transcriptional activation by 
various factors including c- and N-myc (Wood et al., 2000, Amati et al., 2001, Park et 
al., 2001, Knoepfler et al., 2006, Cotterman et al., 2008). This role by DDB is further 
supported by studies demonstrating the DDB1-Cul4A
DDB2 
ligase can ubiquitylate 
several nucleosome histones to promote chromatin loosening and facilitate the NER 
process (Kapetanaki et al., 2006, Wang et al., 2006, Guerrero-Santoro et al., 2008). 
Britton and colleagues found DDB1 expression not to be required for UVC-induced 
downregulation of c-Myc (Britton et al., 2008). If DDB E3 ligase activity is similarly 
dispensable for N-myc degradation following UVC irradiation, the interaction observed 
between DDB2 and N-myc could reflect instead a role by the latter in the NER pathway 
possibly unrelated to the downregulation induced by this genotoxic agent. 
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The DDB complex has been found to physically associate with the E2F1 transcription 
factor and enhance its transcriptional activity (Hayes et al., 1998). Mutant DDB2 
proteins that failed to interact with DDB1 and could not as a result stimulate its nuclear 
accumulation were still able to bind E2F1 but failed to stimulate E2F1-activated 
transcription demonstrating the requirement for an intact DDB complex in this effect 
(Shiyanov et al., 1999a). Like pRb, DDB interacts with the activation domain of E2F1 
and appears to compete for binding to this region suggesting it can alleviate E2F1 
inhibition by pRb. In light of these studies, it is possible that the association of DDB2, 
and possibly DDB1, and N-myc functions instead to modulate the transcriptional 
activity of the latter. 
 
As described above, a role for ATR in the UVC-dependent regulation of N-myc could 
not be investigated (section 5.2.5.1). Inhibition of ATM with a specific inhibitor, KU-
55933, attenuated Chk2 activation but did not seem to prevent UV-induced 
downregulation of N-myc (Figure 5.8A). This observation could indicate ATR is 
instead the apical kinase mediating suppression of N-myc expression, consistent with its 
primary role in the response to UV exposure (Guo et al., 2000b, Heffernan et al., 2002). 
The KU-55933 inhibitor affected the basal levels of N-myc independently of UVC 
irradiation (Figures 5.8B and 5.8C). Although a possible off-target effect by this 
inhibitor cannot be excluded, it is also possible that ATM is involved in the regulation 
of N-myc expression. The levels of cyclin D1 were also examined in cells treated with 
KU-55933 and were also found to be suppressed by this treatment. Similar effects were 
observed in LAN-1 and SK-N-DZ cells thereby excluding a role for p53 in mediating 
this response. Alao and Sunnerhagen reported a similar effect by the ATM/ATR 
inhibitors caffeine and CGK733 on cyclin D1 expression using different human cancer 
cell lines (Alao and Sunnerhagen, 2009). Although they did not observe a similar 
decrease in cells treated with the ATM inhibitor KU-55993, all three inhibitors reduced 
proliferation in these cell lines as well as in various non-transformed mouse fibroblast 
cells suggesting the changes in cyclin D1 levels may have been too subtle to be 
detected. ATM and ATR were shown by Hitomi and colleagues to regulate 
phosphorylation of cyclin D1 at Thr286 both in normal proliferating cells as well as 
following genotoxic stress (Hitomi et al., 2008). Phosphorylation of this residue by 
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GSK3 promotes nuclear export, ubiquitylation and consequent degradation of cyclin 
D1 (Diehl et al., 1997, Diehl et al., 1998, Lin et al., 2006). The stability of N-myc is 
similarly regulated through phosphorylation at Thr58 by GSK3 (Kenney et al., 2004, 
Sjostrom et al., 2005, Yaari et al., 2005). ATM inhibition can suppress cell proliferation 
by blocking activation of Akt signaling following mitogen stimulation or DNA damage, 
an effect that appears to require downregulation of cyclin D1 (Viniegra et al., 2005, 
Halaby et al., 2008, Golding et al., 2009, Li and Yang, 2010). Akt can stabilize cyclin 
D1 and N-myc through inhibition of GSK3 (van Weeren et al., 1998). Indirect 
inhibition of Akt by KU-55933, or ATM inhibitors in general, could therefore account 
for the decreased levels of cyclin D1 and N-myc in NB cells.  
 
To understand the mechanisms of proteasome-dependent N-myc degradation induced 
by UVC, various Rat-1 cell lines were established expressing FLAG-tagged mouse N-
myc variants lacking amino acids segments encompassing MBI, MBI and MBII or the 
C-terminus (Figure 5.13A). The C-terminal N-myc mutant (N-myc 1-370) was 
downregulated following UVC irradiation, similar to wild-type N-myc whereas the N-
terminal mutants (del63, del124 and del1177) resisted degradation induced by UVC 
(Figure 5.13B). All N-myc mutants tested carry a sequence previously demonstrated to 
direct the human protein into the nucleus and which is perfectly conserved in the mouse 
protein (amino acids 343-350) (DePinho et al., 1986, Stanton et al., 1986, Dang and 
Lee, 1989). Therefore, it is unlikely the difference in the UVC response results from 
cytoplasmic retention. As described above TRUSS protein interacts with the C-terminus 
of N-myc and this observation appears therefore to exclude a role by the DDB1-
Cul4A
TRUSS
 ubiquitin ligase in targeting N-myc for proteolysis (Choi et al., 2010). The 
presence of the N-terminal 63 amino acids seemed to be required for UVC-induced N-
myc downregulation possibly via phosphorylation of Thr58 and Ser62 located in the 
MBI domain (Sears et al., 2000, Kenney et al., 2004, Sjostrom et al., 2005). To 
investigate this hypothesis, the role of Thr58, targeted by GSK3, was tested as before 
(Welcker et al., 2004, Sjostrom et al., 2005, Yaari et al., 2005, Chesler et al., 2006, Otto 
et al., 2009). The T58A mutant exhibited a greatly attenuated response to irradiation in 
comparison to wild-type N-myc indicating phosphorylation at this residue may be 
determinant for UVC-induced degradation of N-myc (Figures 5.14B and 5.14C). 
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Alternatively, mutation of this residue could be responsible for conformational changes 
that prevent the association with effectors of the UV response. Various studies have 
employed this mutant or the equivalent mutant of c-Myc, whose MBI domain is highly 
homologous to the MBI of N-myc, and have observed a greatly enhanced biological 
activity on account of the greater stability conferred by the abrogation of the 
phosphorylation site (Sears et al., 2000, Kenney et al., 2004, Yeh et al., 2004, Browd et 
al., 2006, Chesler et al., 2006). These reports seem to indicate there is no loss of 
function associated with changes in this residue thus suggesting the proper protein 
conformation is preserved in the phospho-mutant. 
 
Only GSK3 kinase has so far been implicated in destabilization of N-myc through 
phosphorylation at Thr58 (Kenney et al., 2004, Sjostrom et al., 2005). GSK3 activity 
has been linked to a number of UV-responsive events. For instance, mouse embryonic 
fibroblasts with GSK3β deletion were unable to activate stress-responsive MAPK 
kinase kinase 1 (MEKK1) or c-Jun N-terminal kinase (JNK) in response to UV 
irradiation (Kim et al., 2003a, Liu et al., 2004). Lee and colleagues also demonstrated 
that GSK3-dependent phosphorylation of p21 determines its degradation following 
UV irradiation (Lee et al., 2007). Similarly, cyclin D1 phosphorylation at Thr286 
induced by replicational stress is mediated by GSK3 and destabilizes this protein 
(Mukherji et al., 2008). Thus, it will be of interest to investigate the role of GSK3 in 
mediating UVC-induced degradation of N-myc. 
 
Britton and colleagues also analyzed a similar range of c-Myc mutants but failed to 
identify a deletion or phosphorylation mutant resistant to UV-induced degradation since 
all c-Myc variants were similarly downregulated (Britton et al., 2008). Although the 
discrepancy could be due to distinct mechanisms being involved in the regulation by 
UVC irradiation of the two Myc proteins, it is possible they resulted also from 
differences in the experimental approach used in the previous report and this study. In 
their study, the effect of c-Myc mutations was investigated by transient transfection in 
immortalized human lung fibroblasts, MRC5-SV, as opposed to using stable 
transfection of immortalised rat fibroblasts, Rat-1. Furthermore, cells were exposed to 
UV soon after transfection (6h) likely generating lesions in both genomic and episomal 
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DNA (plasmid). UV-induced DNA lesions in the template strand of active genes 
inhibits the progression of RNA polymerase II and a single UV-induced CPDs is 
thought to be sufficient to inhibit construct gene expression (Protić-Sabljić and 
Kraemer, 1985, Donahue et al., 1994, Francis and Rainbow, 1999). Thus, it is possible 
that ectopic c-Myc expression in this report was transcriptionally downregulated in all 
mutants analysed masking the effect of UV irradiation on protein stability. 
 
The effect of N-myc expression on cell cycle progression and cell viability following 
UVC exposure was analysed in Rat-1 cells expressing wild-type and truncated mutants 
of this protein (Figures 5.15 and 5.16). Consistent with previous studies in rodent cells, 
Rat-1 control cells seemed to accumulate in S phase and did not exhibit changes in the 
G2/M fraction suggesting activation of both S- and G2/M-phase checkpoints in response 
to UVC exposure (Orren et al., 1995, Orren et al., 1997). Rat-1 cell lines expressing N-
myc mutants responded similarly to control cells (except N-myc del124) unlike Rat-
1/N-myc cultures which did not accumulate in S phase thus suggesting N-myc renders 
these cells resistant to this cell cycle checkpoint. Rat-1/N-myc cultures were strongly 
depleted in G2/M cells following irradiation; this effect may have been responsible for a 
marked reduction in cell viability since none of the mutant proteins exhibited the same 
cellular outcome. An intact N- and C-terminus appear therefore to be required for the 
observed effects of N-myc in cell proliferation and survival following UVC exposure of 
Rat-1 cells. N-myc mutants who were not downregulated in response to UVC exposure 
and therefore persisted in Rat-1 cells at higher levels were not able to overcome the 
growth arrest observed in control cells likely due to loss of protein function. N-myc 1-
370 levels were decreased in response to irradiation, similarly to wild-type N-myc, but 
these cells also responded as the control ones. These observations suggest the UV-
induced degradation of N-myc does not constitute a cellular response to the N-myc-
dependent suppression of the cell cycle block and it does not appear to result from the 
activation of cell death in Rat-1 fibroblasts.    
 
The ability of Myc proteins to maintain cell proliferation in response to various stresses 
appears to arise from their ability to override the cell cycle block normally imposed 
under inappropriate growth conditions. It is not clear if promotion of cell cycle 
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progression under normal conditions and bypass of proliferative arrest depend on 
distinct Myc functions. There does however, seem to be a correlation between 
transcriptional repression of genes involved in growth suppression and cell cycle arrest 
and, conditional on p53 expression, enhancement of apoptosis under cellular stress 
conditions (Hermeking and Eick, 1994, Yu et al., 1997, Conzen et al., 2000, Oster et al., 
2003). The apoptotic potential of Myc appears particularly dependent on transrepression 
of genes regulated by the transcription factor Miz-1 such as p21, p15 or Bcl-2 (Staller et 
al., 2001, Herold et al., 2002, Seoane et al., 2002, Patel and McMahon, 2006, Patel and 
McMahon, 2007). Repression of growth arrest genes appears however, to be a normal 
component of Myc activity and of its ability to promote cell proliferation which can in 
turn potentiate apoptosis if uncoupled from survival signals (Bellosta et al., 2005, Etard 
et al., 2005). An artificial N-myc truncation carrying a deletion of the N-terminal 80 
amino acids was shown to rescue, dependent on the presence of the MBII domain, the 
proliferative defect of MYC-null cells to the same extent as full-length N-myc (Cowling 
and Cole, 2008). N-myc del80 exhibited reduced transactivation potential compared to 
the full-length protein but retained the ability to repress most gene targets; the ability of 
this mutant to induce apoptosis under stress conditions was however not examined.  
 
Expression of the N-myc del63 mutant did not induce a marked cell death in Rat-1 cells 
exposed to UVC. Evan and colleagues also observed an impaired apoptotic ability by a 
similar c-Myc mutant lacking amino acids 7-91 (Evan et al., 1992). Specific deletion of 
the MBI domain (amino acids 41-53) did not impair this c-Myc activity suggesting the 
regions upstream or downstream of MBI are important for regulating apoptosis. 
Interestingly, the amino-terminal region of c-Myc equivalent to residues 1-63 in N-myc  
is involved in the recruitment of the P-TEFb complex, a cofactor required for activation 
of RNA pol II essential for c-Myc-induced cellular proliferation and apoptosis 
(Eberhardy and Farnham, 2002, Kanazawa et al., 2003, Cowling and Cole, 2007). An 
interaction between N-myc and P-TEFb has not been established but expression of N-
myc in NB cells is associated with increased RNA pol II activity suggesting that N-myc 
activity could be similarly dependent on P-TEFb (Cowling and Cole, 2007). Thus, 
abolishment of this association by an N-terminal deletion could be in part responsible 
for the proliferative and apoptotic deficiencies observed in the N-terminal mutants. The 
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inability of N-myc 1-370 to sensitize Rat-1 cells to UV radiation is consistent with the 
previously demonstrated requirement for dimerization with Max in order to promote 
apoptosis (Evan et al., 1992, Amati et al., 1993b). 
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Figure 5.1 - Analysis of protein expression in MYCN-amplified neuroblastoma cell 
lines following exposure to DNA damaging agents. SK-N-DZ (A) and LAN-1 (B) cells 
were exposed to different doses of ultraviolet C (UVC) or ionizing radiation (IR) and 
lysed 3h post-exposure. Whole cell lysates were resolved by SDS-PAGE and analysed 
by immunoblotting against N-myc, cyclin D1, p21 and -tubulin (loading control). 
Results are representative of two independent experiments. Results are representative of 
two independent experiments. MW: Protein Molecular Weight Marker.  
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Figure 5.2 - Analysis of protein expression in MYCN-amplified neuroblastoma cell 
lines following exposure to ultraviolet C (UVC) radiation. SK-N-DZ and LAN-1 cells 
were treated with different doses of UVC and lysed 3h post-exposure. Whole cell 
lysates were resolved by SDS-PAGE and analysed by immunoblotting against N-myc, 
cyclin D1, p21, H2AX and -tubulin (loading control). Results are representative of 
two independent experiments. Results are representative of two independent 
experiments. MW: Protein Molecular Weight Marker.  
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Figure 5.3 - Analysis of protein expression in MYCN-amplified neuroblastoma cell 
lines following exposure to ultraviolet C (UVC) radiation. LAN-1 (A) and SK-N-DZ 
(B) cells were treated with different doses of UVC and lysed following incubation for 
the indicated times. Whole cell lysates were resolved by SDS-PAGE and analysed by 
immunoblotting against N-myc, cyclin D1, H2AX and -tubulin (loading control). 
Results are representative of two independent experiments. 
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Figure 5.4 - Analysis of protein expression in MYCN-amplified neuroblastoma cell 
lines following exposure to ionizing radiation (IR). LAN-1 cells were treated with 
different doses of IR and lysed following incubation for the indicated times. Whole cell 
lysates were resolved by SDS-PAGE and analysed by immunoblotting against N-myc, 
cyclin D1, H2AX and -tubulin (loading control). Results are representative of two 
independent experiments. 
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Figure 5.5 - Analysis of protein expression in MYCN-amplified neuroblastoma cell 
lines following exposure to etoposide. (A, B) LAN-1 cells were treated with different 
doses of etoposide and lysed following incubation for the indicated times. Whole cell 
lysates were resolved by SDS-PAGE and analysed by immunoblotting against N-myc, 
cyclin D1, H2AX and -tubulin (loading control). Results are representative of two 
independent experiments. 
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Figure 5.6 - Analysis of protein expression in MYCN-amplified neuroblastoma cell 
lines following exposure to cisplatin. (A, B) LAN-1 cells were treated with different 
doses of cisplatin and lysed following incubation for the indicated times. Whole cell 
lysates were resolved by SDS-PAGE and analysed by immunoblotting against N-myc, 
cyclin D1, H2AX and -tubulin (loading control). Protein levels were quantified using 
the AIDA software and normalised against -tubulin levels. The relative protein 
expression (%) is displayed at the bottom of the respective panel and was determined in 
respect to the untreated sample. Results are representative of two independent 
experiments. 
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Figure 5.7 - Analysis of protein expression in MYCN-amplified neuroblastoma cell 
lines following exposure to 4NQO. LAN-1 (A) and SK-N-DZ (B) cells were treated 
with different doses of 4NQO and lysed 6h post-exposure. Whole cell lysates were 
resolved by SDS-PAGE and analysed by immunoblotting against N-myc, cyclin D1, 
H2AX and -tubulin (loading control). Results are representative of two independent 
experiments. 
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Figure 5.8 - Analysis of the effect of the ATM inhibitor, KU-55933, on N-myc 
expression in MYCN-amplified neuroblastoma cell lines exposed to ultraviolet C (UVC) 
radiation. (A) LAN-1 cells were incubated with 10M KU55933 inhibitor for 30min 
prior to exposure to 50J/m
2
 UVC. Protein levels were quantified using the AIDA 
software and normalised against -tubulin levels. The relative protein expression (%) is 
displayed at the bottom of the respective panel and was determined in respect to the 
untreated (N-myc, lane 1) or UVC-treated (phospho-Chk2, lane 2) sample. (B, C) LAN-
1 (B) and SK-N-DZ (C) cells were incubated with 50M KU55933 inhibitor for 30min 
prior to exposure to 50J/m
2
 UVC. Cells were lysed 3h post-exposure and whole cell 
lysates were resolved by SDS-PAGE and analysed by immunoblotting against N-myc, 
phospho-Chk2, cyclin D1 and -tubulin (loading control). The experiments were 
carried out a single time. MW: Protein Molecular Weight Marker. 
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Figure 5.9 - Analysis of protein expression in Rat-1/N-myc (mouse cDNA) cells 
following exposure to ultraviolet C (UVC) radiation. Rat-1/N-myc cells were exposed 
to different doses of UVC and lysed 6h post-exposure. Whole cell lysates were resolved 
by SDS-PAGE and analysed by immunoblotting against FLAG and -tubulin (loading 
control). Protein levels were quantified using the AIDA software and normalised 
against -tubulin levels. The relative protein expression (%) is displayed at the bottom 
of the respective panel and was determined in respect to the untreated sample. Results 
are representative of two independent experiments. MW: Protein Molecular Weight 
Marker.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  A. Duarte 
164 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 - Analysis of the effect of the proteasome inhibitor MG132 on N-myc 
expression in human MYCN-amplified neuroblastoma cell lines exposed to ultraviolet C 
(UVC) radiation. LAN-1 and SK-N-DZ cells were incubated with DMSO or 50M 
MG132 for 30min prior to exposure to different doses of UVC; cells were lysed 3h 
post-exposure. Whole cell lysates were resolved by SDS-PAGE and analysed by 
immunoblotting against N-myc and -tubulin (loading control). N-myc protein levels 
were quantified using the AIDA software and normalised against -tubulin levels. The 
relative N-myc protein expression (%) in the absence or presence of MG132 is 
displayed at the bottom of the panel and was determined in respect to the UV-untreated 
sample. Results are representative of two independent experiments.  
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Figure 5.11 - Analysis of the interaction between DDB2 and p21 (A) or N-myc (B) by 
protein co-immunoprecipitation in HEK293T cells. Cells were transfected with different 
constructs encoding FLAG-tagged human DDB2 and HA-tagged human p21 or mouse 
N-myc, as indicated. Cells were incubated in the presence or absence of 10M MG132 
for 30min prior to lysis and whole cell extracts were immunoprecipitated with anti-HA 
antibody. Immunoprecipitates (IP) were resolved by SDS-PAGE and analysed by 
immunoblotting against HA, FLAG and -tubulin (loading control). 10% of the protein 
input was analysed in parallel as a reference. The experiment was carried out a single 
time. MW: Protein Molecular Weight Marker. 
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Figure 5.12 - Analysis of the interaction between N-myc and DDB2 by protein co-
immunoprecipitation using SK-N-DZ cells. Cells were exposed to 50J/m
2
 ultraviolet C 
(UVC) radiation and lysed 3h post-exposure. Cells were incubated in the presence or 
absence of 10M MG132 for 30min prior to lysis and whole cell extracts were 
immunoprecipitated with anti-DDB2 antibody. Immunoprecipitates (IP) were resolved 
by SDS-PAGE and analysed by immunoblotting against DDB2, N-myc (the two images 
are from the same immunoblot subjected to different exposures), H2AX and -tubulin 
(loading control). 10% of the protein input was analysed in parallel as a reference. N-
myc was only weakly detected and the protein band is therefore indicated. The 
experiment was carried out a single time. MW: Protein Molecular Weight Marker. 
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Figure 5.13 – Analysis of N-myc expression in Rat-1 cells expressing FLAG-tagged 
mouse N-myc variants following exposure to ultraviolet C (UVC) radiation. (A) Whole 
cell lysates of the indicated Rat-1 cell cultures were analyzed by immunoblotting 
against FLAG and -tubulin (loading control). (B) Rat-1/N-myc variants cells were 
exposed to 200J/m
2
 UVC and lysed 6h post-exposure. Whole cell lysates were resolved 
by SDS-PAGE and analysed by immunoblotting against FLAG and -tubulin (loading 
control). (C) The protein levels of the N-myc variants were quantified using the AIDA 
software and normalised against -tubulin levels. The relative protein expression was 
determined in respect to the untreated sample. Results are representative of two 
independent experiments. MW: Protein Molecular Weight Marker.  
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Figure 5.14 – Analysis of protein expression in Rat-1 cells expressing FLAG-tagged 
wild-type or phospho-mutant mouse N-myc following exposure to ultraviolet C (UVC) 
radiation. (A) Whole cell lysates of Rat-1/N-myc and N-myc (T58A) cell cultures were 
analysed by immunoblotting against FLAG and -tubulin (loading control). (B) Rat-
1/N-myc and N-myc (T58A) cells were exposed to 200J/m
2
 UVC in the presence or 
absence of MG132 and lysed 6h post-exposure. Whole cell lysates were resolved by 
SDS-PAGE and analysed by immunoblotting against FLAG, cyclin D1, H2AX and -
tubulin (loading control). (C) N-myc protein levels were quantified using the AIDA 
software and normalised against -tubulin levels. The relative protein expression was 
determined in respect to the untreated sample; error bars represent standard deviations 
calculated from three independent experiments. Asterisk represents p<0.01, Student’s t 
test. MW: Protein Molecular Weight Marker. 
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Figure 5.15 – Analysis of cell cycle distribution of Rat-1 fibroblasts transfected with 
pBabepuro-FLAG-N-myc (mouse cDNA) or empty vector exposed to ultraviolet C 
(UVC) radiation. (A) Rat-1/pBabe and Rat-1/N-myc cell cultures were exposed to the 
indicated doses of UVC and collected 24h after treatment. PI staining was performed 
prior to flow cytometry analysis. For each sample, 10,000 events were acquired and 
DNA profiles were analysed using the FlowJo software; error bars represent standard 
deviations calculated from three independent experiments (see appendix XII for data). 
(B) The proportion of cells exhibiting sub-G1 DNA content was quantified in a similar 
manner from same set of experiments. 
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Figure 5.16 – Analysis of cell cycle distribution of ultraviolet C (UVC)-irradiated Rat-1 
fibroblasts transfected with pBabepuro empty vector or FLAG-tagged full-length or 
truncated N-myc constructs (mouse cDNA). Rat-1 cell cultures were exposed to the 
indicated doses of UVC and collected 24h after treatment. PI staining was performed 
prior to flow cytometry analysis. For each sample, 10,000 events were acquired and 
DNA profiles were analysed using the FlowJo software (see appendix XIII for data). 
The experiment was carried out a single time. 
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CHAPTER 6 - CYCLIN D1 AND THE DNA DAMAGE RESPONSE 
 
6.1 Introduction 
The ubiquitin-dependent degradation of cyclin D1 by genotoxic stress is an important 
element of the cellular response to DNA damage as it induces a rapid G1 cell cycle 
arrest that prevents aberrant DNA replication (Agami and Bernards, 2000, Pontano et 
al., 2008, Santra et al., 2009). Phosphorylation at Thr286 is an important signalling 
event targeting cyclin D1 for proteolysis both during normal cell cycle progression and 
under stress conditions (Alao, 2007). Several kinases have been shown to destabilize 
cyclin D1 through this residue including IKK a subunit of the IKK complex that 
activates, together with IKK and IKK (NEMO), the NF-B transcription factor by 
phosphorylating and hence targeting for degradation its inhibitor, IB (DiDonato et al., 
1997, Kwak et al., 2005, Hacker and Karin, 2006). IKK has also been shown to 
regulate transcriptional expression of cyclin D1 by mediating both NF-B-dependent 
and independent cyclin D1 promoter induction following mitogen stimulation 
(Guttridge et al., 1999, Hinz et al., 1999, Albanese et al., 2003, Park et al., 2005). 
Exposure to DNA damaging agents can activate NF-B signalling through degradation 
of IB (Brach et al., 1991, Devary et al., 1993, Perkins, 2007). Cyclin D1 
downregulation has been reported in response to different genotoxic insults but the 
regulatory cascade(s) involved has not been fully elucidated. This chapter describes the 
studies undertaken to understand the role of NF-B signalling in regulating cyclin D1 
levels following DNA damage. 
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6.2 Results 
6.2.1 Role of NF-B activity in the cyclin D1 response to DNA damage 
A possible role for NF-B in regulating cyclin D1 expression in response to genotoxic 
stress was investigated using the compound Bay 11-7082 (Calbiochem). Bay 11-7082 
was shown to block activation of NF-B by TNF by inhibiting phosphorylation and 
consequent degradation of IκB (Pierce et al., 1997). U2OS cells were incubated with 
Bay 11-7082 prior to exposure to a dose range of different DNA damaging agents (UV, 
IR, 4NQO and H2O2) as described (Materials and Methods), all of which are reported to 
induce cyclin D1 proteolysis (Agami and Bernards, 2000, Miyakawa and Matsushime, 
2001, Barnouin et al., 2002, Suwaki et al., 2010). The levels of cyclin D1 were analysed 
by immunoblotting 3h following exposure; phosphorylation of the H2AX marker was 
also monitored to determine activation of DDR signalling. As shown in Figure 6.1, all 
the DNA damaging agents tested induced accumulation of H2AX and reduction of 
cyclin D1 levels; the response was found to be dose-dependent in cells treated with all 
agents except 4NQO which equally decreased cyclin D1 levels at all doses tested. In the 
absence of genotoxic treatment cells treated with Bay 11-7082 exhibited decreased 
expression of cyclin D1; the effect is possibly due to inhibition of basal transcriptional 
activation of cyclin D1 by NF-B (Hinz et al., 1999). Incubation with the inhibitor 
attenuated cyclin D1 downregulation following UV, 4NQO and H2O2 exposure. The 
inhibition was less clear in IR-treated cells possibly due to the weaker effect of this 
agent on cyclin D1 levels.  
 
To determine if Bay 11-7082 affects the DNA damage-dependent decrease in cyclin D1 
levels by increasing protein stability, U2OS cells were exposed to a single dose of the 
different genotoxic agents in the presence of the protein synthesis inhibitor CHX alone 
or in combination with Bay 11-7082 and harvested at different times afterwards. Cyclin 
D1 and H2AX expression were analysed by immunoblotting as presented in Figure 
6.2. Incubation with the inhibitor led to a decreased turnover of cyclin D1 protein 
following treatment with all agents. The effect was however, less pronounced in IR-
exposed cells which possibly results from a weaker cyclin D1 response to this agent, as 
observed before. Together these observations suggest Bay 11-7082 blocks cellular 
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signaling(s) required for cyclin D1 degradation in response to different genotoxic 
stresses. 
 
To exclude the possibility that the action of Bay 11-7082 on cyclin D1 expression 
results from a general inhibition of proteolysis, U2OS cells were incubated with the 
proteasome inhibitor MG132 or Bay 11-7082 prior to exposure to a range of 4NQO 
doses and collected 3h post-exposure. The immunoblotting analysis of cyclin D1 
expression presented in Figure 6.3 demonstrates the ability of MG132 to prevent cyclin 
D1 degradation following 4NQO treatment as previously reported. The basal levels of 
both p27 and cyclin D1 were also increased in MG132-treated cells due to inhibition of 
normal protein turnover (Pagano et al., 1995, Diehl et al., 1997). Treatment with Bay 
11-7082 however, did not lead to accumulation of p27 but prevented 4NQO-induced 
downregulation of cyclin D1 supporting the notion that this agent is not a general 
proteasome inhibitor. 
 
6.2.2 Regulation of cyclin D1 expression following DNA damage by IKK proteins 
Activation of NF-B in response to DNA damaging agents is mediated, in some cases, 
by the IKK complex through phosphorylation and consequent proteolysis of IκB 
(Huang et al., 2000, Bottero et al., 2001, Li et al., 2001b, Huang et al., 2002, Kenneth et 
al., 2010). Given that Bay 11-7082, described as an inhibitor of IκB phosphorylation, 
prevents DNA damage-induced degradation of cyclin D1 the role of the IKK complex 
in this response was investigated. For this purpose, IKK null 3T3 cells were analysed 
following treatment with the agents tested in the previous section. The lack of 
IKKexpression in these cells was confirmed by immunoblotting (Figure 6.4A). Wild-
type and mutant cells were subjected to treatment with a single dose of the different 
genotoxic agents as before and analysed by immunoblotting. The IKK kinase has been 
implicated in phosphorylation of cyclin D1 at Thr286 leading to ubiquitylation and 
degradation (Kwak et al., 2005). The levels of phospho-cyclin D1 were therefore 
examined to determine whether knockout of IKK affects its accumulation following 
DNA damage. Incubation with the proteasome inhibitor MG132 was performed prior to 
the treatments to prevent degradation of phospho-cyclin D1. As can be observed in 
Figures 6.4B-E, IKK-/- cells exhibited lower basal levels of cyclin D1 compared to 
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wild-type. Phospho-cyclin D1 was detected in these cells, albeit at lower levels possibly 
due to the lower expression of total cyclin D1, indicating that Thr286 is not solely 
dependent on IKK (Alao, 2007). Deletion of IKK in 3T3 cells did not prevent 
downregulation of cyclin D1 following treatment with the different genotoxic agents 
which was observed in both wild-type and mutant cells, suggesting that IKK is not 
essential for the DNA damage response of cyclin D1. Proteasome inhibition blocked 
this effect demonstrating that protein turnover is accelerated in both lines following 
genotoxic stress. IKK-/- cells showed higher levels of H2AX in response to all the 
agents tested but this did not appear to induce a more pronounced decrease in cyclin D1. 
Ionizing radiation exerted a limited effect on cyclin D1 expression that correlated with a 
weaker accumulation of H2AX (Figure 6.4C). 
 
The role of the IKK subunit was then investigated in the same manner by employing 
IKK null 3T3 cells. As can be observed in Figure 6.5A, basal expression of cyclin D1 
was found to be reduced in these cells compared to wild-type similarly to IKK-/- cells. 
IKK-/- cells exhibited a marked decrease in the levels of cyclin D1 following exposure 
to the different genotoxic agents (Figures 6.5B-E). Cyclin D1 downregulation was 
reversed by treatment with MG132 inhibitor suggesting the DNA damage-induced 
proteolysis of cyclin D1 is independent of IKK activity. 
 
Some observations suggest that activation of NF-B in response to certain stimuli can 
be predominantly mediated by a particular IKK subunit or may require an intact IKK 
complex (Hacker and Karin, 2006). To determine whether the combined deletion of 
IKK and IKK could prevent the downregulation of cyclin D1 following genotoxic 
treatment, wild-type and double knockout mutants were exposed to a range of UV, IR, 
4NQO and H2O2 doses and analysed as before. As shown in Figure 6.6, basal 
expression of cyclin D1 was severely reduced in DKO cells compared to wild-type, as 
observed for the IKK single mutants. Both cell lines exhibited a dose-dependent 
increase in phosphorylated H2AX in response to the different treatments but H2AX 
expression appeared attenuated in treated DKO cells in comparison to wt cells. 
Downregulation of cyclin D1 was nevertheless observed in DKO cells and the dose-
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dependent decrease closely follows the response observed in wild-type cells suggesting 
cyclin D1 regulation following DNA damage is conserved in IKK/ double mutants. 
 
The compound Bay 11-7082, an inhibitor of IB phosphorylation by IKK complex, was 
observed to attenuate cyclin D1 downregulation following exposure of U2OS cells to 
different genotoxic agents (Figure 6.1). However, cells lacking expression of IKK, 
IKK or both exhibited a cyclin D1 response that resembled that of wild-type cells. To 
determine if treatment with the inhibitor can prevent DNA damage-induced degradation 
of cyclin D1 in the absence of the IKK subunits, the 3T3 lines described above were 
treated with 4NQO in the presence or absence of Bay 11-7082 and analysed as before. 
As shown in Figure 6.7, the inhibitor was able to attenuate, albeit with different 
efficiencies, the decrease in cyclin D1 levels induced by 4NQO exposure in wt and 
IKK/ single and DKO cells. This observation indicates that at least part of the effect 
of Bay 11-7082 on the cyclin D1 response is independent of IKK activity. 
 
6.2.3 Role of IKK proteins on cell cycle progression following DNA damage 
IKK and IKK proteins have been implicated in the response to DNA damage through 
activation of NF-B (Huang et al., 2000, Bottero et al., 2001, Li et al., 2001b, Huang et 
al., 2002, Kenneth et al., 2010). To explore the role of the IKK subunits in the cellular 
response to different types of DNA damage, cell cycle progression was analysed in wt 
and mutant 3T3 cells exposed to the genotoxic agents used above. Cell cycle analysis 
was performed by staining DNA with propidium iodide; progression of cells through 
G1/S boundary was additionally examined by measuring incorporation of the thymidine 
nucleotide analogue, BrdU. Figure 6.8 and 6.9 illustrates the cell cycle distribution of 
the three lines as determined from three independent experiments and a representative 
analysis of BrdU incorporation versus PI staining. 
 
Cells were first analysed following treatment with UVC (15 and 50J/m
2
) or ionizing 
radiation (1 and 6Gy) and collected 24h post exposure for comparative analysis. 
Treatment with UV did not produce marked changes in the DNA profile of wt cells at 
either dose tested but induced a modest increase in the G2/M fraction of knockouts of 
IKK and (Figure 6.8). Analysis of BrdU fluorescence however, revealed a 
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dramatic decrease in BrdU incorporation in all cell lines following UVC exposure. The 
block on DNA replication in response to UVC irradiation is indicative of checkpoint 
activation and suggests this treatment triggered a multi-phase arrest in both wt and 
mutant 3T3 lines. Still, IKK and IKK lines appeared to be more resistant to G1 
arrest following exposure to the lower UVC dose as illustrated by the small fraction of 
BrdU-incorporating cells.  
 
Ionizing irradiation of wt 3T3 cells induced dose-specific changes in cell cycle 
distribution. Treatment of wt cells with 1Gy resulted in a small increase in G1 cells and 
concomitant reduction in S-phase cells; exposure to 6Gy imposed a marked cell-cycle 
block in G2/M accompanied by depletion of G1- and S-phase cells suggesting that IR-
induced DNA damage may not result in a strong G1/S arrest unlike the response 
observed following UVC exposure (Figure 6.8A). In agreement with this, DNA 
synthesis was not inhibited by IR, in contrast to UVC, suggesting the lesions inflicted 
by this agent do not activate G1/S-phase checkpoints in 3T3 cells but rather the G2/M. 
IKK-/- cells were unaffected by the lowest IR dose, but showed a response to the 
higher dose similar to wt cells with a marked increase in G2/M cells and corresponding 
reduction in the populations in G1 and S phases. IKK
-/-
 cells on the other hand 
exhibited a considerably weaker accumulation of cells in G2/M following exposure to 
6Gy accompanied by a decrease in the S-phase fraction but not G1. Analysis of BrdU 
incorporation demonstrated these cells were not arrested in G1 but actively transiting 
into S phase (Figure 6.8B). Together, these observations suggest that IKK-/- cells are 
more resistant to IR-induced G2/M arrest. 
 
The cellular response of 3T3 cell lines after exposure to 2.5 and 10M 4NQO, and 25 
and 100M H2O2 was then analysed. The changes in the cell cycle distribution of each 
of the three cell lines under study were similar following treatment with both doses of 
4NQO (Figure 6.9A). In the case of wt cells, accumulation in S and G2/M phases of the 
cell cycle was observed, accompanied by a decrease in G1 population. IKK
-/-
 and 
IKK-/- cells exhibited an increase in G2/M fraction but the S-phase fraction was not 
affected. The G1 population of IKK
-/-
 cells was also unaffected by the treatment 
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whereas IKK-/- cells showed a modest decrease. BrdU incorporation was strongly 
reduced or abolished in all cell lines in response to both 4NQO doses (Figure 6.9B). 
 
The H2O2-treated 3T3 cells, wt and mutants, responded to both doses with accumulation 
of cells in G2/M phase accompanied by depletion of G1-phase cells (Figure 6.9A). In 
cells treated with 100M H2O2 dose however, an accumulation of cells in S phase was 
also observed possibly due to activation of the intra-S checkpoint in response to 
increased H2O2-induced DNA damage. Assessment of BrdU incorporation suggests 
H2O2 does not induce G1 arrest, in agreement with the analysis on cell cycle 
distribution, given that DNA synthesis was reduced but not suppressed within 24h of 
exposure (Figure 6.9B). IKK-/- and IKK-/- cells, in particular, exhibited only a 
moderate decrease in BrdU incorporation (approximately 50%) at the highest dose 
tested that seems to correlate with a resistance to G1- and S-phase arrest. 
 
Together, this data appears to indicate that deletion of IKK or  in 3T3 cells does not 
abolish cell cycle arrest in response to the various DNA damaging agents. Nevertheless, 
these mutants appear to exhibit a greater resistance to the cell cycle checkpoints since 
they retain the ability to progress through S phase, particularly following exposure to 
the lowest doses, as determined by BrdU incorporation, with no subsequent 
accumulation in G1 or G2/M being evident. 
 
 
6.3 Discussion 
This chapter describes the analyses undertaken to investigate the role of NF-B in the 
cyclin D1 response to genotoxic stress. For this purpose, the NF-B inhibitor Bay 11-
7082, identified based on its ability to irreversibly block TNF-induced IB 
phosphorylation, was employed (Pierce et al., 1997). The investigations described 
above seemed to indicate the Bay 11-7082 inhibitor can prevent downregulation of 
cyclin D1 following exposure to different genotoxic stresses. Treatment of U2OS cells 
with Bay 11-7082 prior to exposure to UVC, IR, 4NQO or H2O2 attenuated 
downregulation of cyclin D1 following induction of DNA damage by these agents 
(Figure 6.1). In cells treated with Bay 11-7082, cyclin D1 exhibited an increased 
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stability following exposure to the different genotoxic agents suggesting the inhibitor 
acted by preventing protein turnover (Figure 6.2). This effect did not appear to arise 
from a cellular inhibition of proteasomal activity as it did not stabilize basal expression 
of cyclin D1 or p27 which are in part regulated through this pathway (Figure 6.3B) 
(Pagano et al., 1995, Diehl et al., 1997). Treatment with the proteasome inhibitor 
MG132 on the other hand, raised the levels of cyclin D1 and p27 and blocked 
downregulation of the former in 4NQO-treated cells (Figure 6.3A). 
 
As described above, activation of NF-B by DNA damage generated by IR or UV 
exposure is at least partly dependent on IKK-mediated IB phosphorylation and 
degradation  (Li and Karin, 1998, Huang et al., 2002, O'Dea et al., 2008, Tsuchiya et al., 
2010). Despite this, treatment of 3T3 cells lacking expression of IKK (Figure 6.4), 
IKK (Figure 6.5) or both proteins (Figure 6.6) to the DNA damaging agents employed 
before did not prevent DNA damage-induced downregulation of cyclin D1. Moreover, 
the decrease in cyclin D1 levels as a result of 4NQO exposure was attenuated by Bay 
11-7082 in wt 3T3 cells as well as IKK and IKK single and double knockout cells 
(Figure 6.7). The results described here thus suggest that intact NF-B signaling is not 
required for the DNA damage-induced cyclin D1 downregulation in 3T3 cells.  
 
Although the exact molecular target of Bay 11-7082 was initially unknown, the 
constitutive phosphorylation of IB by CK2 was shown not to be affected by this 
inhibitor (Pierce et al., 1997). The subsequent characterization of the IKK complex and 
its role in the activation of NF-B through phosphorylation of IB made it an 
attractive target. Bay 11-7082 has been shown to block IKK-dependent IB 
degradation in response to a variety of stimuli including endotoxins, mitogens and 
cytotoxic drugs (Beinke et al., 2004, Garcia et al., 2005, Kundu et al., 2006). 
Furthermore, Bay 11-7082 can block phosphorylation of additional IKK targets such as 
the Rel proteins, Rel-A and p50 which could indicate a direct effect by the inhibitor on 
IKK activity (Sakurai et al., 2003, Beinke et al., 2004, Dai et al., 2011, Kar et al., 2011). 
Treatment with Bay 11-7082 can also prevent IB degradation in response to UVC 
and IR radiation as well as ROS (Thévenod et al., 2000, Huang et al., 2002, Kloster et 
al., 2011). These findings therefore suggest that the ability of Bay 11-7082 to attenuate 
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the cyclin D1 response to DNA damage observed in U2OS (Figure 6.1-6.3) and wt and 
IKK mutant 3T3 cells (Figure 6.7) is at least partly independent of its inhibitory action 
on the IKK/IB/NF-B pathway.  
 
Abrogation of Rel-A, IKK or IKK expression can result in lower levels of cyclin D1 
protein expression, consistent with a role for NF-B in transactivating the cyclin D1 
gene (Demicco et al., 2005, Ouyang et al., 2005, Barré and Perkins, 2007, Bakkar et al., 
2008). Furthermore, treatment of cells with Bay 11-7082 or alternative inhibitors of the 
NF-B pathway was also shown to promote downregulation of cyclin D1 expression 
(Mori et al., 2002, Yemelyanov et al., 2005, Bhardwaj et al., 2007, Lee and Han, 2008, 
Rivas et al., 2008, Yoon et al., 2010). In contrast, Kwak and colleagues demonstrated 
that IKK-/- MEF cells had increased levels of cyclin D1 (Kwak et al., 2005). This study 
suggested a role for IKK in mediating cyclin D1 proteolysis through phosphorylation 
at Thr286 and abrogation of this kinase therefore led to stabilization of cyclin D1. 
However, other kinases such as GSK3 and p38SAPK2 can also promote degradation of 
cyclin D1 through this residue (Diehl et al., 1997, Diehl et al., 1998, Casanovas et al., 
2000). Therefore, the overall stability of cyclin D1 protein is probably the cumulative 
result of the activity of these different kinases and this is in turn likely to be dependent 
on a number of key variables in the experimental conditions including the cell type and 
cell density.  
 
The IKK and IKK single and double KO cells employed in this study exhibited 
markedly lower levels of cyclin D1 than wt cells (Figures 6.4-6.6), an effect that could 
be partly due to attenuated IKK/NF-B signaling. On the other hand, the wt and mutant 
cell lines used are likely to have distinct genotypes given their different origins and this 
may have also played a role in creating molecular and cellular differences. U2OS cells 
treated with Bay 11-7082 also exhibited a reduction in the basal expression of cyclin D1 
(Figures 6.1 and 6.3). However, this effect was similarly noted in Bay 11-7082-treated 
IKK and IKK single and double KO cells suggesting the inhibitor affects cyclin D1 
regulation at least in part independently of IKK activity (Figure 6.7). Although IKK-
independent mechanisms of NF-B activation have been described, to my knowledge 
no studies employing Bay 11-7082 have demonstrated NF-B inactivation through a 
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pathway that does not require IKK activity. There are however, reports of NF-B-
independent cellular effects of Bay 11-7082 that suggest this inhibitor has nonspeciﬁc 
activities unrelated to IKK inhibition which may be responsible for its regulation of 
cyclin D1 levels. Pierce and colleagues observed enhanced phosphorylation and 
consequent activation of the stress-activated protein kinase, p38
SAPK2
, in the presence of 
Bay 11-7082 both in TNF-treated and untreated cells (Pierce et al., 1997). These 
findings have been reproduced in subsequent studies and have been extended to the 
structurally-related Bay 11-7085 which was also identified in the original work but the 
mechanism of p38
SAPK2
 activation remains uncertain (Hu et al., 2001, Santos et al., 
2001, Sakurai et al., 2003, Ferreiro et al., 2010, Langereis et al., 2010). Both inhibitors 
have also been shown to promote apoptosis independently of NF-B activity possibly 
through their effect on p38
SAPK2
 activity (Hu et al., 2001, Cory and Cory, 2005, White 
and Burchill, 2008). Although a possible cross-talk between the NF-B and p38SAPK2 
pathways cannot be excluded, the results described above using IKK and IKK single 
and double KO cells nevertheless suggest the existence of off-target effects by Bay 11-
7082. p38
SAPK2
 is activated by different stimuli including TNF, UV radiation, IR and 
osmotic stress (Raingeaud et al., 1995, Chen et al., 1996c, Price et al., 1996, Casanovas 
et al., 2000). Phosphorylation of cyclin D1 at Thr286 in response to osmotic stress is 
mediated by p38
SAPK2
 and promotes ubiquitin-dependent degradation of cyclin D1 
(Casanovas et al., 2000). Furthermore, p38
SAPK2
 was also shown to negatively regulate 
transcription of cyclin D1 (Lavoie et al., 1996, Page et al., 2001). Thus, the potential 
activation of p38
SAPK2
 by Bay 11-7082 could have contributed to the reduced levels of 
cyclin D1 observed in U2OS cells (Figure 6.1) as well as in the various 3T3 lines 
employed (Figure 6.7) in the presence of the inhibitor.  
 
Analysis of unstressed wild-type, IKK and IKK single KO 3T3 cells by flow 
cytometry revealed differences in the cell cycle distribution of asynchronous 
populations. In comparison to the wt cell line, the IKK mutant cell lines exhibited a 
reduced G1 population and an increased S and G2/M fractions (Figures 6.8A and 6.9A). 
Consistent with these observations, analysis of G1/S transition by BrdU incorporation 
suggested that cells of both IKK mutant lines more rapidly progressed through G1 phase 
and initiated DNA synthesis, despite the lower levels of cyclin D1 observed in these cell 
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lines (Figures 6.8B and 6.9B). These results suggest other molecular differences 
between wt and mutant cell lines may exist which could have given rise to differences at 
the cellular level, as discussed above. Increased expression of cyclin E, for instance, is 
also associated with an accelerated entry into S phase and appears to exert a greater 
effect in actively cycling cells than cyclin D1 (Ohtsubo and Roberts, 1993, Resnitzky et 
al., 1994, Wimmel et al., 1994, Ohtsubo et al., 1995). The genotoxic agents used 
seemed to induce relatively similar cellular changes in IKK and IKK KO cells as 
determined from their cell cycle distributions and BrdU incorporation profiles. The 
mutant cell lines appeared to exhibit a greater resistance to the DNA damage-induced 
block on DNA synthesis than wt cells. The exact role of IKK or IKK deletion in 
these differences is however, difficult to assess given the differences observed between 
unstressed populations.  
 
As described above, IKK, but not  has been implicated in the regulation of the 
ATR-mediated cell cycle checkpoint in response to UV by activating NF-B (Kenneth 
et al., 2010). In contrast with these reports, similar effects cellular were observed in 
IKK and IKK KO cells in response to the genotoxic agents used in this study. 
Furthermore, abrogation of IKK was shown to promote expression of H2AX in 
response to replication stress and IR whereas the IKK/IKK double KO cells 
employed in this study accumulated lower levels of H2AX than wt cells in response to 
the different genotoxic agents used including UV and IR (Figure 6.6) (Kenneth et al., 
2010, Wu et al., 2011). These discrepancies may, as mentioned above, have resulted 
from genotypic differences between the wt and mutant cells and highlight the 
importance of using isogenic cell lines in analysing the role of individual molecules in 
cellular responses. This seems to be particularly relevant for the study of DNA damage 
signaling which involves pathways controlling DNA repair, cell proliferation and cell 
survival. 
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Figure 6.1 - Analysis of the effect of the NF-B inhibitor Bay 11-7082 on cyclin D1 
expression in U2OS cells exposed to DNA damaging agents. U2OS cells were treated 
with different doses of ultraviolet C radiation (UVC, A), ionizing radiation (IR, B), 
4NQO (C) and H2O2 (D) in the absence or presence of 5M Bay 11-7082. Cells were 
lysed 3h post-exposure and whole cell lysates were resolved by SDS-PAGE and 
analysed by immunoblotting against cyclin D1, H2AX and -tubulin (loading control). 
Results are representative of two independent experiments. MW: Protein Molecular 
Weight Marker. 
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Figure 6.1 (cont) - Analysis of the effect of the NF-B inhibitor Bay 11-7082 on cyclin 
D1 expression in U2OS cells exposed to DNA damaging agents.  
For legend, see previous page. 
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Figure 6.2 - Analysis of the effect of the NF-B inhibitor Bay 11-7082 on cyclin D1 
stability in U2OS cells treated with DNA damaging agents. U2OS cells were incubated 
with 0.1mg/ml cycloheximide (CHX) in the absence or presence of 5M Bay 11-7082 
for 5min prior to exposure to the indicated dose of ultraviolet C radiation (UVC, A), 
ionizing radiation (IR, B), 4NQO (C) and H2O2 (D); cells were lysed at the indicated 
times post-exposure. Whole cell lysates were resolved by SDS-PAGE and analysed by 
immunoblotting against cyclin D1, H2AX and -tubulin (loading control). Cyclin D1 
protein levels were quantified using the AIDA software and normalised against -
tubulin levels. The relative cyclin D1 protein expression (%) in the absence or presence 
of Bay 11-7082 is displayed at the bottom of the panel and was determined in respect to 
the control sample (0min). Results are representative of two independent experiments. 
MW: Protein Molecular Weight Marker. 
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Figure 6.2 (cont) - Analysis of the effect of the NF-B inhibitor Bay 11-7082 on cyclin 
D1 stability in U2OS cells treated with DNA damaging agents. 
For legend, see previous page. 
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Figure 6.3 - Analysis of the effect of the inhibitors MG132 and Bay 11-7082 on cyclin 
D1 expression in U2OS cells exposed to 4NQO. U2OS cells were incubated with 50M 
MG132 for 30min (A) or 5M Bay 11-7082 for 5min (B) prior to exposure to different 
doses of 4NQO; cells were lysed 3h post-exposure. Whole cell lysates were resolved by 
SDS-PAGE and analysed by immunoblotting against cyclin D1, p27 and -tubulin 
(loading control). Results are representative of two independent experiments. MW: 
Protein Molecular Weight Marker. 
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Figure 6.4 - Analysis of cyclin D1 expression in wild-type (wt) and IKK-/- 3T3 cells 
following treatment with DNA damaging agents. 
For legend, see following page. 
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Figure 6.4 (cont) - Analysis of cyclin D1 expression in wild-type (wt) and IKK-/- 3T3 
cells following treatment with DNA damaging agents. (A) Whole cell lysates were 
analysed by immunoblotting against IKK and -tubulin (loading control). (B-E) Cells 
were incubated with 10M MG132 for 30min prior to exposure to the indicated dose of 
ultraviolet C radiation (UVC, B), ionizing radiation (IR, C), 4NQO (D) and H2O2 (E). 
Cells were lysed 3h post-exposure and whole cell lysates were resolved by SDS-PAGE 
and analysed by immunoblotting against cyclin D1, phospho-cyclin D1, H2AX and -
tubulin (loading control). Results are representative of two independent experiments. 
MW: Protein Molecular Weight Marker. 
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Figure 6.5 - Analysis of cyclin D1 expression in IKK-/- 3T3 cells following treatment 
with DNA damaging agents. (A) Wild-type (wt) and IKK-/- whole cell lysates were 
analysed by immunoblotting against IKK and -tubulin (loading control). (B-E) 
IKK-/- 3T3 cells were incubated with 10M MG132 for 30min prior to exposure to the 
indicated dose of ultraviolet C radiation (UVC, B), ionizing radiation (IR, C), 4NQO 
(D) and H2O2 (E). Cells were lysed 3h post-exposure and whole cell lysates were 
resolved by SDS-PAGE and analysed by immunoblotting against cyclin D1, phospho-
cyclin D1, H2AX and -tubulin (loading control). Results are representative of two 
independent experiments. MW: Protein Molecular Weight Marker. 
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Figure 6.6 - Analysis of cyclin D1 expression in wild-type (wt) and IKK/ DKO 3T3 
cells following treatment with DNA damaging agents. 
For legend, see following page. 
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Figure 6.6 (cont) - Analysis of cyclin D1 expression in wild-type (wt) and IKK/ 
DKO 3T3 cells following treatment with DNA damaging agents. Cells were treated 
with the following doses: 15, 50, 250 and 500J/m
2
 UVC (A); 1, 6 and 21Gy IR (B); 1, 
2.5, 5 and 10M 4NQO (C); 10, 25, 50 and 100M H2O2 (D). Whole cell lysates were 
extracted 3h post-exposure and resolved by SDS-PAGE and analysed by 
immunoblotting against cyclin D1, H2AX and -tubulin (loading control). Results are 
representative of two independent experiments. MW: Protein Molecular Weight 
Marker. 
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Figure 6.7 - Analysis of the effect of the NF-B inhibitor Bay 11-7082 on cyclin D1 
expression in 3T3 cells exposed to DNA damaging agents. Wt (A), IKK-/- (B), IKK-/- 
(C) and IKK/ DKO (D) 3T3 cells were treated with 5uM Bay 11-7082 for 5min prior 
to exposure to 2.5M 4NQO. Cells were lysed 3h post-exposure and whole cell lysates 
were resolved by SDS-PAGE and analysed by immunoblotting against cyclin D1, 
H2AX and -tubulin (loading control). Results are representative of two independent 
experiments. 
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Figure 6.8 – Analysis of cell cycle distribution of 3T3 cells treated with DNA 
damaging agents. Wt, IKK-/- and IKK-/- 3T3 cell cultures were exposed to the 
indicated doses of ultraviolet C (UVC) or ionizing radiation (IR) and collected 24h after 
treatment; cells were incubated for the last 30minutes in the presence of 10M BrdU. 
Cells were processed and stained with FITC-conjugated BrdU antibody and PI prior to 
flow cytometry analysis. For each sample, 10,000 events were acquired and DNA 
profiles were analysed using the FlowJo software; error bars represent standard 
deviations calculated from three independent experiments (see appendix XIV for data). 
(A) PI analysis, (B) BrdU incorporation analysis. 
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Figure 6.8 (cont) – Analysis of cell cycle distribution of 3T3 cells treated with DNA 
damaging agents. 
For legend, see previous page. 
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Figure 6.9 – Analysis of cell cycle distribution of 3T3 cells treated with DNA 
damaging agents. Wt, IKK-/- and IKK-/- 3T3 cell cultures were exposed to the 
indicated doses of 4NQO or H2O2 and collected 24h after treatment; cells were 
incubated for the last 30minutes in the presence of 10M BrdU. Cells were processed 
and stained with FITC-conjugated BrdU antibody and PI prior to flow cytometry 
analysis. For each sample, 10,000 events were acquired and DNA profiles were 
analysed using the FlowJo software; error bars represent standard deviations calculated 
from three independent experiments (see appendix XV for data). (A) PI analysis, (B) 
BrdU incorporation analysis.  
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Figure 6.9 (cont) – Analysis of cell cycle distribution of 3T3 cells treated with DNA 
damaging agents. 
For legend, see previous page. 
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CHAPTER 7 – SUMMARY AND GENERAL DISCUSSION 
Progression through the different stages of the cell cycle is tightly regulated to ensure 
the correct order of events is respected and the mechanisms by which cells can actively 
interrupt this process are termed checkpoints (Hartwell and Weinert, 1989). Cell cycle 
checkpoints are particularly important in the response to DNA damage to coordinate the 
cell cycle block and the DNA repair process or alternatively to trigger cell death (Kastan 
and Bartek, 2004, Harper and Elledge, 2007). The DNA damage response is also 
thought to be an important barrier to the early development of tumours by triggering 
cellular senescence or cell death (Bartkova et al., 2005, Gorgoulis et al., 2005). 
Oncogenes can generate replication stress and DNA damage as a result of unscheduled 
S-phase entry and DNA synthesis (Bartkova et al., 2006, Di Micco et al., 2006). The 
consequent activation of DNA damage signaling creates selective pressure in cells with 
deregulated oncogene expression for the development of defects in the machinery that 
protects genomic stability thereby promoting tumour progression (Bartek et al., 2007, 
Halazonetis et al., 2008). Since most cancer therapies are actually based on DNA 
damaging it is of importance to fully understand the response mounted by cells to 
genotoxic stress and how it impacts on molecules that can oppose this response such as 
the Myc proteins and cyclin D1. 
 
N-myc is a member of the Myc family of proto-oncogenes which integrate a 
transcriptional regulatory network that directly affects the machinery of cell growth and 
proliferation (Massari and Murre, 2000, Adhikary and Eilers, 2005, Meyer and Penn, 
2008). N-myc is fundamental during the embryonic development of the nervous system 
and deregulated N-myc expression is hence associated with development of tumours of 
neural origin particularly neuroblastoma (Knoepfler et al., 2002, Oliver et al., 2003, 
Schwab, 2004, Hatton et al., 2006). MYCN amplification is the only example of 
oncogene activation known to occur with substantial frequency in neuroblastomas and 
is associated with rapid tumour progression and treatment failure (Seeger et al., 1985, 
Maris et al., 2007, Murphy et al., 2011). The reason why MYCN amplification is 
associated with a more aggressive phenotype in neuroblastoma remains however 
unclear and understanding the pathways involved in the pathogenesis of these tumours 
could provide insights into the development of more specific and biologically-based 
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therapies. Similarly unclear are the mechanisms by which MNA-NB cell lines evade the 
cell cycle arrest imposed by genotoxic stress. This study aimed to determine if 
expression of N-myc is associated with physical and/or functional suppression of the 
growth-arresting protein p21 and characterize the response of N-myc to different DNA 
damaging agents.  
 
A potential physical interaction between N-myc and p21 was first investigated by 
performing pull-down assays using mouse N-myc fusion proteins expressed using a 
bacterial host (Figure 3.2) or the in vitro transcription/translation system (Figure 3.4). 
The assays showed N-myc could bind p21 in vitro and by employing various N-myc 
deletion mutants (Figure 3.1) seemed to indicate the interaction was mediated by the C-
terminal region of N-myc, responsible for DNA binding and heterodimerization with 
Max (Figures 3.3 and 3.5) (Murre et al., 1989a, Wenzel et al., 1991). Analysis of the 
putative N-myc/p21 association by immunoprecipitation of endogenous or ectopic 
proteins from human MNA-NB and non-NB cells failed however, to demonstrate the 
occurrence of an intracellular interaction between the two proteins (Figures 3.6-3.9 and 
4.6). Binding to p21 was nevertheless observed using an N-myc truncation mutant 
lacking the N-terminal 124 amino acids (Figures 3.12 and 3.13). Interestingly, both the 
immunoprecipitation studies as well as additional analyses carried out (section 3.2.3) 
suggested MNA-NB cells may express short polypeptides which share homology with 
the C-terminal region of N-myc but not the N-terminal. The MYC transcript, coding for 
c-Myc, is thought to give rise to short forms of this protein as a result of ribosomal 
leaky scanning at the canonical initiation codons (Spotts et al., 1997). Two N-terminally 
truncated forms of N-myc were expressed in vitro using internal initiation codons in the 
human MYCN transcript and were found to exhibit electrophoretic motilities similar to 
the endogenous polypeptides expressed in MNA-NB cells (Figure 3.11).  
 
The dominant negative effect of Myc mutant proteins carrying deletions within the N-
terminal region, particularly in the MBII domain, over Myc-dependent proliferation and 
transformation has been demonstrated extensively (Mukherjee et al., 1992, Sawyers et 
al., 1992, MacGregor et al., 1996, Spotts et al., 1997, Oliver et al., 2003). Thus, these 
putative N-myc isoforms may affect the activity of full-length N-myc and regulation of 
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MYCN at the translational level could modulate expression of the different isoforms and 
influence gene activation and cell proliferation. The C/EBP family of transcription 
factors provides a striking example of the relevance of regulated isoform expression on 
cellular fate. Both C/EBP and C/EBP transcripts generate multiple isoforms that 
exhibit distinct biological activities; the full-length proteins are transcriptional activators 
that promote differentiation and cell cycle arrest whereas truncated isoforms appear to 
block or even counteract these functions (Descombes and Schibler, 1991, Lin et al., 
1993, Ossipow et al., 1993, Buck et al., 1994, Calkhoven et al., 1997). These studies 
suggested the truncated isoforms resulted from ribosomal leaky transcript scanning and 
consequent translation initiation at downstream start codons. Clakhoven and colleagues 
demonstrated that the expression ratio of C/EBP isoforms was in fact controlled by 
differential activity of the translation machinery in response to cellular signaling 
cascades (Calkhoven et al., 2000). Mechanisms of control of Myc expression at the 
translational level have also been described. The 5’ UTR of c-, L-, and N-myc mRNAs 
each contain a complex RNA structural element known as an internal ribosome entry 
segment (IRES) (Nanbru et al., 1997, Jopling and Willis, 2001, Jopling et al., 2004). 
These elements allow mRNA translation to occur independently of canonical translation 
initiation factors and of the 
7
methyl guanosine capped structure located at the 5’end of 
the transcript. In the IRES-mediated mechanism, the translation machinery associates 
with the IRES either directly or following recruitment by noncanonical cofactors 
(ITAFs) that appear to act as RNA chaperones (Vagner et al., 2001, Marilyn, 2002). The 
c-Myc IRES has been shown to sustain c-Myc expression during apoptosis or following 
genotoxic stress, conditions which compromise cap-dependent translation, and can also 
regulate its expression during different stages of development (Stoneley et al., 2000, 
Créancier et al., 2001, Subkhankulova et al., 2001, Holcik and Sonenberg, 2005). The c-
Myc response to apoptosis or genotoxic stress was shown to be dependent on the p38 
and ERK MAPK pathways likely through the regulation of the activity or amount of 
specific ITAFs (Komar and Hatzoglou, 2011). Although IRES-mediated translation of 
Myc proteins shares some regulatory ITAFs, Jopling and Willis demonstrated that the 
N-myc but not the c-Myc IRES was strongly activated in neuronal cells suggesting the 
existence of tissue- and transcript-specific cofactors (Jopling and Willis, 2001, Cobbold 
et al., 2008). Conditional on the decisive establishment of the polypeptides observed in 
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MNA-NB cells as N-myc isoforms, it will be of interest to examine if, as discussed 
above, mechanisms of translation regulation can enhance their expression and determine 
their role in the biology of NB cells. This study failed to observe an interaction between 
p21 and the endogenous polypeptides under the conditions tested. These polypeptides 
were also only weakly detected in Max immunoprecipitates and it is therefore possible 
that under cellular conditions that result in upregulation of the putative N-myc isoforms 
a potential interaction with p21 will become apparent. Nevertheless, the possibility that 
the N-myc/p21 interaction observed in vitro or by immunoprecipitation using the N-
terminally truncated mutant are artefacts resulting from protein overexpression cannot 
be excluded. 
 
Ectopic expression of N-myc in Rat-1 cells (Figure 4.1) promoted accelerated 
progression through the cell cycle, most notably at the G1/S boundary (Figure 4.3). 
Although this effect is related to the increased levels of positive regulators of cell cycle 
progression (Figure 4.4), this function alone likely does not account for the cellular 
responses described here. So far, no direct role for N-myc in promoting DNA 
replication during S phase, as shown for c-Myc, has been demonstrated (Dominguez-
Sola et al., 2007). However, both neuronal and non-neuronal cells expressing N-myc 
exhibit increased rates of DNA synthesis and targeted deletion of this protein in 
neuronal progenitor cells decreases the proportion of S-phase and mitotic cells 
(Cavalieri and Goldfarb, 1988, Lutz et al., 1996, Knoepfler et al., 2002). Given the 
functional similarities between N- and c-Myc, it is possible N-myc can likewise induce 
DNA synthesis by directly participating in the firing of replication origins (Malynn et 
al., 2000). Enforced expression of p21, and to a lesser extent p27, in Rat-1 control and 
N-myc cells (Figure 4.5) promoted a similar G1 arrest in both cell lines (Figure 4.7). 
This effect was directly attributable to p21 as illustrated by the dose-dependent response 
observed in these cells (Figure 4.8). Rat-1/N-myc cells failed however, to undergo 
proliferative arrest under conditions of serum starvation and exhibited as a result a more 
marked decrease in cell viability than control cells (Figure 4.10). Expression of p21 as 
well as p27 in serum-starved Rat-1/N-myc cells restored the G1 block observed in 
control cells and protected these cells from the deleterious effects of aberrant 
progression through the cell cycle, particularly in p21-expressing cells. The results 
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presented above suggest that deregulated N-myc, as in MNA-NB cells, is dependent on 
transcriptional control of genes that can impose proliferative arrest in order to drive cell 
cycle progression under conditions of stress such as nutritional deprivation or following 
DNA damage. The range of potential targets whose transrepression mediates this effect 
is better characterized for c-Myc than N-myc. The negative regulation of p21 gene 
expression by c-Myc has been extensively characterized and is associated for instance, 
with suppression of cell differentiation and the DNA damage response to UV (Mitchell 
and El-Deiry, 1999, Claassen and Hann, 2000, Gartel et al., 2001, Herold et al., 2002, 
Seoane et al., 2002, Wu et al., 2003b, Li and Wu, 2004). A role for c-Myc in inhibiting 
transcriptional expression of the cdk inhibitors p27 and p15 has also been suggested 
(Seoane et al., 2001, Staller et al., 2001, Yang et al., 2001, Chandramohan et al., 2004). 
Notably, c-Myc can repress transcription of the GADD34, GADD45 and GADD153 
genes encoding members of the growth arrest and DNA damage (GADD) family of 
proteins which are induced by a variety of cellular stresses (Chen et al., 1996a, Marhin 
et al., 1997, Amundson et al., 1998). Among other functions, GADD45, the best 
characterized GADD protein, contributes to the G2/M checkpoint by disrupting the 
association between cyclin B and cdk1 required for M-phase entry, and contributes to 
DNA damage repair via the NER pathway possibly through its interaction with PCNA 
(Smith et al., 1994, Wang et al., 1999, Zhan et al., 1999, Smith et al., 2000).  
 
Analysis of N-myc expression in two different MNA-NB cells exposed to various DNA 
damaging agents revealed a dose-dependent downregulation in response to UVC 
irradiation (Figures 5.1-5.3). The levels of N-myc were however, only affected at 
intermediate (25-50J/m
2
) or higher UVC doses (100-200J/m
2
) unlike cyclin D1 whose 
expression was dramatically decreased at most doses tested, including at lower UVC 
doses (10J/m
2
). Cyclin D1 was also found to be negatively regulated following exposure 
to IR, etoposide, cisplatin and 4NQO (Figures 5.1, 5.4-5.7). In contrast, N-myc 
expression was only decreased in cells treated with the UV-mimetic 4NQO but not the 
remaining agents analysed. In wild-type p53 SK-N-DZ cells, p21 was strongly 
upregulated in response to all doses of IR but exhibited a biphasic response to UVC 
exposure; at a low dose (5J/m
2
) the levels of p21 were markedly increased whereas 
irradiation with doses of 25J/m
2
 or above virtually abolished p21 expression. The IR-
  A. Duarte 
202 
 
induced upregulation of p21 correlated with an increase in cdk2 association in this cell 
line as well as in another MNA-NB cell line employed (NB-1643, Figures 3.6A and 
3.7). These observations indicated that distinct DNA damage-induced signaling 
pathways were activated in MNA-NB cells exerting different effects on the cell cycle 
regulators examined. As discussed above, activation of the ATM and ATR pathways by 
agents that generate DSBs and replication stress, respectively, similarly induced cyclin 
D1 downregulation. In response to IR-induced DSBs, the ATM pathway promoted 
instead accumulation of p21 mediated by p53. The N-myc and p21 responses triggered 
by UVC irradiation appeared to depend on the dose used which possibly reflected the 
extent of damage inflicted and, as a consequence, the activation of different cascades to 
coordinate DNA repair and cell cycle arrest or cell death. The results presented above 
suggested that the UV-induced decrease in N-myc expression is likely independent of 
ATM activity (Figure 5.8). The radiosensitizing agent caffeine has been widely 
employed in the study of ATM and ATR signaling despite the fact that the molecular 
mechanisms by which it acts are not fully understood. Various studies demonstrated in 
vitro inhibition of ATM and ATR by caffeine (Blasina et al., 1999, Hall-Jackson et al., 
1999, Sarkaria et al., 1999). In vivo, caffeine was shown to prevent DNA damage-
induced S and G2/M checkpoints that were dependent on expression of functional ATR 
or ATM suggesting a direct effect on these kinases (Heffernan et al., 2002, Kaufmann et 
al., 2003, Shechter et al., 2004a). Cortez demonstrated however, that the presence of 
caffeine abrogated the G2/M checkpoint in response to IR or hydroxyurea, a DNA 
replication inhibitor that activates ATR, without preventing phosphorylation of 
ATM/ATR substrates including Chk1 and Chk2 (Liu et al., 2000, Ward and Chen, 
2001, Cortez, 2003). These findings were further supported by another study and raised 
the hypothesis that caffeine inhibits checkpoint response without affecting ATM/ATR 
directly (Kaufmann et al., 2003). Moreover, assessing cellular responses in caffeine-
treated cells is additionally complicated by the fact that it can directly contribute to 
accumulation of DNA damage and chromosomal aberrations by intercalating in DNA as 
well as interfering with DNA repair (Tohda and Oikawa, 1988, Tornaletti et al., 1989, 
Selby and Sancar, 1990). A number of groups have demonstrated that cellular 
expression of kinase-dead forms of ATR can prevent UV-induced S-phase checkpoint 
as well as Chk1 and H2AX phosphorylation indicating it effectively blocks ATR 
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signaling (Liu et al., 2000, Ward and Chen, 2001, Heffernan et al., 2002). This tool 
could therefore be employed to examine the role of ATR in UV-dependent regulation of 
N-myc in MNA-NB cells. 
 
Although p21 degradation following UV exposure appears to be a common component 
of the cellular response to the damage inflicted by this type of radiation, it remains 
unclear whether negative regulation of p21 is required for PCNA-dependent DNA 
repair. Recent works actually suggest a direct role for PCNA in p21 degradation both 
during S phase and after UV irradiation by mediating p21 ubiquitylation by the DDB1-
Cul4A
Cdt2
 E3 ligase (Abbas et al., 2008, Kim et al., 2008, Nishitani et al., 2008). A 
similar mechanism regulates the levels of Cdt1, a replication licensing factor involved 
in the assembly of the pre-replicative complex at DNA replication origins (Maiorano et 
al., 2000, Nishitani et al., 2000, Rialland et al., 2002). During S phase and following 
DNA damage induced by different agents including IR, UV and 4NQO, chromatin-
bound PCNA recruits Cdt1 and promotes its ubiquitylation by the DDB1-Cul4A
Cdt2
 
ligase and consequent degradation by the proteasome (Higa et al., 2003, Hu et al., 2004, 
Nishitani et al., 2006, Ralph et al., 2006). DDB1-Cul4A
Cdt2
-mediated degradation of 
Cdt1 levels during S phase prevents aberrant reinitiation of DNA replication thereby 
maintaining genomic stability (Zhong et al., 2003, Arias and Walter, 2005, Arias and 
Walter, 2006, Jin et al., 2006). Another Cul4A-based ligase, DDB1-Cul4A
DDB2
, has also 
been implicated in the UV-induced degradation of p21 suggesting a possible overlap 
between the Cdt2- and DDB2-mediated pathways under certain conditions (Stoyanova 
et al., 2008, Stoyanova et al., 2009). Unlike PCNA and Ctd2 which appear to bind 
chromatin without discrimination, DDB2, heterodimerized with DDB1, exhibits a 
particular avidity for DNA carrying UV photolesions (Feldberg and Grossman, 1976, 
Chu and Chang, 1988, Batty et al., 2000, Moser et al., 2005, Wittschieben et al., 2005). 
In light of the specific downregulation of N-myc following UVC and 4NQO treatment 
and the requirement for proteasomal activity in this response (Figure 5.10), an 
association between N-myc and DDB2 was investigated and the two proteins were 
found to interact (Figures 5.11 and 5.12). It remains to be established whether this 
interaction mediates UV-induced degradation of N-myc by the DDB1-Cul4A
DDB2 
ligase 
or if it performs a distinct or additional function. The human DDB1 promoter was 
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shown to have an N-myc consensus sequence that is essential for promoter activity 
(Nichols et al., 2003). Interestingly, DDB1 can reciprocally regulate expression of N-
myc as part of the DDB1-Cul4A
TRUSS
 ligase which promotes ubiquitylation and 
consequent proteasomal degradation suggesting a potential feedback mechanism that 
prevents deregulated expression of N-myc (Choi et al., 2010).  
 
Analyses of N-myc mutant proteins in Rat-1 fibroblasts implicated the N-terminal 63 
amino acids in the N-myc response to UVC (Figure 5.13). Furthermore, the results 
suggested that efficient degradation following irradiation required an intact Thr58 
(Figure 5.14), the residue which has been shown to destabilize N-myc upon 
phosphorylation by GSK3 (Kenney et al., 2004, Welcker et al., 2004, Sjostrom et al., 
2005, Yaari et al., 2005, Chesler et al., 2006). GSK3 acts downstream of ATR to 
phosphorylate p21 at Ser114 after UV exposure thus promoting its proteasomal 
degradation (Lee et al., 2007). Consistent with this study, Abbas and colleagues 
demonstrated that in vitro ubiquitylation of p21 by the DDB1-Cul4A
Cdt2 
ligase was 
more efficient when p21 carried a phosphomimetic substitution at Ser114 (Abbas et al., 
2008). Phosphorylation of cyclin D1 at Thr286 by GSK3 in response to hydroxyurea 
also promotes its accelerated proteolysis (Mukherji et al., 2008). Although a 
requirement for ATR in suppression of cyclin D1 expression was not established in that 
study, Hitomi and colleagues reported that the T286 phosphorylation-directed 
degradation of cyclin D1 in response to UV was dependent on the activity of ATR 
(Hitomi et al., 2008). Thus, it is possible that genotoxic agents such as UV and 
hydroxyurea which similarly induce replication stress leading to activation of ATR act 
through a common pathway that involves GSK3 to regulate the levels of various 
proteins such as N-myc, p21 and cyclin D1. In order to test a potential role for the 
DDB1-Cul4A
DDB2
 ligase in regulation of N-myc following UVC exposure, the 
association between DDB2, as well as the remaining factors that form this complex, can 
be investigated in the Rat-1 cell lines expressing UV-sensitive and resistant N-myc 
variants.  
 
The DNA damage response induced by UVC exposure activated S- and G2/M-phase 
checkpoints, particularly at higher radiation doses, in Rat-1 control cells (Figures 5.15 
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and 5.16). As observed in serum-starved Rat-1 fibroblasts, expression of N-myc 
abrogated the cell cycle block imposed in S phase, and possibly in G2/M, and led as a 
result to a dramatic increase in cell death. The UV-induced cell cycle arrests were 
restored by deletion of the N- or C-terminal regions of N-myc demonstrating a 
requirement for transcriptional activity in promoting bypass of the DNA damage 
checkpoints and consequently cell death. MYCN amplification in NB cells is also 
associated with a failure to arrest in G1 following exposure to IR and an increased level 
of apoptosis (Tweddle et al., 2001b, McKenzie et al., 2003, Bell et al., 2006). NB cells 
which failed to arrest in G1 exhibited significantly lower levels of p21 following 
irradiation. These studies and the findings described above indicate that overexpression 
of N-myc in different cell types can contribute to suppression of the cell cycle 
checkpoints activated in response to genotoxic stress. Unlike IR, the cellular and 
molecular responses to UV irradiation have not been characterized in MNA-NB cells 
and further work is required to determine the targets that mediate resistance to the UV-
induced cell cycle block. Given its critical role in cell proliferation and the strong 
association between MYCN amplification and the development of neuroblastoma 
tumours that can resist therapy and rapidly progress, N-myc is undoubtedly a promising 
target for developing cancer treatment. By understanding the role of N-myc in the DNA 
damage response, it may become possible to develop treatments tailored to induce a 
specific cellular response in cancer cells with deregulated expression of this protein.  
 
This study additionally aimed to investigate a potential role for NF-B in mediating the 
DNA damaged-induced response of cyclin D1, a component of the cell cycle machinery 
involved in the G1/S phase transition. For this purpose, an inhibitor of NF-B activation 
by the IKK complex, Bay 11-7082, was employed. The levels of cyclin D1 were 
examined following exposure to DNA damaging agents (UV, IR, 4NQO and H2O2) 
previously shown to suppress cyclin D1 expression (Agami and Bernards, 2000, 
Miyakawa and Matsushime, 2001, Barnouin et al., 2002, Suwaki et al., 2010). 
Treatment of U2OS cells with Bay 11-7082 prior to genotoxic exposure attenuated the 
DNA damage-induced downregulation of cyclin D1 (Figure 6.1), potentially by 
preventing protein degradation since a stabilization of cyclin D1 was observed in the 
presence of the inhibitor (Figure 6.2). The reduction in cyclin D1 levels associated with 
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genotoxic exposure was however intact in 3T3 cells lacking expression of IKK (Figure 
6.4), IKK (Figure 6.5) or both IKK subunits (Figure 6.6). These observations 
suggested the DNA damage-induced changes in cyclin D1 expression do not require 
activation of NF-B by the IKK complex. Treatment with Bay 11-7082 also prevented 
4NQO-induced downregulation of cyclin D1 in the single and double IKK mutant cell 
lines indicating the inhibitor affects cyclin D1 regulation through a mechanism 
independent of the IKK/IB/NF-B pathway. Assessing the transcriptional activity of 
NF-B in IKK and IKK single and double KO cells in the presence or absence of 
Bay 11-7082 should help elucidate if the inhibitor can repress NF-B via IKK-
independent mechanisms. To further analyse a role for NF-B in regulating cyclin D1 in 
response to genotoxic stress, alternative inhibitors of NF-B could be employed. The 
cell-permeable peptide NBD (NEMO-binding domain) containing the C-terminal 
domain of IKK, required for interaction with IKK, was shown to effectively block 
NF-B activation in cells by disrupting IKK/IKK binding (May et al., 2000, May et 
al., 2002). Another synthetic peptide, SN50, carries the NLS of the NF-B subunit 
p105(p50) and can prevent intracellular recognition of the NLS of p65, p105(50) and c-
Rel and therefore block their nuclear import (Lin et al., 1995). Considering the 
oncogenic properties of cyclin D1 and the detrimental consequences associated with 
defects in DNA damage responses, it is essential to understand the functions and 
regulation of this protein in molecular detail. 
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APPENDIX I - Sequence alignment: Human - Mouse N-myc 
 
 
Protein sequence alignment of human N-myc (hN-myc) and mouse N-myc (mN-myc). 
Functional domains are boxed; in order: MBI, MBII, BR, HLH, Zip. Dots above 
sequence indicate translation start sites for the two N-myc full-length polypeptides (464 
and 456 amino acids); asterisks above sequence indicate putative translation start sites 
for N-myc short isoforms. 
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APPENDIX II - Sequence alignment: Human N-myc – c-Myc 
 
Protein sequence alignment of human N-myc (hN-myc) and human c-Myc (hc-Myc). 
Functional domains are boxed; in order: MBI, MBII. 
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APPENDIX III – Nucleotide coding sequence of mouse N-myc 
 
 
Nucleotide coding sequence of the mouse N-myc. The internal restriction site for SpeI 
enzyme is underlined. The rare codons are highlighted in grey. 
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APPENDIX IV – Transcript sequence of human and mouse N-myc 
 
 
Transcript sequence of the human (h) and mouse (m) N-myc. The translation initiation 
sites for the two N-myc full-length polypeptides and putative short isoforms are 
highlighted in grey; translation start codons are underlined. 
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APPENDIX V – Cell cycle distribution of Rat-1 fibroblasts transfected with 
pBabepuro-N-myc or empty vector submitted to mitotic arrest treatment (Figure 4.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Rat-1/pBabe and Rat-1/N-myc cells were incubated for 18h in normal growth media 
in the absence (asynchronous) or presence of 0.21M nocodazole. Nocodazole-treated 
cells were then incubated under normal growth conditions and collected at the indicated 
times. DNA histograms were obtained by PI staining and flow cytometry as described 
(Materials and Methods); data are representative of three independent experiments. (B) 
Cell cycle populations were determined as illustrated; data represents average 
percentage±standard deviation calculated from three independent experiments. 
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APPENDIX VI – Immunoblotting analysis of HA-p21 and HA-p27 expression in Rat-
1/pBabe and Rat-1/N-myc cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rat-1/pBabe (clones A-B, E-F) and Rat-1/N-myc (clones C-D, G-H) cells carrying an 
IPTG-inducible HA-tagged human p21 (A, clones A-D) or p27 (B, clones E-H) were 
incubated for 48h in normal growth media in the presence or absence of 1mM IPTG. 
Whole cell lysates were resolved by SDS-PAGE and analysed by immunoblotting 
against FLAG, HA and -tubulin (loading control). 
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APPENDIX VII – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
carrying an IPTG-inducible p21 or p27 construct (Figure 4.7) 
 
Rat-1/pBabe and Rat-1/N-myc cells carrying an IPTG-inducible p21 (A-D) or p27 (E-
H) construct were incubated for 48h in normal growth media in the absence (-) or 
presence (+) of 1mM IPTG. DNA histograms were obtained by PI staining and flow 
cytometry as described (Materials and Methods); data are representative of three 
independent experiments. 
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APPENDIX VII (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
cells carrying an IPTG-inducible p21 or p27 construct (Figure 4.7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data represents average percentage±standard deviation calculated from three 
independent experiments. 
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APPENDIX VIII – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
carrying an IPTG-inducible p21 or p27 construct (Figure 4.8) 
 
Rat-1/pBabe and Rat-1/N-myc cells carrying an IPTG-inducible p21 construct were 
incubated for 24 or 36h in normal growth media in the presence 0-10M IPTG. DNA 
histograms were obtained by PI staining and flow cytometry as described (Materials and 
Methods). 
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APPENDIX VIII (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
cells carrying an IPTG-inducible p21 or p27 construct (Figure 4.8) 
 
Rat-1/pBabe and Rat-1/N-myc cells carrying an IPTG-inducible p27 construct were 
incubated for 24 or 36h in normal growth media in the presence 0-10M IPTG. DNA 
histograms were obtained by PI staining and flow cytometry as described (Materials and 
Methods). 
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APPENDIX VIII (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
cells carrying an IPTG-inducible p21 or p27 construct (Figure 4.8) 
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APPENDIX IX – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
carrying an IPTG-inducible p21 or p27 construct (Figure 4.9) 
 
Rat-1/pBabe and Rat-1/N-myc cells carrying an IPTG-inducible p21 or p27 construct 
were incubated for 1-5 days in growth media supplemented with 10% serum. DNA 
histograms were obtained by PI staining and flow cytometry as described (Materials and 
Methods). 
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APPENDIX IX (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
carrying an IPTG-inducible p21 or p27 construct (Figure 4.9) 
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APPENDIX X – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells carrying 
an IPTG-inducible p21 or p27 construct (Figure 4.10) 
 
Rat-1/pBabe and Rat-1/N-myc cells carrying an IPTG-inducible p21 construct were 
incubated at day 1 in growth media supplemented with 0.5% serum and 1mM IPTG was 
added 24h later. DNA histograms were obtained by PI staining and flow cytometry as 
described (Materials and Methods). 
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APPENDIX X (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
carrying an IPTG-inducible p21 or p27 construct (Figure 4.10) 
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APPENDIX X (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
carrying an IPTG-inducible p21 or p27 construct (Figure 4.10) 
 
Rat-1/pBabe and Rat-1/N-myc cells carrying an IPTG-inducible p27 construct were 
incubated at day 1 in growth media supplemented with 0.5% serum and 1mM IPTG was 
added 24h later. DNA histograms were obtained by PI staining and flow cytometry as 
described (Materials and Methods). 
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APPENDIX X (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
carrying an IPTG-inducible p21 or p27 construct (Figure 4.10) 
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APPENDIX XI – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
exposed to ultraviolet C (UVC) radiation (Figure 5.15) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rat-1/pBabe and Rat-1/N-myc cell cultures were exposed to the indicated doses of 
UVC and collected 24h after treatment. DNA histograms were obtained by PI staining 
and flow cytometry as described (Materials and Methods); data are representative of 
three independent experiments. 
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APPENDIX XI (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc cells 
exposed to ultraviolet C (UVC) radiation (Figure 5.15) 
 
 
 
 
 
 
 
 
 
 
 
Data represents average percentage±standard deviation calculated from three 
independent experiments. 
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APPENDIX XII – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc (full-length 
and truncated variants) cells exposed to ultraviolet C (UVC) radiation (Figure 5.16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rat-1/pBabe and Rat-1/N-myc (full-length and truncated variants) cell cultures were 
exposed to the indicated doses of UVC and collected 24h after treatment. DNA 
histograms were obtained by PI staining and flow cytometry as described (Materials and 
Methods). 
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APPENDIX XII (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
(full-length and truncated variants) cells exposed to ultraviolet C (UVC) radiation 
(Figure 5.16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For legend, see previous page. 
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APPENDIX XII (cont.) – Cell cycle distribution of Rat-1/pBabe and Rat-1/N-myc 
(full-length and truncated variants) cells exposed to ultraviolet C (UVC) radiation 
(Figure 5.16) 
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APPENDIX XIII – Cell cycle distribution of 3T3 cells treated with DNA damaging 
agents (Figure 6.8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wt, IKK-/- and IKK-/- 3T3 cell cultures were exposed to the indicated doses of 
ultraviolet C (UVC) or ionizing radiation (IR) and collected 24h after treatment. DNA 
histograms were obtained by PI staining and flow cytometry as described (Materials and 
Methods); data are representative of three independent experiments. 
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APPENDIX XIII (cont.) – Cell cycle distribution of 3T3 cells treated with DNA 
damaging agents (Figure 6.8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data represents average percentage±standard deviation calculated from three 
independent experiments. 
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APPENDIX XIV – Cell cycle distribution of 3T3 cells treated with DNA damaging 
agents (Figure 6.9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wt, IKK-/- and IKK-/- 3T3 cell cultures were exposed to the indicated doses of 4NQO 
or H2O2 and collected 24h after treatment. DNA histograms were obtained by PI 
staining and flow cytometry as described (Materials and Methods); data are 
representative of three independent experiments. 
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APPENDIX XIV (cont.) – Cell cycle distribution of 3T3 cells treated with DNA 
damaging agents (Figure 6.9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data represents average percentage±standard deviation calculated from three 
independent experiments. 
 
 
 
 
 
